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In northwestern Ontario the Indigenous First Nations (FN) population have an increased 
prevalence of chronic kidney disease (CKD). There is an increased rate of infectious disease 
caused by Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae in the FN 
population. The 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent 
pneumococcal protein-polysaccharide conjugate vaccine (PCV13) are used to prevent 
pneumococcal disease in Canada. Since the implementation of H. influenzae type b (Hib) 
vaccine programs, invasive H. influenzae type a (Hia) disease has replaced invasive Hib disease 
in the FN population. However, there is no vaccine to prevent disease caused by non-Hib strains. 
To maintain immunological memory in adults, stimulation of pre-existing memory is 
achieved through immunization. To determine if patients with CKD have the ability to respond 
to conjugate vaccines specific for Hia or pneumococcus, naturally acquired humoral immunity 
against these pathogens must be evaluated. Immunization with PPV23 is recommended for 
adults with CKD, however PPV23 is suboptimal at inducing antibody responses in adults with 
CKD compared to healthy adults. PCV13 is recommended for certain immunocompromised 
adults, but only two studies evaluated the immunogenicity of PCV13 in adults with CKD with 
conflicting results. To determine if PCV13 is immunogenic in patients with CKD and the effect 
of previous PPV23 immunization on subsequent immunization with PCV13, quantification of B-
cell subpopulations, pneumococcal specific B cells and their relationship with antibody 
responses to PCV13 must be evaluated. 
The results suggest that the increased prevalence of invasive disease caused by 
pneumococcus and Hia in the FN population is not due to decreased numbers of B cells or 
concentrations of naturally acquired antibodies. The increased prevalence of diseases such as 
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CKD causing immune dysfunction in a higher proportion of the FN population increases their 
risk for invasive disease. Results suggest that a new Hia-conjugate vaccine may be immunogenic 
in adults with CKD, as it will potentially re-activate Hia specific immunological memory. Our 
findings suggest that previous immunization with PPV23 has a negative effect on the humoral 
immune response that results in long-term changes in B-cell subpopulations and decreases 
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 Chapter 1A: Literature Review 
Introduction 
Chronic kidney disease (CKD) is a serious disease that is characterized by high mortality 
rates. Cardiovascular disease and infection are the top two causes of mortality in this group. In 
northwestern Ontario the Indigenous population (First Nations peoples) have an increased 
incidence of CKD (1). First Nations peoples in northwestern Ontario also have an increased rate 
of infectious disease, including disease caused by Streptococcus pneumoniae and Haemophilus 
influenzae (2). In this review the issues associated with CKD resulting in immune dysfunction, 
focus on humoral immune responses and the importance of immunological memory will be 
discussed.  
There are currently two types of pneumococcal vaccines available in Canada (PPV23: 23-
valent pneumococcal polysaccharide (PPV23) and PCV13: 13-valent pneumococcal protein 
polysaccharide vaccine) to prevent disease caused by S. pneumoniae in infants, 
immunocompromised adults and the elderly. However, studies have shown that the capsular 
polysaccharide vaccines are less immunogenic in some immunocompromised adults compared to 
protein-polysaccharide conjugate vaccines (3, 4). This chapter will describe the differences 
between the types of pneumococcal vaccines, as well as the vaccine recommendations for adults 
at increased risk for invasive pneumococcal disease (IPD). Current data available on the humoral 
immune responses of patients with CKD in response to pneumococcal immunization will 
investigate the differences in immunogenicity between pneumococcal vaccines.   
As of present, there is no vaccine available to prevent disease caused by non-H. 
influenzae type b strains. Since the implementation of publicly funded H. influenzae type b (Hib) 
vaccine programs, invasive disease caused by H. influenzae type a (Hia) has replaced the 
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invasive Hib disease in the Indigenous population. To understand the need for the development 
of a Hia vaccine, current epidemiological data on the prevalence of invasive Hia disease as well 
as naturally acquired humoral immunity against Hia in the northwestern Ontario First Nations 
population will be investigated. 
 
Chronic kidney disease 
CKD is a common condition and is considered a major public health issue with 3,467,822 
(95% uncertainty interval (UI): 3,213,111 – 3,766,495) Canadians being affected by this disease 
as of 2017. CKD affects approximately 9.1% (95% UI: 8.5 – 9.8) of the global population (5). 
Mortality rates are high amongst this population, more than double the rate of people without 
CKD at 103.0 per 1000 patient-years when adjusted for age, sex, and ethnicity (6). CKD is 
defined as the presence of kidney damage for more than 3 months, and the 5 stages of CKD are 
based on the glomerular filtration rate (GFR). A rate of less than 60 mL/ min/ 1.73 m2 is 
considered abnormal, and greater than this is considered abnormal if accompanied by abnormal 
urine sediment, abnormal imaging or biopsy results. Stages 1 to 3 range from kidney damage 
with normal/ increased GFR (stage 1, ≥ 90 mL/ min/ 1.73 m2) or mildly decreased GFR (stage 2, 
60-89 mL/ min/ 1.73 m2) to moderately decreased GFR (stage 3, 30-59 mL/ min/ 1.73 m2). 
Severe or end-stage CKD includes stages 4 (15-29 mL/ min/ 1.73 m2) and 5 (< 15 mL/ min/ 1.73 
m2) (7).  
Once a patient has reached a GFR of less than 15 mL/ min/ 1.73 m2 they require renal 
replacement therapy which can be achieved through dialysis or kidney transplantation (8). 
Hemodialysis was the first intervention that was able to partially replace lost kidney function and  
is used to prevent or decrease the progression of CKD by decreasing further damage caused by 
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waste materials (9, 10). This process involves blood diffusing through a semipermeable 
membrane by means of an electrochemical concentration gradient to remove excess waste 
products such as urea. (11). A solution called dialysate, containing sodium, potassium, calcium, 
magnesium, chloride, bicarbonate and glucose or dextrose is required for hemodialysis as it aids 
in the removal of low molecular weight molecules such as urea and restores the extracellular pH 
and concentration of electrolytes (12).  
 
Uremic syndrome and oxidative stress 
Uremic syndrome (uremia) is the retention of compounds normally excreted in the urine 
by the kidneys. Uremia causes significant metabolic issues and is a serious condition which 
affects the whole body. The increased amounts of these compounds interfere with biological 
functions and result in toxicity. These retained compounds can become altered through oxidation 
causing them to become pro-inflammatory (13). Oxidative stress contributes to the progression 
of CKD by promoting apoptosis and inflammation. Oxidative stress is also a consequence of 
other conditions that are commonly associated with CKD such as diabetes, hypertension, and 
atherosclerosis that also contribute to kidney damage. The hemodialysis process has been found 
to promote the production of reactive oxygen species (ROS), as well as inflammation. In patients 
undergoing hemodialysis, the amounts of ROS in plasma are increased and antioxidant levels are 
decreased. Exposure to the dialysis membrane has also been associated with increased 
complement factors, platelets and polymorphonuclear white blood cells (14).  
 
CKD and dysfunction of the immune system 
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Increased inflammation is a major issue that results in the development and progression 
of cardiovascular disease, which is the number one cause of mortality in patients with CKD 
followed by infection (15, 16). Patients with CKD are at an increased risk for infection because 
they are immunocompromised. Patients with CKD are unique among other high-risk groups 
because they have multiple factors predisposing them to infection. Aging of the immune system 
is referred to as immunosenescence, and is a decline in the immune system resulting in increased 
susceptibility to disease, increased inflammation and poorer response to immunization (17). 
Severe CKD related changes in the immune system that have resulted in decreased immune 
function comparable to healthy elderly adults is known as premature immunological aging. In 
patients with CKD, this is characterized by uremia, increased oxidative stress and increased 
inflammation (18). 
The principle clinical feature of uremia in regard to the immune system is low response 
to vaccination and increased sensitivity to infectious diseases (19). Chronic kidney disease and 
uremia affects multiple cells and functions of the immune system including: decreased 
bactericidal ability of neutrophils, decreased granulocyte and monocyte/ macrophage phagocytic 
function, defective antigen presenting capacity of antigen presenting cells, reduced numbers of B 
cells and decreased antibody producing capacity of plasma cells, increased T- and B cell 
apoptosis, decreased thymic T-cell output, and  impaired activation of T-cell response (20) (21).  
  Among immune abnormalities, patients with CKD have noticeable alterations in B cells 
and B-cell functions. It is also thought that epigenetic changes caused by CKD decrease 
production of lymphoid cells at the hematopoietic stem cell level (22) resulting in patients with 
CKD having decreased absolute numbers of B cells and T cells (23). Pahl et al. 2010 found that 
patients with CKD had decreased numbers of B cells as well as decreased naïve and memory B 
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cells compared to healthy controls. They concluded that B cell lymphopenia in patients with 
CKD was due to uremia related decrease in transitional B cell BAFF receptor expression, 
causing a decrease their survival (24). Patients with CKD also have an increased incidence of 
underlying diseases which also contribute to their susceptibility to infections such as diabetes 
mellitus, hypertension, cardiovascular disease, COPD, cancer, dyslipidemia and peripheral 
vascular disease (25, 26). We must also consider that these patients have an increased exposure 
to infectious agents due to disruptions in the skin from needles and venous catheters, as well as 
an increased frequency of exposure to the hospital environment and proximity to other patients 
(27).  
 
CKD in the Canadian Indigenous population 
In North America, CKD disproportionally affects Indigenous populations. The rate of 
CKD amongst Indigenous people is two to four times higher than in non-Indigenous people (28). 
The burden of CKD among Indigenous peoples is mostly influenced by the high prevalence of 
obesity and type 2 diabetes mellitus, which results in an increased rate of diabetic nephropathy, 
and an increased prevalence of glomerulonephritis (29, 30). In northwestern Ontario, the 
population of First Nations Indigenous peoples has been found to have a higher proportion of 
adults with CKD compared to non-Indigenous adults. Specifically, CKD has a high prevalence in 
the First Nations population of northwestern Ontario. The rate of CKD in the First Nations 
population (7%) is double the rate of the general Canadian population. This high rate of CKD 




   
11 
Humoral Immunity 
Adaptive immunity can be separated into humoral immunity and cell mediated immunity. 
Cell mediated immunity involves two types of T cells, CD4+ (helper) and CD8+ T cells 
(cytotoxic). Humoral immunity is mediated by B cells, which upon activation can proliferate and 
differentiate into memory B cells and plasma cells which produce antibodies. Response to 
immunization is assessed by quantifying the humoral immune response. The production of class 
switched antigen-specific antibodies and class switched memory B cells are indicators that 
immunological memory against a pathogen has been established. This next section will discuss 
the components of humoral immunity and B-cell responses to antigens.  
 
Cellular development and maturation of B cells 
B cells originate from hemopoietic stem cells in bone marrow, beginning as common 
lymphoid progenitor cells. B cells develop from pro-B cell to pre-B cell to immature B cells 
through the rearrangement of light and heavy chain gene segments. The B cells leave the bone 
marrow once the surfacing of pre- B cell receptor µ chains results in the expression of IgM. 
These B cells migrate through the blood as transitional B cells to the secondary lymphoid organs 
such as the lymph nodes and spleen. Transitional B cells then develop into mature B cells that 
are called either follicular or marginal zone B cells after entering the secondary lymphoid organs 
(31). It is important to note that in the secondary lymphoid organs in humans, the follicles are not 
separated from the marginal zone by sinuses like in murine models which are often described in 
the literature (32). There are three lineages of B cells which have been identified in rodents B-1, 
B-2 and marginal zone B cells. However, it has been suggested that human B cells are more 
similar to B-2 cells, which give rise to both follicular and marginal zone B cells. Human 
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marginal zone B cells have the ability to re-circulate unlike murine models which remain in the 
spleen. Some human marginal zone B cells have undergone somatic mutations (IgM memory B 
cells, IgM+CD27+) unlike murine marginal zone B cells which are not mutated and are 
described as pre-activated naïve B cells that do not undergo genetic diversification. Human 
follicular B cells and rodent B-2 cells are the main subsets in humans and rodents. Similarly, 
both undergo somatic hypermutation and class switching (33).   
The process of a B-2 cell becoming either a follicular or marginal zone B cell begins with 
transitional 1 (T1) B cells maturing into transitional 2 B cells (T2). This is achieved through 
tonic BCR signals, B cell activating factor (BAFF) survival signals and non-canonical nuclear 
factor-kB (NF-kB) signals. Weak BCR signals initiate the process of a T2 cell becoming a 
marginal zone B cell. Signals from delta-like 1 (DL1) and Notch2 through interactions with 
endothelial cells, causes the activation of mastermind-like 1 (MAML1) and RBP-Jk. When 
BAFF interacts with the BAFF receptor (BAFFR), this activates the canonical NF-kB pathway. 
Additional signals from integrin signaling and a coupled Ga12 or Ga13 serpentine receptor help 
B cells to remain in the marginal zone. Follicular B cells develop when T2 B cells receive strong 
BCR signals, this activates Bruton’s tyrosine kinase (BTK) which blocks Notch2 signaling and 
leads to the activation of the canonical NF-kB pathway. This results in commitment to the 
follicular B cell fate also known as follicular type 1 B cell. BAFFR activation is not required for 
dedication to this cell fate but is required for survival. There is another type of follicular B cell 
(follicular type 2) that derives from T2 B cells through tonic BCR signals, BAFF survival signals 
and non-canonical NF-kB signals. It has also been thought that these cells are a potential 
reservoir for marginal zone B cells (33).  
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B cell receptors 
B cell receptors (BCR) are transmembrane proteins responsible for antigen recognition. A 
single BCR consists of two immunoglobulin (Ig) heavy and two light chains, which are 
responsible for ligand binding. In addition, the BCR also consists of two subunits Iga and Igb, 
which are responsible for signal transduction. The constant region of the heavy chain is classified 
as either IgM, IgD, IgG, IgA or IgE isotypes. Naïve B cells express IgD and IgM, while the other 
isotypes are expressed on activated and memory B cells (34).  
 
T cell-independent B-cell responses 
T cell-independent antigens are antigens that can activate a B cell without T cell help. T 
cell independent type 1 (TI-1) antigens can cause B cells to proliferate and differentiate through 
polyclonal stimulation. An example would be bacterial lipopolysaccharide (LPS) which can 
activate B cells through toll-like receptor 4 (TLR4). T cell independent type 2 (TI-2) antigens 
have highly repetitive structures (e.g. bacterial capsular polysaccharides), which activate B cells 
by crosslinking of BCRs and B cell coreceptors (CD19, CD21, CD81). BCR cross-linking 
activates Src-family tyrosine kinases (Blk, Fyn, and Lyn) followed by the activation of Syk 
tyrosine kinase which results in the activation of transcription factors NF-kB, NFAT and AP-1. 
This induces gene transcription that results in cell proliferation and differentiation (35). Marginal 
zone B cells respond to TI-1 antigens. For example, these cells would respond to the capsular 
polysaccharides included in 23-valent pneumococcal polysaccharide vaccine (PPV23). These 
cells are important for rapid response to pathogens and differentiate into plasma cells that secrete 
IgM (36). Memory B cells can be produced by a T cell-independent response, however, these 
cells do not have enhanced sensitivity upon re-stimulation with the same antigen (their response 
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is more similar to that of a naïve B cell rather than a memory B cell) and they are not long lived 
like class switched memory B cells produced during a T cell-dependent response (37).  
 
T cell-dependent B-cell responses 
T cell-dependent responses occur in response to antigens such as proteins and involve 
interactions between follicular B cells and helper T cells (CD4+). For example, responses to 
protein-polysaccharide conjugate vaccines such as the 13-valent pneumococcal protein-
polysaccharide vaccine results in a T cell-dependent response. In order for a B cell to be 
activated by a T cell-dependent antigen, two signals are required. The first is from the antigen 
activating BCRs and the second is from a T cell that has been activated by the same antigen. T 
cells are initially activated by dendritic cells that have displayed a protein antigen from 
extracellular microorganisms as a small peptide bound to a class II major histocompatibility 
complex (MHC) molecules. These helper T cells differentiate into effector T cells, which 
migrate towards the edges of lymphoid follicles. B cells that have been stimulated by the same 
antigen also migrate towards the edges of lymphoid follicles due to changes in chemokine 
receptor expression (e.g. CCR7 and CXCR5). The B cell displays the endocytosed antigen as a 
class II MHC peptide. The effector T cell that is able to recognize the class II MHC peptide 
presented by the B cell, also expresses CD40 ligands. This activates the production of cytokines 
(e.g. IL-2, IL-4 etc.) which results in the initial proliferation of B cells and antibody production. 
Some of the T cells that were activated by the B cells migrate to adjacent follicles that have high 
numbers of B cells which are then called follicular helper T cells. The B cells that interacted with 
the follicular helper T cells migrate back into lymphoid follicles. Here they divide rapidly 
forming a germinal center where proliferation, isotype switching, somatic hypermutation, and 
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affinity maturation occurs. This produces memory B cells, long-lived plasma cells and class 
switched, high affinity antibodies. The memory B cells produced will be able to respond rapidly 
upon secondary exposure to the antigen and when stimulated will result in the production of high 
affinity class switched antibodies (31, 35, 38).  
 
Antibodies  
The five antibody isotypes have different biological roles. IgM antibodies are produced 
during the primary immune response to an antigen. These antibodies are polyreactive and have 
low affinity to an antigen because they have not undergone somatic hypermutation. However, 
these antibodies are able to respond rapidly to multiple antigens. IgM is superior to other 
isotypes when activating the classical complement pathway and is able opsonize pathogens 
resulting in phagocytosis. On mucosal surfaces, IgA is the most predominant antibody isotype. It 
is able to neutralize toxins, bind microorganisms and prevents adhesion of microorganisms to 
mucosal surfaces. There are two subclasses of IgA, IgA2 is the more predominant subclass on 
mucosal surfaces and is less susceptible to bacterial proteases than IgA1. IgG is the most 
predominant isotype in the body and has the longest half-life. These antibodies aid to neutralize 
toxins and viruses as well as opsonization of microorganisms for phagocytosis. IgG antibodies 
are classified into four subclasses. IgG1 and IgG3 antibodies are produced in response to a 
protein antigen while IgG2 and IgG4 antibodies are typically produced in response to 
polysaccharide antigens, upon secondary exposure to an antigen. IgG antibodies are important 
for classical complement pathway activation, but the affinity for C1q is not equal for all 
subclasses with IgG3 having the highest affinity followed by IgG1 and IgG2, while IgG4 is 
unable to activate the classical complement pathway. IgE is found in the lowest concentrations in 
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serum but binds to an antigen with high affinity. It is present during allergic reactions and in 
response to infection by parasitic worms. The function of circulating IgD is unclear, but it has 
been found to react with specific bacterial proteins (e.g. IgD binding protein of Moraxella 
catarrhalis) (39). 
 
Pathogens of interest: Haemophilus influenzae and Streptococcus pneumoniae 
The Canadian Indigenous population has increased rates of invasive bacterial diseases 
such as invasive pneumococcal disease (IPD), invasive Haemophilus influenzae disease, invasive 
Group A streptococcal disease, invasive meningococcal disease, and invasive Group B 
streptococcal disease (2). Due to the immune dysfunction associated with CKD, they are 
immunocompromised and therefore at an increased risk for invasive disease caused by 
Haemophilus influenzae and Streptococcus pneumoniae. In the next section of this review, these 
two pathogens as well as epidemiology of invasive diseases they cause in Canada, and 
immunization against these pathogens will be discussed.  
 
Haemophilus influenzae  
 Haemophilus influenzae (H. influenzae) is a Gram-negative, coccobacillus, which 
inhabits the upper respiratory, urinary and genital tracts of humans. It is categorized based on the 
presence or lack of a polysaccharide capsule. The encapsulated forms are classified as serotypes 
a - f, and the non-encapsulated are referred to as nontypeable (NTHi). H. influenzae can spread 
through respiratory droplets and have been found to be a major cause of invasive (bacteremia, 
meningitis, bacteremic pneumonia, epiglottitis, septic arthritis) and non-invasive infections (otitis 
media, sinusitis) (40, 41).  
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Invasive disease caused by Haemophilus influenzae in Canada  
 Prior to the introduction of the H. influenzae type b (Hib) vaccine in Canada in 1988, Hib 
was the most predominant serotype that caused invasive disease. Since the introduction of the 
Hib vaccines, invasive disease caused by Hib has decreased by 95% from 1.76 cases per 100,000 
population (1979–1988) to 0.08 cases per 100,000 population (2006–2012) (42). Invasive disease 
caused by non-Hib strains became nationally notifiable in 2007, however not all provinces or 
territories reported these cases to the Public Health Agency of Canada. Based on the available 
data on non-Hib invasive disease, there was an average incidence of 1.36 per 100,000 population 
per year (range was 0.87 – 1.87 per 100,000 population per year) between 2007 and 2017 (43). 
Based on the limited data available, Tsang and Ulanova (2017) (44) summarized invasive H. 
influenzae disease since the implementation of publicly funded Hib vaccine programs. Of the 
encapsulated serotypes, invasive disease caused by H. influenzae type f (Hif) is the most 
common amongst the North American and European Caucasian infants, immunocompromised 
individuals and elderly adults. NTHi strains have also been major causes of invasive disease and 
caused more disease than Hif. Haemophilus influenzae type a (Hia) has replaced Hib and has 
become a significant cause of invasive diseases in the Indigenous peoples of North America 
residing in Alaska, northern Canada, southwestern US as well as Australia. Invasive Hia disease 
is most prevalent in children under 5 years old, and adults with immunocompromising conditions 
or comorbidities (44).   
 
Invasive Haemophilus influenzae disease in northwestern Ontario  
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 The study by Cerqueira et al. (2019) (45) reported the most recent epidemiological data 
on invasive H. influenzae disease in northwestern Ontario over seven years between 2011 – 2018 
based on findings in Thunder Bay, Ontario. There were 24 cases of invasive H. influenzae 
disease in individuals between 0 – 88 years old (mean age = 51.4 years). Of these cases 15.4% 
occurred in children under 3 years old and 25% of all cases occurred in people of Indigenous 
descent. A large proportion (70.8%) of cases had major comorbidities that potentially decrease 
immune function such as type 2 diabetes mellitus, chronic obstructive pulmonary disease, etc. Of 
the isolates that went for serotype identification (22 of the 24 total cases), 9.1% were Hib, 40.9% 
were Hia and 50.0% NTHi. The invasive Hia cases resulted in severe disease such as bacteremic 
pneumonia, septic shock, and epiglottitis with a 11% fatality rate (45). This study demonstrates 
that there are adults at risk for invasive Hia disease that could benefit from immunization with 
the Hia conjugate vaccine. Eton et al. (2017) (46) investigated the incidence of invasive H. 
influenzae disease in Sioux Lookout, Ontario between 2010 – 2015. The local hospital Meno Ya 
Win Health Centre, services 28 communities in northwestern Ontario and has a total catchment 
population of 29,000 with 82% of patients being Indigenous. There were 10 invasive H. 
influenzae cases of which 90% occurred in Indigenous peoples aged 3 months to 71 years old 
(mean age = 33.4 years old). Thirty percent of these cases occurred in children aged 3 – 35 
months. Of the 10 cases, information regarding potential immune disorders was available for 8 
patients (low birth weight, type 2 diabetes mellitus, alcoholism, chronic lymphatic leukemia 
etc.). The average annual incidence rate of invasive H. influenzae disease was 6.25/ 100, 000 
population, with the highest rate occurring in the 71 – 75 years old range (35.5/ 100,000/ year). 
The most common serotype was Hia which accounted for 50% of cases, 20% were NTHi, one 
case was Hie, one case was Hib and the last case was an unknown non-Hib strain. Fifty percent 
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of cases had pneumonia, of these cases one was associated with septic shock, two with sepsis and 
one with pericarditis. There was a case fatality rate of 10% (46). These studies emphasize that 
there is a growing need for development of immunizations against Hia and non-typeable H. 
influenzae strains in the Indigenous population.  
 
Risk factors for invasive Haemophilus influenzae disease in the North American Indigenous 
population 
 The study by Tsang et al. (2014) (41) summarized the risk factors for invasive H. 
influenzae disease. A major issue for the Indigenous population is low socioeconomic status.  
This is associated with poor living conditions such as overcrowding and lack of adequate 
amounts of clean water. Indicators of low socioeconomic status, such as indoor wood heating, 
poor hygiene, rodents in the home, multiple children in the family, shared childcare facilities, 
parental smoking and lack of breastfeeding also have an association with increased risk for 
invasive H. influenzae disease. The indicators of low socioeconomic status listed increase the 
transmission rates of the pathogen in these communities, resulting in a higher probability of 
colonization of the pathogen. These communities also have a high burden of chronic conditions 
such as obesity, diabetes, chronic obstructive pulmonary disease, tuberculosis and substance 
abuse issues that increases their risk for invasive H. influenzae disease (41).  
 
Immunization against invasive Haemophilus influenzae type b disease and 
recommendations in Canada 
The Hib conjugate vaccine consists of the capsular polysaccharide polyribosylribotol 
phosphate (PRP) covalently linked to a carrier protein such as tetanus toxoid (PRP-T), diphtheria 
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toxoid (PRP-D or Neisseria meningitidis group B outer membrane protein (PRP-OMP) as well as 
Hib oligomers conjugated to non-toxic variant of diphtheria toxin CRM197 (HbOC) (41). In 
Canada for children under 5 years, a schedule that administers between 1 – 3 doses of Hib 
conjugate vaccine based on age that first dose was received is recommended. For individuals ≥ 5 
years, Hib immunization is recommended for those with asplenia, hyposplenism, cochlear 
implant, congenital immunodeficiency, HIV, hematopoietic stem cell transplantation (HSCT) 
recipients, malignant hematologic disorders and organ transplant recipients. (47).  
 
Immunogenicity of Haemophilus influenzae type b conjugate vaccine in adults with CKD 
 Due to the increased risk of invasive Hib disease in the Indigenous population and adults 
with CKD, our group has previously assessed humoral immune responses to the Hib PRP-T 
vaccine (Act-Hib; Sanofi Pasteur) in adults with CKD receiving hemodialysis between 24 – 80 
years old in adults residing in northwestern Ontario. PRP IgG geometric mean concentrations 
(GMC) were determined with enzyme-linked immunosorbent assay (ELISA) and the functional 
abilities of Hib specific antibodies was reported as geometric mean titres (GMT) determined 
using the serum bactericidal assay (SBA). One-month post-immunization, IgG GMCs increased 
23-fold and 97% of patients had a minimum antibody concentration of 1 µg/ mL; SBA GMTs 
also increased significantly. There was a correlation between the post-immunization IgG 
concentrations and the SBA GMTs in CKD patients which indicated the functional importance 
of the antibodies generated from immunization with PRP-T. IgG concentrations decreased 
significantly at 6 months compared to 1 month post-immunization, but did not change 
significantly between months 6, 9 or 12 post-immunization. However, antibody GMTs and SBA 
GMTs at 12 months remained significantly higher compared to pre-immunization. These results 
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were comparable to the healthy controls. Although this is the only study to assess antibody 
responses to Hib immunization in adults with CKD, this study demonstrated that adults with 
CKD are able to develop antibodies specific for Hib PRP capsular polysaccharide and the 
presence of IgG suggests that class switched memory B cells were produced in response to the 
PRP-T Hib conjugate vaccine (48).  
 
Naturally acquired immunity against Haemophilus influenzae type a in First Nations 
Adults 
 Although there is no vaccine to protect against disease caused by Hia, our group has 
assessed naturally acquired humoral immunity against Hia in adults. This was performed in order 
to determine if the increased incidence of invasive disease caused by Hia in the Indigenous 
population of northwestern Ontario was due to lack of Hia specific antibodies. Nix et al. (2015) 
measured IgG and IgM GMCs as well as SBA GMTs specific for Hia in healthy adults and 
adults with CKD that self-identified as either First Nations or non-First Nations. There were no 
significant differences in SBA GMTs between healthy and CKD patients, but First Nations 
participants had significantly higher GMTs compared to non-First Nations participants in both 
healthy and CKD groups. There were no significant differences in IgM or IgG GMCs between 
all CKD and all healthy adults, First Nations CKD and First Nations healthy adults, or non-First 
Nations CKD and non-First Nations healthy adults. These results suggested that the higher SBA 
GMTs in the First Nations adults are due to increased circulation of Hia in First Nations 
communities (49). 
 Increased incidence rates of invasive Hia disease for all ages in the First Nations 
population has been reported from northwestern, but not from southern Ontario. To determine if 
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the higher Hia SBA GMTs in the Indigenous population were due to increased circulation of Hia 
and prevalence of invasive Hia disease in the First Nations communities of northwestern Ontario, 
antibody concentrations and functional abilities were assessed in First Nations adults from 
northwestern Ontario (FNNO) and southern Ontario (FNSO). The antibody concentrations and 
SBA titres of First Nations adults were compared to those of non-First Nations adults from 
Kenora, located in northwestern Ontario (NFNK) and non-Indigenous elderly non-frail adults (≥ 
65 years old) from across Canada (NFNC). The highest SBA titres were found in the FNSO 
group, but both FNSO and FNNO had significantly higher SBA GMTs compared to NFNC and 
slightly higher GMTs compared to NFNK. Similarly, FNSO had the highest IgM GMCs 
followed by FNNO, NFNK and NFNC. There were no significant differences in IgG GMCs 
between groups, but FNNO and FNSO had a higher ratio of IgM to IgG, while NFNK and 
NFNC had a higher ratio of IgG to IgM. This study found that amount of naturally acquired 
antibodies against Hia are higher in First Nations adults and is not dependent on potential 
exposure to Hia. It is still unclear how these antibodies are acquired, but it is thought that they 
are part of the natural antibody repertoire that is present without the requirement of antigenic 
stimulation in the First Nations population (50).  
 
Virulence factors as potential vaccine candidates against non-Haemophilus influenzae type 
b strains 
 Currently there is no vaccine available to protect against non-Hib strains. The study by 
Nix et al. (2018) (50) addressed two questions, whether bactericidal Hia antibodies are strain 
specific and what antigenic components of Hia are recognized by these antibodies. To answer the 
first question, serum bactericidal activity against strains that do not circulate locally and do not 
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belong to sequence type 23 were measured. Pooled serum of First Nations adults from 
northwestern Ontario showed bactericidal activity for invasive isolates from Manitoba that were 
not genetically related to sequence type 23 and have not caused disease in northwestern Ontario. 
To determine which antigenic components of Hia are recognized by antibodies that result in 
bactericidal activity, antigen specific antibodies were absorbed. When cross-reactive Hia 
capsular polysaccharide antibodies (antigenically distinct Hib or Streptococcus pneumoniae 
serotype 6B) as well as protein D specific antibodies were absorbed separately, the remaining 
serum had significantly decreased bactericidal activity. When Hia capsular polysaccharide 
specific antibodies and lipooligosaccharide (LOS) specific antibodies were absorbed 
individually, a significant decrease in serum bactericidal activity occurred (50). Choi et al. 
(2015) (51) also found that naturally acquired LOS antibodies significantly contribute to the 
serum bactericidal activity against encapsulated and non-typeable H. influenzae strains (51). 
LOS is similar to lipopolysaccharide (LPS) but lacks repeating units of O-antigen side chain. 
LOS stimulates the expression of antigen presenting and co-stimulatory molecules but has 
decreased pro-inflammatory abilities than LPS, which makes it a promising vaccine candidate 
(52). These studies demonstrate the importance of Hia capsular polysaccharides and LOS as 
potential vaccine candidates against Hia and possibly H. influenzae non-typeable strains.  
  
Streptococcus pneumoniae 
Streptococcus pneumoniae (pneumococcus) a Gram-positive diplococcus, encapsulated 
extracellular bacterium that colonizes the upper respiratory tract and spreads through respiratory 
droplets (53, 54). There are 98 different serotypes that have been identified through antigenic 
differences in the polysaccharide capsule (55). Pneumococcus can cause non-invasive disease 
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(e.g. otitis media, sinusitis, non-bacteremic pneumonia) and invasive disease (e.g. meningitis, 
septicemia, pericarditis, etc.) when it overcomes host defenses (56, 57). It is the most common 
cause of community acquired pneumonia (CAP) worldwide (58). Children under 5 years of age, 
the elderly, and immunocompromised adults have the highest incidence of invasive 
pneumococcal disease (IPD) and CAP (56, 59). The majority of global CAP cases are caused by 
S. pneumoniae, and 30-70 % of adult CAP cases require hospitalization (58, 60). 
 
Invasive pneumococcal disease and community acquired pneumonia in Canada 
There are multiple studies that discuss IPD and CAP in Canada, but the two studies 
described have collected data from across Canada and have the most recent data. 
  The streptococcus annual 2017 report by the National Microbiology Laboratory (NML) 
reported in 2017 there were 3006 isolates that caused IPD in Canada. The five most predominant 
serotypes that caused IPD were 3, 22F, 4, 9N and 8. There are two pneumococcal vaccines 
available in Canada, the 23-valent penumococcal polysaccharide vaccine (PPV23) and the 13-
valent pneumococcal protein-polysaccharide conjugate vaccine. Of the five serotypes identified 
that resulted in the highest amount of IPD cases, all five are serotypes included in PPV23 and 2/5 
are included in PCV13. When adult IPD cases were separated based on age, there were three 
groups: 15 – 49, 50 – 64 and ≥ 65 years. The five serotypes causing the highest incidence of IPD 
for the adult groups are: serotypes 4, 12F, 3, 7F and 8 for the 15 – 49 years group, serotypes 3, 4, 
22F, 9N and 20 for the 50 – 64 years group, and serotypes 22F, 3, 15A, 9N and 23A for the ≥ 65 
years group. Of the 3006 isolates, nearly half (1238 isolates) were from the ≥ 65 years group 
(61).  
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The Serious Outcomes Surveillance (SOS) of the Canadian Immunization Research 
Network (CIRN) investigated the incidence of hospitalized CAP cases from nine hospitals 
located in British Columbia, Ontario, Québec, New Brunswick and Nova Scotia in December of 
2010. There were 4769 all-cause CAP cases, of these 434 had pneumococcal tests performed on 
blood, sputum and urine along with nasopharyngeal swabs analyzed. The majority of these cases 
were in adults 65 years and older with comorbidities. Of these cases, 22.1% (96/ 434) were 
pneumococcal CAP cases, among these cases 29.2 % were bacteremic and 70.8% were non-
bacteremic. The five serotypes that caused most pneumococcal CAP cases were 7F, 3, 19A, 22F 
and 6A. Of these serotypes 3/ 5 are included in both PPV23 and PCV13, while serotype 22F is 
included in PPV23 and serotype 6A is included in PCV13 (62).  
 
Invasive pneumococcal disease in the First Nations Indigenous population in northwestern 
Ontario 
Eton et al. (2017) (46) investigated the incidence of IPD in northwestern Ontario through 
retrospective chart review of the Sioux Lookout Meno Ya Win Health Center (SLMHC). The 
incidence of IPD over a 5.5-year period from January 2010 – July 2015 was 23.1/ 100 000/ year, 
more than double the 2013 rate for all of Canada (9.0/ 100 000/ year). The age specific incidence 
of IPD was highest in the 71-75 years group (106.5/ 100 000/ year) (46). Eton and Ulanova 
(2018) (63) also investigated the incidence of IPD in Kenora, Ontario Lake of the Woods District 
Hospital (LTWDH). Between 2010 – 2016 there were 31 cases of IPD in individuals 3 – 90 years 
old (mean age = 51.3 years). Nearly half of the cases occurred in individuals that identified as 
Indigenous (48.4%) and 90% of cases occurred in individuals with underlying conditions. The 
incidence of IPD was 26.6/ 100,000/ year which at the time was almost three times the rate for 
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the whole Canadian population 9.0/ 100,000/ year. Serotypes that caused the highest incidence of 
disease were 3 (23%), 22F (10%), 20 (7%), and 15C (7%). Serotypes (35B, 33F, 19A, 16F, 15B, 
15C, 12F, 11A, 9N, and 8) caused 3% of IPD cases. For 19.4% of cases the serotype was not 
specified. In a large proportion of adult cases (66.7%), IPD was caused by serotypes included in 
PPV23. For the pediatric cases (2 of the 31 total cases), all serotypes that caused IPD were not 
serotypes that are included in PCV13 (63). A study by our group evaluated hospitalized cases of 
IPD in adults residing in Thunder Bay, Ontario that occurred between 2006 and 2015. It was 
reported that 29.1% of patients with IPD were Indigenous, and the likelihood of 
immunocompromising conditions was higher amongst the Indigenous patients than in the non-
Indigenous. Of the serotypes that were isolated 79.2% were included in PPV23 and 28.3% in 
PCV13. The incidence rate in adults 18 – 64 years old was 8.9 – 25.9/ 100,000/ year and for 
adults ≥ 65 years old the range was 18.5 – 60.7/ 100,00/ year (64). These studies demonstrate the 
increased rate of IPD in northwestern Ontario and the high proportion Indigenous peoples with 
comorbidities being hospitalized with IPD.  
 
Risk factors for invasive pneumococcal disease  
It has been found that the incidence of IPD is 3 - 5 times more common amongst 
Indigenous Navajo adults compared to the general US population. The risk factors for IPD 
include CKD, congestive heart failure, alcohol use or alcoholism, extremely high or low body 
max index (BMI), and unemployment are more prevalent in Navajo communities compared to 
the general United States population (65). Similarly, to this North American Indigenous 
population, Indigenous Canadians have an increased prevalence of diseases such as obesity, 
diabetes, circulatory diseases and cancer resulting in a decreased life expectancy (66). These 
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studies suggest that the increased incidence rate of IPD could be due to the higher proportion of 
Indigenous peoples that suffer from IPD risk factors, which result in immune dysfunction within 
the FN population (1).  
 
Pneumococcal vaccination programs and recommendations for adults 
Pneumococcal immunization programs are publicly funded in Canada for specific groups 
at increased risk for IPD. PPV23 was implemented for adults 65 years and older in 1996. In 2005 
the 7-valent pneumococcal protein-polysaccharide conjugate vaccine (PCV7) for infants was 
introduced, but replaced in 2009 with PCV10, then PCV13 in 2010 (67). The two pneumococcal 
vaccines currently used in Canada are PPV23 and PCV13. PPV23 contains purified capsular 
polysaccharides from the 23 pneumococcal serotypes most commonly associated with IPD (1, 2, 
3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). 
It is currently recommended in Canada for adults with CKD (68). PPV23 and PCV13 have 12 
serotypes in common, with serotype 6A being unique to PCV13. The PCV13 consists of purified 
capsular polysaccharides of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, and 
23F) conjugated to a carrier protein (CRM197). PCV13 is routinely used for immunization of 
young children and is recommended for some categories of immunocompromised adults, such as 
those with asplenia or splenic dysfunction, bone marrow transplantation recipients, HIV-infected 
individuals etc. (69). As of 2016, the National Advisory Committee on Immunization updated 
pneumococcal immunization recommendations for healthy adults 65 years and older. If adults 
have not previously received PPV23, they are to receive one dose of PCV13 followed by one 
dose of PPV23. If they have been immunized with PPV23 previously, they are to receive one 
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dose of PCV13, but depending on age and IPD risk they may need an additional dose of PPV23 
(70).  
Although there are publicly funded pneumococcal immunization programs for adults at 
increased risk for IPD in Canada, pneumococcal vaccine uptake in adults is low. Statistics 
Canada reported that amongst the adult population with chronic conditions, only 17.3% (13.7 - 
20.8, 95% confidence intervals, CI) of 18 – 64 year-olds and 36.5% (32.7 – 40.3, 95% CI) of 65 
years and older, correspondingly, received at least one dose of PPV23 (71). 
 
Effectiveness and immunogenicity of PPV23 
The publicly funded pneumococcal immunization program with PPV23 for adults of 65 
years and older was implemented in Canada in 1996. A study conducted by Toronto Invasive 
Bacterial Diseases Network (TIBDN) investigated the incidence of IPD between 1995 – 2011. 
Prior to the introduction of PCV7 in 2005, the incidence of IPD caused by the 23 serotypes in 
PPV23 decreased by 49% in older adults. The estimated vaccine efficacy of PPV23 for all 
eligible adults was found to be 42.2%. For other groups such as healthy adults 65 years and 
older, PPV23 efficacy was 68.6% and for adults of any age with immunocompromising 
conditions efficacy was 23.3% (72).  
Immunogenicity of PPV23 in adults has been previously assessed using the 
opsonophagocytic assay (OPA). Shiramoto et al. (2015) (73) immunized healthy pneumococcal 
vaccine naïve adults ≥ 65 years with one dose of PPV23. The OPA GMTs were significantly 
higher one month post-immunization and the fold change was between 8.2 – 65.4 times higher 
than pre-immunization (73). Ahn et al. (2015) (74) also assessed OPA GMTs of pneumococcal 
vaccine naïve adults ≥ 65 years post PPV23 with underlying conditions (e.g. diabetes, cardiac 
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disease etc.). Participants were separated based on age, group 1 (65 – 74 years) and group 2 (≥ 
75 years). The range of the proportions of participants that were able to have a ≥ four-fold OPA 
GMT increase was 53% - 93% for group 1, and 38% - 84% for group 2 (74). Ciprero et al. 
(2016) (75) assessed the response to PPV23 with ELISA and defined a response to immunization 
as a ≥ two-fold increase in IgG for adults ≥ 50 years. For the six serotypes tested, the range of the 
proportion of participants that achieved ≥ two-fold increase was 79.2% - 89.6% (75). However, 
in comparison to younger adults, elderly adults have been found to have decreased OPA titres 
compared to younger adults. Younger adults had significantly higher IgG, IgM and IgA 
concentrations post-PPV23 compared to pre-immunization for the two serotypes tested. The 
elderly participants only had higher IgM concentrations for one serotype and higher IgG 
concentrations for both serotypes, suggesting that PPV23 is less immunogenic in elderly adults 
(76). These studies demonstrate that older adults have the ability to respond to PPV23 but it is 
less immunogenic compared to responses in younger adults. However, the data is difficult to 
interpret because there is no accepted OPA titre or antibody concentration that would suggest 
prevention of IPD in adults.  
 
Immunogenicity of PPV23 in adults with CKD  
A study by Mahmoodi et al. (2009) (77) evaluated for antibody response to PPV23 in 
CKD patients 18 – 64 years and controls. Because there is no minimum antibody concentration 
known to prevent IPD in adults, response to immunization was based on healthy control IgG 
concentrations. Of the 66 vaccinated CKD patients, 21% were categorized as hyporesponsive to 
PPV23, while 79% responded. The hyporesponsive patients had significantly lower 
concentrations and fold-changes in IgG concentrations compared to the CKD patients that 
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responded to PPV23 and healthy controls 1-month post-immunization. There was no significant 
difference in IgG fold changes between healthy controls and the CKD patients that responded to 
PPV23. The hyporesponsive patients also had a higher incidence of pneumococcal infections (18 
infectious episodes in the hyporesponsive group compared to 1 infectious episode in the 
responsive group) (77). Pourfarziani et al. (2008) (78) immunized kidney transplant recipients 
and stable dialysis patients with one dose of PPV23. One-month post-PPV23 antibody 
concentrations were significantly higher and remained higher 6 months post-immunization 
compared to pre-immunization concentrations. However, concentrations 1-year post-
immunization were significantly lower compared to 6 months post-immunization (78). Similarly, 
Kazancioglu et al. (2000) (79) found that antibody concentrations of renal transplant patients 
were significantly higher 6 and 12 weeks post-PPV23 for 20/ 21 participants compared to pre-
immunization concentrations however, antibody concentrations were not measured past 12 
weeks post-PPV23 (79). These studies suggest that some patients with CKD and renal transplant 
patients are able to respond to PPV23, however the response appears to be inconsistent and 
suboptimal.   
 
Effectiveness of pneumococcal conjugate vaccines and immunogenicity of PCV13 
 The effectiveness of pneumococcal conjugate vaccines has had a significant impact on 
the incidence of IPD in Canada. TIBDN investigated the incidence of IPD between 1995 – 2011, 
and since the introduction of the publicly funded pneumococcal infant immunization program 
with PCV7 in 2005, the incidence of IPD in Ontario has decreased significantly. Between 2001 
and 2011, the incidence of IPD caused by PCV7 serotypes decreased by 88% in adults 15 – 64 
years old and by 89% in adults ≥ 65 years old, but IPD caused by serotypes not included in 
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PCV7 increased. The incidence of PCV10 and PCV13 serotypes that caused IPD in adults 
increased until their implementation in 2009 and 2010 (72). Between 2010 to 2016, 3787 IPD 
cases in adults ≥ 65 years old from British Columbia, Saskatchewan, Manitoba, Ontario, New 
Brunswick, Nova Scotia, Prince Edward Island, Yukon, Northwest Territories and Nunavut were 
collected from public health laboratories for isotype identification at the NML. It was found that 
over the 6-year period, the number of IPD cases did not change significantly, but the incidence of 
IPD caused by serotypes included in PCV13 decreased and IPD caused by non-PCV13 vaccine 
serotypes increased. The incidence of IPD cases caused by all serotypes included in PCV13 
decreased from 48.6% to 25.2% in Canada (80). These studies demonstrated that pneumococcal 
conjugate vaccines are effective in reducing the incidence of IPD in adults. 
PCV13 has been shown to be immunogenic for healthy adults and those with 
comorbidities such as diabetes mellitus, heart disease, liver disease etc. A study by van Deursen 
et al. (2017) (81) compared responses to PCV13 and a placebo in adults ≥ 65 years old who were 
pneumococcal vaccine naïve. The main finding from the study was that PCV13 was able to 
significantly increase OPA GMTs and IgG concentrations compared to pre-immunization in 
immunocompetent adults. OPA GMTs and IgG concentrations remained higher than pre-
immunization 2 years post-PCV13 regardless of age or comorbidity (81). Because PPV23 and 
PCV13 are recommended for adults in Canada, studies that have assessed the immunogenicity of 
PCV13 and compared responses to PPV23 will be discussed. Jackson et al. (2013) (82) found 
that in adults 60 – 64 years old immunized with PCV13 had significantly higher OPA GMTs for 
9/ 13 serotypes compared to participants immunized with PPV23 (82). Shiramoto et al. (2015) 
(73) also immunized healthy adults ≥ 65 years old with either PPV23 or PCV13. One month 
post-immunization PCV13 immunized participants had significantly higher OPA titers for 9/ 12 
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shared serotypes and 6A compared to PPV23 immunized participants (73). These studies 
demonstrate that PCV13 is more immunogenic in older adults compared to PPV23. 
 PPV23 is recommended for adults ≥ 65 years old, therefore it is important to investigate 
the effect of previous PPV23 immunization on subsequent immunization with PCV13. Another 
study by Jackson et al. (2013) (83) assessed the immunogenicity of PCV13 in adults ≥ 70 years 
that were previously immunized with PPV23. Compared to adults that only received one dose of 
PCV13, adults that were immunized with PPV23 followed by PCV13 had significantly lower 
OPA GMTs for all 13 serotypes. Greenberg et al. (2014) (84) immunized pneumococcal vaccine 
naïve adults aged 60 – 64 years old with PPV23 followed by PCV13 one year later. OPA GMTs 
in adults immunized with PPV23 followed by PCV13 were significantly lower for all 13 
serotypes compared to adults immunized with one dose of PCV13 (84). These studies suggest 
that previous immunization with PPV23 has a negative effect on the immunogenicity of 
subsequent immunization with PCV13.  
 
Immunogenicity of PCV13 in adults with CKD 
 There have been two studies that have assessed the immunogenicity of PCV13 in adults 
with CKD. Mitra et al. (2016) (85) immunized patients with CKD ≥ 50 years old, a portion of 
these patients received PPV23 ≥ 5 years prior to PCV13 but the number was not specified. 
Patients were considered to have responded to PCV13 if IgG concentrations post-immunization 
were ≥ 1 µg/ mL and increased ≥ two-fold. All patients responded to at least one serotype at 2 
and 12 months post-PCV13. Two months post-immunization 53% of the patients responded to 
10/ 13 serotypes. At 12 months post-immunization, 24% of patients responded to 10/ 13 
serotypes and 35% of participants responded to 3/ 13 serotypes. This study suggests that CKD 
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patients are able to respond to PCV13, but responses decrease 1-year post-PCV13 (85). The 
second study by Vandecasteele et al. (2018) (86) consisted of adults with CKD that were either 
pneumococcal vaccine naïve or previously immunized with PPV23. Antibody concentrations 
were back-transformed and reported as ELISA GMTs, OPA GMTs were also reported. At day 
28, ELISA GMTs for pneumococcal vaccine naïve patients immunized with PCV13 were 1.85- 
to 2.34-fold higher for 6/ 13 serotypes compared to pneumococcal vaccine naïve patients 
immunized with PPV23. There were no significant differences in OPA GMTs between groups. 
At day 365, ELISA GMTs for pneumococcal vaccine naïve patients immunized with PCV13 
were significantly higher for serotype 6A only compared to pneumococcal vaccine naïve patients 
immunized with PPV23. This suggests that in pneumococcal vaccine naïve CKD adults, PCV13 
is more immunogenic compared to PPV23. Next, CKD patients previously immunized with 
PPV23 were compared to pneumococcal vaccine naïve patients. Pre-immunization with PCV13, 
ELISA GMTs were significantly lower in pneumococcal vaccine naïve patients for 2/ 13 
serotypes and 4/ 13 serotypes for OPA GMTs compared to patients previously immunized with 
PPV23. At day 28 post-PCV13, pneumococcal vaccine naïve patients had significantly higher 
ELISA GTMs for 12/ 13 serotypes, and 11/ 13 serotypes for OPA GMTs. At day 28 post-
PCV13, pneumococcal vaccine naïve patients had significantly higher ELISA GTMs for 10/ 13 
serotypes, and 9/ 13 serotypes for OPA GMTs (86). This study suggests that immunization with 
one dose of PCV13 is immunogenic in adults with CKD and previous immunization with PPV23 
decreases antibody responses to PCV13.  
 
B-cell responses to pneumococcal immunization 
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A small number of studies have quantified B cell subpopulations to determine if 
pneumococcal specific immunological memory has been established post-immunization. Some 
of these studies have compared B-cell responses to PPV23 and PCV7 in healthy adults, but none 
in response to PCV13. The studies that have compared B-cell responses to PPV23 and PCV7 in 
healthy adults will be described. In the study by Baxendale et al. (2010) (87) healthy adults aged 
52 – 74 years old and received either one dose of PPV23 or PCV7. Exclusion criteria included 
immunization with PPV23 ≤ 5 years, but the proportion of the participants that were previously 
immunized with PPV23 was not reported. There were no significant differences in 
pneumococcal memory B cells detected through enzyme-linked immunospot assay (ELISPOT) 
between healthy adults immunized with PPV23 or PCV7 day 7 or day 28 post-immunization 
(87). Truck et al. (2013) (88) immunized healthy pneumococcal vaccine naïve adults 50 – 70 
years old with either one dose of PPV23 or PCV7. Memory B cells specific for pneumococcal 
serotypes 1 and 3 were detected via ELISPOT. One-month post-immunization numbers of 
memory B cells specific for serotype 1 did not change significantly in PCV7 immunized adults, 
but adults immunized with PPV23 experienced a significant decrease in memory B cells 
compared to pre-immunization numbers. Similarly, PPV23 immunized adults experienced a 
decrease in serotype 3 specific memory B cells compared to pre-immunization numbers while 
PCV7 immunized adults had no significant difference in memory B cells 1-month post-
immunization (88). Clutterbuck et al. (2012) (89) investigated combinations of pneumococcal 
immunization schedules in the same adults that participated in Truck et al. (2013) (88). Memory 
B cells were quantified using both ELISPOT and flow cytometry analysis. One-month post-
immunization, adults immunized with PCV7 had an increase in memory B cells while adults 
immunized with PPV23 had a decrease in memory B cells compared to pre-immunization. Six 
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months post-immunization, adults that were immunized with PCV7 experienced a decrease in 
the number of memory B cells back to pre-immunization amounts, and the numbers of memory 
B cells in the PPV23 immunized adults decreased further below pre-immunization amounts. To 
summarize, these studies suggest that immunization with PCV7 does not have a negative effect 
on the memory B cell population in healthy adults. However, the study by Truck et al. (2013) 
and Clutterbuck et al. (2012) suggests that immunization with PPV23 may have a negative effect 
on the numbers of serotype specific memory B cells. 
The study by Clutterbuck et al. (2012) (89) also measured pneumococcal specific class 
switched memory B cells (CD19+CD20+CD27hiIgM-) for two groups of adults that received 
either two doses of PCV7 (PCV7-PCV7) or one dose of PPV23 followed by PCV7 (PPV23-
PCV7). One month after the second immunization, PCV7-PCV7 adults had more class switched 
memory B cells compared to the PPV23-PCV7 group. This study also investigated the change in 
CD5 expression in B cells within the B1 (CD19+CD20+CD27-IgMhi) B cell population. Two 
populations were quantified, the B1a (CD5int) and B1b (CD5-). The B1b subpopulation was 
quantified because these cells have an important role in protecting mice against pneumococcus. 
There were no significant differences between groups in the amounts of B1a, but the PPV23-
PCV7 group had less B1b cells compared to the PCV7-PCV7 group (89). Moens et al. (2015) 
(90) investigated the roles of CD5+ and CD5- B cells in the antibody responses to pneumococcal 
capsular polysaccharides. It was found that CD5- B cells produced in response to PPV23 have an 
important role in producing IgG specific for pneumococcal capsular polysaccharides. A positive 
association was found between the concentrations of IgG capsular polysaccharide antibodies and 
the number of CD5- B cells (90). In the Clutterbuck et al. (2012) (89) study the PPV23-PCV7 
immunized adults also experienced decreased antibody concentrations also known as 
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hyporesponsiveness in addition to decreased memory B cells and CD5- B cells compared to 
PCV7-PCV7 immunized adults. The capsular polysaccharides in PPV23 stimulate a T cell-
independent response of marginal zone B cells that does not result in the production of class 
switched memory B cells. The decreased antibody response and decline in memory B cells in 
adults immunized with PPV23 is thought to be due to PPV23 driving pre-existing class switched 
memory B cells to terminal differentiation and depletion of the memory B cell pool making the 
response to subsequent doses with PCV7 to be decreased (89).  
 
B-cell responses to pneumococcal immunization in immunocompromised adults 
B-cell responses to pneumococcal immunizations have not been previously measured in 
patients with CKD, therefore studies that have assessed responses in adults with 
immunocompromising conditions will be described. Farmaki et al. (2018) (91) immunized HIV 
positive adults with one dose of PCV13 followed by one dose of PPV23 1 year later. Patients 
were excluded from the study if they were previously immunized with PCV13 or PPV23 ≤ 1 
year ago. Flow cytometry quantified class switched memory B cells (CD19+CD10-
CD21++CD27+IgM- and IgM memory B cells (CD19+CD10-CD21++CD27+IgM+). Memory B 
cell numbers were not negatively affected by PCV13 after 1 month and the numbers did not 
significantly decrease at 12 months post-immunization. When patients received PPV23, there 
was a significant decrease in the IgM memory B cell pool compared to pre-immunization with 
PCV13. However, amounts of class switched memory B cells remained higher than pre-
immunization with PCV13 (91). Papadatou et al. (2014) (92) immunized adults with β-
thalassemia and asplenia between 19 – 48 years old that were previously immunized with one 
dose of PCV7 as well as 1– 4 doses of PPV23. All patients were vaccinated with one dose of 
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PCV13 and memory B cells were quantified using ELISPOT. It was found that as the number of 
PPV23 doses increased, the numbers of pneumococcal memory B cells decreased (92). These 
studies suggest that immunization with PPV23 has a negative effect on pre-existing memory B 
cells in immunocompromised adults.  
 
Conclusion  
Patients with CKD in northwestern Ontario are at increased risk for invasive disease 
caused by pneumococcus and Hia. Due to their immune dysfunction, immunization is needed to 
maintain immunological memory by stimulating the production of antigen specific memory B 
cells and antibodies. Based on previous studies on humoral immune responses to conjugate 
vaccines to prevent disease caused by pneumococcus and Hib, these vaccines are able to elicit a 
response in these patients suggesting immunological memory has been established. This also 
suggests that immunization with a new conjugate Hia vaccine could be successful. However, it is 
uncertain how long protection will last. Considering the conflicting data on responses to PCV13 
in adults with CKD, it is also important to determine the effect of previous capsular 
polysaccharide immunization on responses to protein-polysaccharide conjugate vaccine 
responses in adults with CKD. More studies will need to be performed in order to establish an 
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Chapter 1B: Research Rationale, Questions, Hypotheses and Objectives  
Adults with CKD are immunocompromised which makes them more susceptible to 
infections. In northwestern Ontario, there is an increased prevalence of CKD in the First Nations 
population compared to non-First Nations adults. Amongst the First Nations population of 
northwestern Ontario, there is also an increased incidence of invasive disease caused by H. 
influenzae type a (Hia) and S. pneumoniae (pneumococcus). In order to maintain immunological 
memory in adults, stimulation of pre-existing memory is achieved through immunization. 
Therefore, in order to determine if patients with CKD have the ability to respond to 
immunization, naturally acquired humoral immunity against Hia and pneumococcus needs to be 
evaluated in adults with CKD. Quantification of naturally acquired B-cell subpopulations and 
antigen specific antibodies in Canadian adults with CKD have not been investigated previously. 
Immunization against pneumococcus is recommended for adults with CKD in Canada, however 
immunization with PPV23 is suboptimal at inducing antibody responses in adults with CKD 
compared to healthy adults. PCV13 is recommended for certain groups of immunocompromised 
adults, but there have been only two studies that have measured the immunogenicity of PCV13 
in adults with CKD with conflicting results. Quantification of B-cell subpopulations, 
pneumococcal specific B cells and their relationship with antibody responses to PCV13 have not 
been reported previously. In addition, the effect of previous immunization with PPV23 in 
response to PCV13 on B-cell and antibody responses in adults with CKD have not been 
previously investigated.  
The first question that will be addressed is: are there differences in naturally 
acquired humoral immunity against Hia and pneumococcus in healthy adults and adults 
with CKD, or First Nations and non-First Nations adults of the same health status? Due to 
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the immune dysfunction in adults with CKD, it is hypothesized that humoral immunity against 
Hia and pneumococcus could be decreased in CKD patients compared to healthy adults. The 
increased incidence of invasive disease in the First Nations population of northwestern Ontario, 
also suggests that humoral immunity in First Nations adults could be decreased compared to non-
First Nations adults. Chapters 2 and 3 will address this question.  
Chapter 2 objectives 
1. Quantify the proportions and absolute numbers of B cells and subpopulations in First 
Nations and non-First Nations patients with CKD. 
2.  Quantify the concentrations of IgM and IgG Hia capsular polysaccharide specific antibodies 
and the functional abilities of Hia antibodies.  
3. Determine if there are differences between healthy adults and adults with CKD in the 
proportions of B cells and B-cell subpopulations, as well as Hia antibody capsular 
polysaccharide specific concentrations and functionality.  
Chapter 3 objectives  
1. Compare the concentrations of naturally acquired IgG antibodies against pneumococcal 
serotypes 6B and 14 in pneumococcal unimmunized First Nations and non-First Nations 
healthy adults.  
2. Compare the concentrations of naturally acquired IgG antibodies against pneumococcal 
serotypes 6B and 14 in healthy adults with pneumococcal unimmunized First Nations and 
non-First Nations adults with CKD.  
 The second question that will be addressed is: are adults with CKD able to respond 
to PCV13 immunization and does previous immunization with PPV23 affect their ability to 
respond to subsequent immunization with PCV13? Although patients with CKD are 
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immunocompromised, they have shown the ability to respond to the conjugate Hib vaccine, 
therefore it is hypothesized that they will be able to respond to PCV13. Considering that other 
studies have shown that previous immunization with PPV23 has a negative effect on 
pneumococcal specific humoral immune response to subsequent immunization with PCV13, it is 
hypothesized that patients with CKD that have previously been immunized with PPV23 will also 
have decreased humoral immune responses to immunization with PCV13. Chapters 4A and 4B 
will address this question by quantifying humoral immune responses to immunization with one 
dose of PCV13 in CKD patients that are either pneumococcal vaccine naïve or have received 
PPV23 ≥ 1 year ago.  
Chapter 4A objectives 
1. Quantify the proportions and absolute numbers of B cells and subpopulations pre-
immunization and 7 days post-immunization.  
2. Quantify the numbers of total IgG and antigen specific (pneumococcal serotypes 6B and 14) 
antibody secreting cells 7 days post-immunization.  
Chapter 4B objectives 
1. Quantify IgG, IgM and IgA concentrations pre-immunization, day 28 and day 365 post-
immunization specific for seven pneumococcal serotypes (3, 6B, 9V, 14, 19A, 19F, and 
23F). 
2. Perform correlation analyses to determine the relationship between B cells and the fold 
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Abstract 
Individuals suffering from severe chronic kidney disease (CKD) are 
immunocompromised and therefore highly susceptible to various infections including 
Haemophilus influenzae type a (Hia), an emerging pathogen in North American Indigenous 
populations. Immunocompromised Indigenous adults are considered a target for a new Hia 
vaccine under development. In an attempt to foresee their response to Hia immunization, we 
studied natural immunity against Hia and B-cell subpopulations in sixty patients with CKD 
residing in a geographic region with noticeable presence of Hia invasive disease. Serum 
bactericidal activity (SBA) against Hia, concentrations of IgG and IgM antibodies specific to Hia 
capsular polysaccharide, and B-cell subpopulations were studied in patients with CKD and 35 
healthy controls of the same age. Of the patients with CKD, proportions and absolute numbers of 
B-cell subpopulations were determined for 28 patients. The patients had lower SBA titres 
compared to controls.  Although no significant differences in anti-Hia IgG or IgM antibody 
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concentrations between control and CKD groups were found, IgM antibody concentrations were 
higher in Indigenous than non-Indigenous patients. Patients with CKD had a higher proportion of 
B cells (CD19+), class switched memory B cells (CD19+CD27+IgM-) and a lower proportion of 
CD19+CD27-IgM- B cells compared to healthy controls. Non-Indigenous patients with CKD 
had significantly higher proportions of IgM memory B cells and CD19+CD27-IgM- B cells 
compared to Indigenous patients with no significant difference in absolute numbers. Because 
72% of CKD patients had detectable SBA titres and 100% had detectable IgG and IgM 
antibodies it is possible that a portion of IgM memory B cells and class switched memory B cells 
are specific for Hia resulting from a natural exposure to the pathogen. The data suggest that a 
Hia-conjugate vaccine may be immunogenic in adult patients with CKD as it will potentially 
induce re-activation of immunological memory against Hia.  
 
Key Words: B cells, Haemophilus influenzae type a, severe chronic kidney disease, flow 
cytometry analysis, serum bactericidal assay, ELISA. 
 
Introduction 
Severe chronic kidney disease (CKD) is defined as a decreased kidney glomerular 
filtration rate (GFR) of less than 30 mL/ min/ 1.73m2 for a minimum of 3 months, and is a 
serious condition characterized by high mortality rates (1, 2). Increased inflammatory responses 
and reactive oxygen species generation associated with uremia contribute to the development of 
other conditions, such as cardiovascular disease and cancer (3). Infection is the second major 
cause of death in these patients after cardiovascular disease (4). In patients with CKD, a high risk 
for septicemia and other severe infections is attributed to their compromised immune system and 
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increased exposure to infectious agents in dialysis units (5, 6). In North America, CKD 
disproportionally affects Indigenous populations. The burden of CKD among Indigenous peoples 
is mostly influenced by dramatically rising incidence of obesity and type 2 diabetes mellitus 
resulting in diabetic nephropathy as well as a high rate of glomerulonephritis (7, 8).    
Haemophilus influenzae type a (Hia) is an emerging infection in North American Indigenous 
populations; invasive Hia disease mostly affects young children, the elderly, and 
immunocompromised individuals (9-11). Our studies over the last 15 years have shown that 
invasive Hia disease is consistently present in Northwestern Ontario, Canada (12). This 
geographic region has 25.4% population of Indigenous peoples (13), and several cases of 
invasive Hia disease occurred in Indigenous peoples suffering from CKD (11, 14, 15). A new 
vaccine against Hia is currently under development in Canada (16). Because 
immunocompromised individuals are highly susceptible to invasive Hia disease, patients with 
CKD are being considered as a target population for a new vaccine.  
We have recently found that healthy Indigenous adults have higher titres of serum 
bactericidal antibodies against Hia compared to non-Indigenous peoples living in the same 
region suggesting that they may have developed immunological memory against Hia as a result 
of exposure to the pathogen (10, 17). While long-lived plasma cells are directly responsible for 
antibody production, memory B cells generated during the primary immune response are able to 
mount rapid recall response upon secondary exposure to the same antigen (18, 19). Therefore, 
the effect of adult immunization is critically dependent on the presence of memory B cells. As no 
previous research on memory B cells in Indigenous patients with CKD had been done, we made 
an attempt to characterize their subpopulations in Indigenous and non-Indigenous patients. We 
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This study was approved by the research ethics boards of Lakehead University and the 
Thunder Bay Regional Health Sciences Centre (TBRHSC). Sixty patients with stage four or five 
CKD (stage 4, GFR < 30 mL/ min/ 1.73m2, stage 5, GFR < 15 mL/ min/ 1.73m2) (2) who 
received hemodialysis in the TBRHSC were recruited from May 2015- January 2018; all were 
required to provide informed consent before determining their eligibility for the study. Ethnicity 
was determined based on self-declaration. Patients with severe CKD were considered eligible if 
they: were over 18 years old, did not have a history of immunocompromising conditions, were 
not taking immunosuppressive medications for more than 14 days in the past 6 months, had not 
received any vaccine in the past month and were not receiving blood transfusions or blood 
products in the past 3 months. The majority of 35 healthy controls were recruited through the 
Thunder Bay 55 Plus Centre, and were considered eligible if they were over the age of 18 years 
old and did not have a history of taking immunosuppressive medications. Table 1 displays the 
demographics of study participants; supplementary table 1 describes additional information on 
the underlying causes of CKD and comorbidities.  
 
Analysis of B cells   
Peripheral blood mononuclear cells were isolated using Lymphoprep (Stemcell 
Tecnologies, Vancouver, BC, CAN). Monocytes were removed using two consecutive 
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incubations in complete culture medium, i.e. RPMI 1640 medium with L-glutamine (Fisher 
Scientific, Whitby, ON, CAN) and 1% antibiotic-antimicotic (Life Technologies, Burlington, 
ON, CAN) supplemented with 20% fetal bovine serum (FBS, Fisher Scientific) in a cell culture 
dish for 1 hr at 37°C, 5% CO2. Non-adherent cells were then washed and re-suspended in 
complete culture medium supplemented with 10% FBS at 2 x 106 cells/ mL. From the cell 
suspension, 200,000 cells were immunostained with PE Mouse Anti-Human CD19, APC Mouse 
Anti-Human IgM, and PerCP-Cy™5.5 Mouse Anti-Human CD27 at 4°C for 1 hr. Samples were 
analyzed with BD FACSCaliburä Flow Cytometer and CELLQUEST PRO software (BD 
Biosciences) to determine proportions of B cells (CD19+) and subpopulations: naïve (CD27-
IgM+), IgM memory (CD27+IgM+), CD27-IgM-, and class switched memory (CD27+IgM-) 
(Figure 1). Purity of CD19+ gated B cells was verified by counterstaining cells with FITC 
Mouse Anti-Human CD3 and PerCP-Cy™5.5 Mouse Anti-Human CD14 (BD Biosciences). 
Analysis of B cells was conducted for 28 out of 60 patients (supplementary table 2). For 
these patients, a complete blood count (CBC) was performed at the TBRHSC clinical lab to 
determine the lymphocyte count (x109 cells/ L). The absolute number of B cells was calculated 
by multiplying the percentage of CD19+ cells of the total gated lymphocyte population by the 
total lymphocyte count. Similarly, the numbers of B-cell subpopulations were determined by 
multiplying the percentage of each subpopulation by the absolute number of B cells 
(supplementary table 3).  
 
Analysis of Haemophilus influenzae type a specific antibodies 
Serum Bactericidal Assay (SBA) was performed as previously described (17) using Hia 
strain 08-191and baby rabbit complement (Pel-Freez, Rogers, AR, USA) as the exogenous 
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complement source. SBA titers were determined as the reciprocal serum dilution required to kill 
≥ 50% of the initial bacterial inoculum (20). Titers below the lower detection limit of 16 were 
reported as 8 for statistical purposes. 
IgG and IgM antibodies specific to Hia capsular polysaccharide were quantified by 
ELISA as previously described (10). Antibody concentrations were determined using our internal 
standard that was standardized to the Hia reference serum provided by the Centers for Disease 
Control and Prevention (10). The internal standard contained 1.25 µg/ mL anti-Hia IgG and 2.09 
µg/ mL anti-Hia IgM. The standard curve was made using a log-log non-linear regression to 
produce the line of best fit. Outliers were deleted and values were considered acceptable if the 
coefficient of variation was below 30%.  
 
Statistical Analysis  
Statistical analysis was performed using Graph-Pad Prism 5 (GraphPad Prism Software 
Inc., San Diego, CA). The means for the percentage of each B-cell subpopulation and absolute 
numbers of B cells were calculated as well as the geometric means for anti-Hia antibody 
concentrations and SBA titres with 95% confidence intervals (CI). Groups were compared either 
using a Student’s t-test, or Mann-Whitney U test, one-way ANOVA, or Kruskal-Wallis test 
depending on data distribution and number of groups compared. Correlation between antibody 
concentrations and B-cell subpopulations was determined using Pearson or Spearman’s 
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Results and Discussion 
To assess natural immunity against Hia in patients with severe CKD, we quantified 
functionally active antibodies using SBA, and anti-Hia capsular polysaccharide specific IgG and 
IgM using ELISA. The patients had lower geometric mean SBA titres than healthy controls (145, 
CI: 86.53 - 244.1 vs. 324.7, CI: 189.4 - 556.4, Student’s t-test, p < 0.05, figure 2A). Moreover, 
larger proportion of patients had SBA titres below lower detection limits compared to healthy 
controls, 28% (17/60) vs. 9% (3/35), p < 0.05 (Fisher’s exact test). These results are in agreement 
with our earlier observations suggesting that CKD may negatively affect natural immunity 
against Hia and therefore this patient population may be at risk of invasive Hia disease (10). 
However, no significant difference in SBA titres between healthy controls, CKD Indigenous, and 
CKD non-Indigenous patients was detected when a multiple comparisons test was performed 
(figure 2A-B). No significant difference in anti-Hia capsular polysaccharide IgM (1.0 µg/ mL, 
CI: 0.8 - 1.3 vs. 1.2 µg/ mL, CI: 0.9 - 1.5) or IgG (0.6 µg/ mL, CI: 0.4 - 0.9 vs. 0.5 µg/ mL, CI: 
0.4 - 0.7) concentrations between patients and controls was detected using either a Student’s t-
test or Mann-Whitney U test, or between healthy controls, CKD Indigenous, and CKD non-
Indigenous using a multiple comparisons test (p > 0.05) (figure 2C-F). 
While SBA geometric mean titres (GMT) in Indigenous CKD patients did not 
significantly differ from non-Indigenous patients (111.4, CI: 51.90 - 239.2 vs. 189.6, CI: 90.98 -
395.0, p > 0.05, figure 2B), the concentration of IgM antibodies specific to Hia capsular 
polysaccharide was significantly higher in Indigenous compared to non-Indigenous patients (1.4 
µg/mL, CI:1.0 - 1.9 vs. 0.7 µg/mL, CI: 0.5 - 1.1, Mann-Whitney U test, p < 0.05, figure 2D). No 
difference in specific IgG concentrations between these groups was detected (figure 2F).  
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In all the groups, the geometric mean concentrations of Hia capsular polysaccharide-
specific IgM were higher than the concentrations of specific IgG (figure 2C-F). Healthy controls 
had a slightly greater ratio of IgM to IgG compared to patients with CKD (2.4:1 vs. 1.7:1, p > 
0.05, figure 2C-E) while the Indigenous and non-Indigenous patients had similar ratios (1.8:1 vs. 
1.4:1, p > 0.05, figure 2D-F). These results confirm our previous findings on the prevalence of 
IgM in the anti-Hia capsular polysaccharide antibody repertoire and higher anti-Hia IgM 
concentrations in Indigenous than non-Indigenous adults (10, 17). Although the prevalence of 
IgM over IgG suggests that anti-Hia capsular polysaccharide antibodies may be part of the 
natural IgM antibody repertoire, this may also be an indicator of a recent exposure to the 
pathogen (17). Indeed, our epidemiological studies have found that during the last two decades, 
Hia has been consistently present in Indigenous communities of this geographic region (11, 14, 
15). Naturally acquired antibodies are largely determined by the colonization, and the 
colonization rates may vary among different populations depending on age, race, living 
conditions, and socio-economic status (22, 23). However, the relationship between the 
development of naturally acquired antibodies and H. influenzae colonization history is complex, 
and potential effects of some cross-reactive antigens present in the environment need to be 
considered (17). 
Severe CKD is associated with chronic inflammation (24). In other inflammatory 
diseases, such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and 
inflammatory bowel disease, B-cell subpopulations are often altered compared to healthy people 
(25). This suggests that patients with CKD may also have alterations in B-cell subpopulations. 
To determine proportions of B cells and their subpopulations, we have used flow cytometry 
analysis to detect the cell surface expression of CD19 as a marker for B cells and CD27 for 
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memory B cells (figure 1). IgM memory B cells and switched memory B cells were defined as 
CD19+CD27+IgM+ and CD19+CD27+IgM- cells, respectively (26).  
 Our analysis showed that patients with CKD had a higher percentage of B cells in 
comparison to healthy controls (11%, CI: 5.9 - 8.0 vs. 7%, CI: 8.4-13.7, Student’s t-test, p < 0.01, 
table 2), with no significant differences between Indigenous and non-Indigenous patients (p > 
0.05, table 2). There was a significant difference in the proportions of B cells between healthy 
controls, CKD Indigenous, and CKD non-Indigenous patients (one-way ANOVA, p < 0.01). 
Higher proportion of B cells in patients with CKD compared to healthy controls is likely due to 
chronic inflammation caused by uremia, and can be associated with common co-morbidities 
found in these patients, such as diabetes mellitus and chronic obstructive pulmonary disease (27, 
28). We also found that patients with CKD had significantly higher proportions of class switched 
memory B cells (CD19+CD27+IgM-) (22%, CI: 16.4 - 28.5 vs. 16%, CI: 12.2 - 19.1, Student’s t-
test, p < 0.05) and lower proportions of CD19+CD27-IgM- B cells (16%, CI: 13.1 - 19.2 vs. 20%, 
CI: 16.4 - 28.5, Mann-Whitney U test, p < 0.05) compared to the controls (figure 3A and B). 
When B-cell subpopulations were compared between healthy controls, CKD Indigenous and 
CKD non-Indigenous patients, no significant differences between the groups were found except 
for CD19+CD27-IgM- B cells (Kruskal-Wallis test, p < 0.001). 
The T-cell-dependent antibody response is characterized by the generation of class 
switched memory B cells (18). Upon re-exposure to the same antigen, these cells are able to 
respond rapidly resulting in the production of more antigen specific memory B cells as well as 
plasma cells that produce high affinity antibodies (19). An increase in proportion of class 
switched memory B cells in CKD patients could suggest that such patients have been exposed to 
pathogens more often than healthy controls. Indeed, patients with CKD undergoing hemodialysis 
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spend a lot of time in close proximity to other patients in the hospital environment, and 
experience frequent disruption of the skin barrier from needles or catheter ports. As part of the 
standard clinical practice these patients receive vaccines prescribed for high-risk adult 
populations (against pneumococcal, hepatitis B virus, and varicella zoster infections) that can 
potentially increase the population of class switched memory B cells.  
It is more difficult to interpret a decrease in the proportion of CD19+CD27-IgM- because 
these cells are not well characterized in the literature. Similarly, to these cells, the origin and 
functional roles of Double Negative (DN) B cells (CD19+CD27-IgD-) are uncertain. Because 
DN B cells accumulate in the elderly, it was suggested that these cells are the exhausted 
terminally differentiated memory B cells (29-31). Accordingly, a higher proportion of 
CD19+CD27-IgM- B cells (18%, CI: 13.4 - 22.6 vs. 13%, CI: 10.8 - 13.5, Mann-Whitney U test, 
p < 0.05) in non-Indigenous compared to Indigenous patients (figure 3D) may be due to the fact 
that the non-Indigenous patients were significantly older (69 ± 3 vs. 54 ± 3 years, Student’s t-
test, p < 0.01, supplementary table 2). 
We have also observed higher proportions of IgM memory B cells in non-Indigenous 
compared to Indigenous patients (12%, CI: 7.1 - 16.24 vs. 7%, CI: 4.3 - 9.5, Student’s t-test, p < 
0.05) (figure 3C). The IgM memory B cells are generated in the process of the T cell-
independent immune response and also increase with age (32-34) that may explain their higher 
proportion in the non-Indigenous group of CKD patients. It is tempting to speculate that higher 
IgM anti-Hia antibody concentrations found in Indigenous compared to non-Indigenous patients 
may potentially be associated with an increased proportion of IgM memory B cells, as previous 
studies demonstrated an essential role of this subpopulation in antibody response to bacterial 
capsular polysaccharides (26).  However, our analysis did not reveal any noticeable correlation 
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between B-cell subpopulations and antibody levels or SBA titres (data not shown). It is not 
surprising because antigen-specific B cells represent a very small fraction of the total B cell 
population.  For example, in healthy unimmunized adults, only 0.5% of total CD19+ B cells are 
specific to any individual pneumococcal polysaccharide antigen (35).  
For the interpretation of changes in B-cell subpopulations found in our patients, it is 
necessary to consider that the total numbers of B-lymphocytes may be decreased in CKD 
patients (36). We calculated the absolute numbers of B cells and their subpopulations for 28 
CKD patients (supplementary table 3). No significant differences between Indigenous and non-
Indigenous patients for absolute number of any of the subpopulations were found (supplementary 
table 3). Because the lymphocyte counts were not available in our control group we compared 
the absolute numbers of B cells and their subpopulations in CKD patients with published data 
(supplementary table 4a and b). The analysis indicated that approximately 60% of our patients 
(16/28) had total lymphocyte counts within normal limits defined by the Medical Council of 
Canada (1.0-4.0 x 109 cells/L) (37), and the remaining 12 had the counts below 1.0 x 109 cells/L. 
In comparison to absolute values of B-cell subpopulations in healthy adults between the ages of 
26 and 50 reported by Morbach et al. (38), our patients had lower numbers of total lymphocytes, 
total B cells, naïve B cells, and IgM (non-switched) memory B cells, but similar numbers of 
class switched memory B cells and higher numbers of CD19+CD27-IgM- compared to reported 
DN cells (supplementary table 4b). However, this comparison needs to be taken with caution 
because of age differences between our patients and their cohort of healthy adults (69 ± 3 vs. 54 
± 3 years, p < 0.01), as well as the use of different markers for defining naïve and IgM memory 
B cells (IgD+ rather than IgM+). Nevertheless, 93% (26/28 patients) of our CKD patients had 
numbers of B cells below the normal values reported by Morbach et al. (199 cells/ µL, age 26-50 
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years) (38) and Qin et al. 2016 (216 cells/ µL, age 19-80 years) (39). Similar to our findings, a 
previous study by Pahl et al. (2010) demonstrated that patients with end-stage renal disease had 
significantly reduced numbers of total B cells and their subpopulations including memory 
(CD19+CD27+) and naïve B cells (CD19+CD27-) in comparison to healthy controls (40). In that 
study, a decrease in the absolute numbers of B cells was found to be associated with a decrease 
in BAFF receptor expression in transitional B cells despite elevated levels of IL-7 and BAFF in 
plasma. Considering that BAFF is a key differentiation and survival factor for B cells, the 
authors concluded that B-cell lymphopenia in end-stage renal disease is caused by the impact of 
uremia on maturation of transitional B cells (40). 
Because the majority of our patients had below normal absolute numbers of B cells, they 
may potentially exhibit a low response to immunization. Indeed, it was previously found that 
some CKD patients were hypo-responsive to pneumococcal polysaccharide vaccine (41). The 
response rates to hepatitis B vaccination in these patients are also lower in comparison to healthy 
controls (42).  However, we have recently found that the pediatric Haemophilus influenzae type 
b (Hib) polysaccharide-protein conjugate vaccine is highly immunogenic in a group of adult 
patients with CKD, which is comparable to the one in present study (43). Because the proposed 
Hia vaccine is designed based on the same principles as Hib-conjugate vaccine, i.e. composed of 
the capsular polysaccharide conjugated to a protein carrier, this may predict its sufficient 
immunogenicity in CKD patients. 
 This study has several limitations. There is a nearly 20-year difference between the mean 
ages of the CKD Indigenous and non-Indigenous patients (Student’s t-test, p < 0.01). This 
difference reflects the demographics of adults suffering from CKD in Canada, i.e. people of 
Indigenous descent tend to develop CKD at a younger age (7). For logistic reasons, we were 
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unable to include a group of healthy Indigenous participants as a control and hence could not 
determine their B-cell subpopulations, although the data of serum Hia antibody levels and serum 
bactericidal activity in healthy Indigenous adults collected by our group in the same region and 
using the same methodology are available (10, 17). We did not study H. influenzae colonization 
rates in study participants although our ongoing studies indicate that approximately 8% of 3 – 5 
year old First Nations children carry Hia in the nasopharynx (unpublished observations). 
However, the development of natural immunity to common bacteria such as H. influenzae is a 
result of multiple exposures to antigens. Given the transient pattern of H. influenzae colonization 
we did not consider data on single-point carriage in adults to be of value regarding the 
understanding of natural immunity to Hia and we were unable to conduct a longitudinal study of 
carriage in our cohorts for logistic reasons. Because we were unable to determine absolute 
lymphocyte numbers in healthy controls we have used the relevant data from literature for 
analysis. Lastly, no correction was applied to the threshold of statistical significance despite the 
many comparisons that were made, most involving small differences between groups. 
 
Conclusion 
Patients suffering from severe CKD may be at an increased risk for invasive Hia disease 
because they have decreased titres of serum bactericidal antibodies against Hia and reduced 
absolute numbers of B lymphocytes. Yet, 72% of CKD patients exhibited detectable serum 
bactericidal activity against Hia and 100% had detectable Hia-specific IgG and IgM.  However, 
the minimum protective antibody concentrations against Hia are still unknown, and we must also 
consider that patients with chronic disease, such as those with CKD might require higher 
antibody concentrations for protection. Considering the presence of an increased proportion of 
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class switched memory B cells in CKD compared to healthy controls, a fraction of memory B 
cells resulting from a natural exposure to the pathogen can be specific for Hia. The data would 
suggest that a new Hia-conjugate vaccine under development may be immunogenic in adult 
patients with CKD, as it will potentially induce re-activation of immunological memory specific 
to Hia.  
 
Conflict of interest statement 
All authors declare there is no conflict of interest.  
 
Acknowledgements 
We would like to thank all the study participants for donating blood for our study, as well 
as the nurses at the Renal Services (TBRHSC) for collecting samples from patients and Hanan 
Alsarmi for collecting healthy control samples. We thank Eli Nix, Angele Desbiens-Forget 
(Northern Ontario School of Medicine) and Lori Moon (Clinical Trials Department, TBRHSC) 
for assistance with patient recruitment and Twyla Biluk (Thunder Bay 55 Plus Center) for 
assistance with recruitment of healthy controls. We thank Victoria Domonkos for collecting 
patient medical histories. We thank Dr. Andrew Cox (National Research Council Canada) for 
providing the Hia antigen for ELISA and Dr. Karen Rudolph (Arctic Investigation Program 
CDC) for donating the reference serum. We thank Eli Nix and Kylie Williams for helping with 
development of methodology, and Brenda Huska for performing some ELISA assays. Funding 
was provided by the Northern Ontario Academic Medicine Association (AFP Innovation Fund 
Project #A-15-05) and the Canadian Immunization Research Network (CT20ON31). 
 
 
   
63 
References 
1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 
Mar 25;389(10075):1238-52. PubMed PMID: 27887750. Pubmed Central PMCID. 
doi:10.1016/S0140-6736(16)32064-5 
2. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines 
for the management of chronic kidney disease. CMAJ. 2008 Nov 18;179(11):1154-62. PubMed 
PMID: 19015566. Pubmed Central PMCID: PMC2582781. doi:10.1503/cmaj.080351 
3. Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, et al. 
Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and 
Outcome. J Immunol Res. 2018;2018:2180373. PubMed PMID: 30271792. Pubmed Central 
PMCID: PMC6146775. doi:10.1155/2018/2180373 
4. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic 
Kidney Dis. 2006 Jul;13(3):199-204. PubMed PMID: 16815225. Pubmed Central PMCID. 
doi:10.1053/j.ackd.2006.04.004 
5. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of 
immune system. J Ren Nutr. 2012 Jan;22(1):149-56. PubMed PMID: 22200433. Pubmed Central 
PMCID: PMC3246616. doi:10.1053/j.jrn.2011.10.020 
6. Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR. Oxidative Stress in 
Hemodialysis Patients: A Review of the Literature. Oxid Med Cell Longev. 2017;2017:3081856. 
PubMed PMID: 29138677. Pubmed Central PMCID: PMC5613374. doi:10.1155/2017/3081856 
7. Ferguson TW, Tangri N, Tan Z, James MT, Lavallee BDA, Chartrand CD, et al. 
Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective. Kidney 
Int. 2017 Jul;92(1):192-200. PubMed PMID: 28433383. Pubmed Central PMCID. 
doi:10.1016/j.kint.2017.02.022 
8. Dyck RF, Tan L. Non-diabetic end-stage renal disease among Saskatchewan aboriginal 
people. Clin Invest Med. 1998 Feb;21(1):33-8. PubMed PMID: 9512883. Pubmed Central 
PMCID.  
9. Ulanova M, Tsang RSW. Haemophilus influenzae serotype a as a cause of serious 
invasive infections. Lancet Infect Dis. 2014 Jan;14(1):70-82. PubMed PMID: 24268829. 
Pubmed Central PMCID. doi:10.1016/S1473-3099(13)70170-1 
10. Nix EB, Williams K, Cox AD, St Michael F, Romero-Steiner S, Schmidt DS, et al. 
Naturally acquired antibodies against Haemophilus influenzae type a in Aboriginal adults, 
Canada. Emerg Infect Dis. 2015 Feb;21(2):273-9. PubMed PMID: 25626129. Pubmed Central 
PMCID: PMC4313637. doi:10.3201/eid2102.140722 
11. Kelly L, Tsang RS, Morgan A, Jamieson FB, Ulanova M. Invasive disease caused by 
Haemophilus influenzae type a in Northern Ontario First Nations communities. J Med Microbiol. 
2011 Mar;60(Pt 3):384-90. PubMed PMID: 21148281. Pubmed Central PMCID. 
doi:10.1099/jmm.0.026914-0 
12. Tsang RSW, Ulanova M. The changing epidemiology of invasive Haemophilus 
influenzae disease: Emergence and global presence of serotype a strains that may require a new 
vaccine for control. Vaccine. 2017 Jul 24;35(33):4270-5. PubMed PMID: 28666758. Pubmed 
Central PMCID. doi:10.1016/j.vaccine.2017.06.001 
13. Census Profile, 2016 Census, Northwest Ontario and Ontario [Internet]. 2016 [cited 
January 21, 2019]. Available from: http://www12.statcan.gc.ca/census-recensement/2016/dp-
pd/prof/details/page.cfm?Lang=E&Geo1=ER&Code1=3595&Geo2=PR&Code2=35&Data=Cou
 




14. Brown VM, Madden S, Kelly L, Jamieson FB, Tsang RS, Ulanova M. Invasive 
Haemophilus influenzae disease caused by non-type b strains in Northwestern Ontario, Canada, 
2002-2008. Clin Infect Dis. 2009 Oct 15;49(8):1240-3. PubMed PMID: 19761408. Pubmed 
Central PMCID. doi:10.1086/605671 
15. Eton V, Schroeter A, Kelly L, Kirlew M, Tsang RSW, Ulanova M. Epidemiology of 
invasive pneumococcal and Haemophilus influenzae diseases in Northwestern Ontario, Canada, 
2010-2015. Int J Infect Dis. 2017 Dec;65:27-33. PubMed PMID: 28951105. Pubmed Central 
PMCID. doi:10.1016/j.ijid.2017.09.016 
16. Cox AD, Barreto L, Ulanova M, Bruce MG, Tsang R, Conference c. Developing a 
vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop. Can Commun Dis 
Rep. 2017 May 4;43(5):89-95. PubMed PMID: 29770071. Pubmed Central PMCID: 
PMC5764720  
17. Nix EB, Choi J, Anthes C, Gaultier GN, Thorgrimson J, Cox AD, et al. Characterization 
of natural bactericidal antibody against Haemophilus influenzae type a in Canadian First 
Nations: A Canadian Immunization Research Network (CIRN) Clinical Trials Network (CTN) 
study. PLoS One. 2018;13(8):e0201282. PubMed PMID: 30110339. Pubmed Central PMCID. 
doi:10.1371/journal.pone.0201282 
18. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015 
Mar;15(3):149-59. PubMed PMID: 25677494. Pubmed Central PMCID. doi:10.1038/nri3802 
19. Inoue T, Moran I, Shinnakasu R, Phan TG, Kurosaki T. Generation of memory B cells 
and their reactivation. Immunol Rev. 2018 May;283(1):138-49. PubMed PMID: 29664566. 
Pubmed Central PMCID. doi:10.1111/imr.12640 
20. Rouphael NG, Satola S, Farley MM, Rudolph K, Schmidt DS, Gomez-de-Leon P, et al. 
Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a. Clin 
Vaccine Immunol. 2011 Feb;18(2):243-7. PubMed PMID: 21177919. Pubmed Central PMCID: 
PMC3067367. doi:10.1128/CVI.00219-10 
21. William Mendenhall RB, Barbara Beaver, S. Ahmed. Introduction to Probability and 
Statistics (3rd Canadian Edition): Nelson Education; 2014. 
22. Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of 
Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr 
Infect Dis J. 1998 Sep;17(9 Suppl):S132-6. PubMed PMID: 9781746. Pubmed Central PMCID.  
23. Scott JR, Millar EV, Lipsitch M, Moulton LH, Weatherholtz R, Perilla MJ, et al. Impact 
of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential 
in Native American communities. J Infect Dis. 2012 Jan 15;205(2):280-8. PubMed PMID: 
22128315. Pubmed Central PMCID: PMC3244367. doi:10.1093/infdis/jir730 
24. Qian Q. Inflammation: A Key Contributor to the Genesis and Progression of Chronic 
Kidney Disease. Contrib Nephrol. 2017;191:72-83. PubMed PMID: WOS:000435366800008. 
Pubmed Central PMCID. English. doi:10.1159/000479257 
25. Miyagaki T, Fujimoto M, Sato S. Regulatory B cells in human inflammatory and 
autoimmune diseases: from mouse models to clinical research. Int Immunol. 2015 
Oct;27(10):495-504. PubMed PMID: WOS:000364767100005. Pubmed Central PMCID. 
English. doi:10.1093/intimm/dxv026 
26. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, et al. 
Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are 
 
   
65 
generated in the spleen. J Exp Med. 2003 Apr 7;197(7):939-45. PubMed PMID: 12682112. 
Pubmed Central PMCID: PMC2193885. doi:10.1084/jem.20022020 
27. Muriach M, Flores-Bellver M, Romero FJ, Barcia JM. Diabetes and the brain: oxidative 
stress, inflammation, and autophagy. Oxid Med Cell Longev. 2014;2014:102158. PubMed 
PMID: 25215171. Pubmed Central PMCID: PMC4158559. doi:10.1155/2014/102158 
28. Polverino F, Seys LJ, Bracke KR, Owen CA. B cells in chronic obstructive pulmonary 
disease: moving to center stage. Am J Physiol Lung Cell Mol Physiol. 2016 Oct 1;311(4):L687-
L95. PubMed PMID: 27542809. Pubmed Central PMCID: PMC5142126. 
doi:10.1152/ajplung.00304.2016 
29. Colonna-Romano G, Bulati M, Aquino A, Pellicano M, Vitello S, Lio D, et al. A double-
negative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people. 
Mech Ageing Dev. 2009 Oct;130(10):681-90. PubMed PMID: 19698733. Pubmed Central 
PMCID. doi:10.1016/j.mad.2009.08.003 
30. Martorana A, Balistreri CR, Bulati M, Buffa S, Azzarello DM, Camarda C, et al. Double 
negative (CD19+IgG+IgD-CD27-) B lymphocytes: a new insight from telomerase in healthy 
elderly, in centenarian offspring and in Alzheimer's disease patients. Immunol Lett. 2014 
Nov;162(1 Pt B):303-9. PubMed PMID: 24951896. Pubmed Central PMCID. 
doi:10.1016/j.imlet.2014.06.003 
31. Bulati M, Buffa S, Candore G, Caruso C, Dunn-Walters DK, Pellicano M, et al. B cells 
and immunosenescence: a focus on IgG+IgD-CD27- (DN) B cells in aged humans. Ageing Res 
Rev. 2011 Apr;10(2):274-84. PubMed PMID: 21185406. Pubmed Central PMCID. 
doi:10.1016/j.arr.2010.12.002 
32. Hara Y, Tashiro Y, Murakami A, Nishimura M, Shimizu T, Kubo M, et al. High affinity 
IgM(+) memory B cells are generated through a germinal center-dependent pathway. Mol 
Immunol. 2015 Dec;68(2 Pt C):617-27. PubMed PMID: 26514429. Pubmed Central PMCID. 
doi:10.1016/j.molimm.2015.10.003 
33. Veneri D, Ortolani R, Franchini M, Tridente G, Pizzolo G, Vella A. Expression of CD27 
and CD23 on peripheral blood B lymphocytes in humans of different ages. Blood Transfus. 2009 
Jan;7(1):29-34. PubMed PMID: 19290077. Pubmed Central PMCID: PMC2652233. 
doi:10.2450/2008.0007-08 
34. Seifert M, Kuppers R. Human memory B cells. Leukemia. 2016 Dec;30(12):2283-92. 
PubMed PMID: 27499139. Pubmed Central PMCID. doi:10.1038/leu.2016.226 
35. Khaskhely N, Mosakowski J, Thompson RS, Khuder S, Smithson SL, Westerink MA. 
Phenotypic analysis of pneumococcal polysaccharide-specific B cells. J Immunol. 2012 Mar 
1;188(5):2455-63. PubMed PMID: 22271652. Pubmed Central PMCID: PMC3288481. 
doi:10.4049/jimmunol.1102809 
36. Xiang FF, Zhu JM, Cao XS, Shen B, Zou JZ, Liu ZH, et al. Lymphocyte depletion and 
subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail. 
2016;38(1):7-14. PubMed PMID: 26539739. Pubmed Central PMCID. 
doi:10.3109/0886022X.2015.1106871 
37. Canada MCo. Clinical Laboratory Tests- Normal Values, White Blood Cells and 
Differentials [Available from: https://mcc.ca/objectives/normal-values/. 
38. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell 
subpopulations from infancy to adulthood. Clin Exp Immunol. 2010 Nov;162(2):271-9. PubMed 
PMID: 20854328. Pubmed Central PMCID: PMC2996594. doi:10.1111/j.1365-
2249.2010.04206.x 
 
   
66 
39. Qin L, Jing X, Qiu Z, Cao W, Jiao Y, Routy JP, et al. Aging of immune system: Immune 
signature from peripheral blood lymphocyte subsets in 1068 healthy adults. Aging (Albany NY). 
2016 May;8(5):848-59. PubMed PMID: 26886066. Pubmed Central PMCID: PMC4931839. 
doi:10.18632/aging.100894 
40. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-
stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. 
Nephrol Dial Transplant. 2010 Jan;25(1):205-12. PubMed PMID: 19684120. Pubmed Central 
PMCID: PMC2796898. doi:10.1093/ndt/gfp397 
41. Mahmoodi M, Aghamohammadi A, Rezaei N, Lessan-Pezeshki M, Pourmand G, 
Mohagheghi MA, et al. Antibody response to pneumococcal capsular polysaccharide vaccination 
in patients with chronic kidney disease. Eur Cytokine Netw. 2009 Jun;20(2):69-74. PubMed 
PMID: 19541592. Pubmed Central PMCID. doi:10.1684/ecn.2009.0153 
42. Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease patients: a call for 
novel vaccines. Expert Rev Vaccines. 2014 Nov;13(11):1317-26. PubMed PMID: 25148051. 
Pubmed Central PMCID. doi:10.1586/14760584.2014.944508 
43. Hawdon N, Nix EB, Tsang RS, Ferroni G, McCready WG, Ulanova M. Immune response 
to Haemophilus influenzae type b vaccination in patients with chronic renal failure. Clin Vaccine 





























   
67 
Tables and Figures  
Table 1. Demographics of study participants. 
Group n Age (years) 
Mean ± SEM  




Healthy Controls 35 62 ± 2 36-85 22 (63) 5 (14) 
CKD Patients 60 61 ± 2 32-85 26 (43) 30 (50) 
CKD Indigenous 30 53 ± 2+* 32-80 15 (50)  
CKD non-Indigenous 30 70 ± 2* 43-85 11 (37)  
+ p < 0.0001, chronic kidney disease (CKD) to healthy controls; *p < 0.01, Indigenous to non-
Indigenous CKD patients (Student’s t-test). The ages were significantly different between 
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Table 2. Percentage of CD19+ lymphocytes determined by flow cytometry. 
Group Percentage of B cells (95% CI) 
Healthy Controls 7.0 (5.9-8.0) 
CKD 11.1 (8.4-13.7) ** 
CKD Indigenous 11.6 (7.7-15.4) ** 
CKD non-Indigenous 10.3 (6.2-14.3) * 
* Comparison of the mean proportions of B cells between patients with chronic kidney disease 
(CKD) to healthy controls (* p < 0.05, ** p < 0.01, Student’s t-test). The proportions of B cells 
were significantly different between healthy controls and both CKD groups (Indigenous and non-
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Figure 1. Flow cytometry analysis. Proportions of naïve (CD27- IgM+), IgM memory (CD27+ 
IgM+), CD27- IgM-, and class switched memory (CD27+ IgM-) B cells were determined by first 
gating the lymphocyte population (A), then gating the CD19+ lymphocytes (FL2) (B). These 
events were then separated based on their CD27 (FL3) and IgM (FL4) expression (C). The 
percent gated values were used for the proportions of B cell subpopulations were determined. 
One representative experiment is shown; CD19+ (9.9%), CD27-IgM+ (60.6%), CD27+IgM+ 
(4.1%), CD27-IgM- (11.5%), and CD27+IgM- (23.8%).  
 
 



























Figure 2A. Serum bactericidal antibody against Haemophilus influenzae type a in healthy 

















































Figure 2B. Serum bactericidal antibody against Haemophilus influenzae type a in Indigenous vs. 





















































Figure 2C. The geometric mean concentrations of anti-Haemophilus influenzae type a capsular  















































Figure 2D. The geometric mean concentrations of anti-Haemophilus influenzae type a capsular  




















Figure 2E. The geometric mean concentrations of anti-Haemophilus influenzae type a capsular 






















Figure 2F. The geometric mean concentrations of anti-Haemophilus influenzae type a capsular 
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Figure 2. Serum bactericidal antibody against Haemophilus influenzae type a in healthy controls 
and CKD patients (A) and Indigenous vs. non-Indigenous CKD patients (B). The antibody titre 
was defined as the reciprocal of serum dilution resulting in ³ 50% killing of Hia strain 08-191. 
The solid line indicates geometrical mean titre (GMT). The number of individual samples below 
the lower limit of detection (dashed line) is indicated on the graph. * p < 0.05, Student’s t-test. 
The geometric mean concentrations (GMC, solid line) of anti-Hia capsular polysaccharide IgM 
(C-D) and IgG (E-F) in healthy controls and CKD patients (C, E) and Indigenous vs. non-
Indigenous CKD patients (D, F). * p < 0.05, Mann-Whitney U test. No significant difference 
between the 3 groups (healthy control, CKD Indigenous, and CKD non-Indigenous) for GMT or 
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Figure 3. Proportions of B cell subpopulations were determined by flow cytometry. 
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Figure 3. Proportions of B cell subpopulations were determined by flow cytometry. Isolated 
peripheral blood mononuclear cells were immunostained for CD19, CD27, and IgM. Naïve 
(CD19+CD27- IgM+), IgM memory (CD19+CD27+IgM+), CD19+CD27- IgM-, and class 
switched memory B cells (CD19+CD27+IgM-) were determined for healthy controls (A), 
patients with chronic kidney disease (CKD) (B), CKD Indigenous (C) and CKD non-Indigenous 
(D). * p < 0.05 when comparing the CKD groups to healthy controls; + p < 0.05 comparing 
Indigenous and non-Indigenous patients with CKD (Student’s t-test or Mann-Whitney U test). 
No significant differences between healthy controls, CKD Indigenous and CKD non-Indigenous 
patients were detected for any subpopulation except for CD19+CD27-IgM- cells, p < 0.001 
































Supplementary table 1. Causes for development of severe chronic kidney disease and 
comorbidities. 
Cause of CKD Patients n (%) 
Diabetic Nephropathy 26 (43) 
Hypertension/ Vascular disease 6 (10) 
Glomerulonephritis 5 (8) 
IgA Nephropathy 4 (7) 
Diabetic Nephropathy + Glomerulonephritis 2 (3) 
Urinary tract obstruction  2 (3) 
Other: 
   Goodpasture disease 1 
   Nephrotic syndrome  1 
   Polycystic kidney disease 1 
   Chronic infection 1 
   Wegener’s Granulomatosis  1 
   Renal agenesis  1 
   Acute tubular necrosis 2 (3) 
   Interstitial nephritis  1 
Unknown  6 (10) 
Major comorbidities   
Diabetes mellitus 33(55) 
Hypertension 40 (67) 
Cardiovascular disease 26 (43) 
Chronic obstructive pulmonary disease 6 (10) 
Cancer 9 (15) 
Alcohol abuse 7 (12) 
Dyslipidemia  11 (18) 







   
80 
Supplementary table 2. Demographics of patients with B cell analysis. 
  Age (years)   
Group n Mean ± SEM Range No. (%) Female 
Chronic Kidney Disease 28 60 ± 3 32-85 13 (46) 
Indigenous 17 54 ± 3 32-80 8 (47) 
non-Indigenous 11 69 ± 3+ 54-85 5 (45) 
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Supplementary table 3. Absolute numbers of lymphocytes and B cell subpopulations. 
Absolute number of cells  CKD Indigenous 
(mean ± SEM cells/µL) 
CKD non-Indigenous 
(mean ± SEM cells/µL) 
Lymphocytes 1,091 ± 150 1,106 ± 107 
B cells (CD19+) 108 ± 12 86 ± 16 
Naïve B cells (CD19+CD27-IgM+) 64 ± 13 63 ± 18  
IgM memory B cells 
(CD19+CD27+IgM+) 
7 ± 1 12 ± 5 
CD19+CD27-IgM- B cells 15 ± 2 17 ± 3 
Class Switched Memory B cells 
(CD19+CD27+, IgM-) 
23 ± 5 19 ± 5 
Total of 28 patients with chronic kidney disease (CKD), 17 Indigenous and 11 non-Indigenous; 
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Supplementary table 4a. Proportions B cell Subpopulations. 
 





Naïve B cells 
(CD27-IgM+) 








CKD 28 60 (32-85) Canada 11 53 16 9 22 This Study  
HC 35 62 (36-85) Canada 7 53 20 11 16 This Study 
HC 22 24 (18-30) USA -- 61.4 9.8 14.3 14.4 (1) 
    CD 19+ CD27-IgD+ CD27-IgD- CD27+ IgD+ CD27+IgD-  
CKD 25 57 (26-74) France -- 65 5.3 10 20 (2) 
HC  27 49 (25-66) France -- 54 3.6 16 27 (2) 
Sarcoidosis  22 47/54 USA 3.2 6.7 4.2 8.4 13.8 (3) 
HC  9 47/54  USA 5.9 7.1 2.4 15.1 16.0 (3) 
HC 32 26-50 Germany 9.2 65.1 3.3 15.2 13.2 (4) 
HC  41 72 (65-80) China 10.2 -- -- -- -- (5) 
-- Information not available.  Healthy control (HC), chronic kidney disease (CKD).
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Supplementary table 4b. Absolute numbers of cells (cells/µL) 
 
Source n Age  Location 
of Study 
Lymphocytes Total B 
cells  
CD 19+ 
Naïve B cells 
CD27-IgM+ 









CKD 28 60 (32-85) Canada 1100 ± 86 100 ± 
10 
63 ± 10 15 ± 1 9 ± 2 21 ± 3 This 
Study 
      CD 19+ CD27-IgD+ CD27-IgD- CD27+IgD+ CD27+IgD-  
Sarcoidosis 22 47/54 USA -- 1149 312 10.3 25.7  29.7 (3) 
HC  9 47/54  USA -- 2346 337.3 14.8 44.5 58.3 (3) 
HC  32 26-50 Germany 2364 199 131 7 35 29 (4) 
HC  41 72 (65-80) China 1946 198 -- -- -- -- (5) 
HC -- -- -- 1000- 4000 -- -- -- -- -- (6) 
     CD 19+ CD19+CD27-  CD19+CD27+ (all memory)  
CKD  21 52 USA 1500 140 104 -- 36 
50 
(7) 
HC  21 47 USA 1900 240 180 -- (7) 
-- Information not available.  HC, healthy control group, CKD, chronic kidney disease 
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 Chapter 3: Antibodies specific for Streptococcus pneumoniae serotypes 6B and 14 in 
Canadian First Nations and Non-First Nations adults. 
 
Abstract 
Streptococcus pneumoniae colonizes the upper respiratory tract and can cause non-
invasive diseases such as non-bacteremic community acquired pneumonia (CAP) or invasive 
pneumococcal disease (IPD). The Canadian Immunization Guide recommends one dose of the 
23-valent pneumococcal polysaccharide vaccine (PPV23) for adults at risk for IPD. This 
includes adults over the age of 65 years as well as adults with certain immunocompromising 
conditions such as chronic kidney disease (CKD). However, adult pneumococcal immunization 
rates are low in Canada. In North America, the rate of IPD in the Indigenous population is higher 
compared to the general population. In northwestern Ontario specifically, the First Nations (FN) 
population has an increased rate of IPD. We quantified pneumococcal IgG concentrations 
specific to serotypes 6B and 14 in 207 pneumococcal vaccine naïve adults. Participants were 
separated based on ethnicity and health: healthy FN, healthy non-First Nations (non-FN), FN 
with severe CKD (FN-CKD) and non-FN with severe CKD (NFN-CKD).  Healthy FN 
participants had higher antibody concentrations for both serotypes 6B and 14 compared to 
healthy non-FN participants. FN-CKD had significantly higher serotype 14 antibody 
concentrations compared to NFN-CKD. Only healthy FN had significantly higher 6B antibody 
concentrations compared to both CKD groups. Healthy non-FN had significantly lower serotype 
14 antibody concentrations compared to healthy FN and FN-CKD. Healthy participants were 
further separated based on community: FN from southern Ontario (FNSO), FN from 
northwestern Ontario (FNNO), non-FN from Thunder Bay (NFNT) and non-FN from Kenora 
(NFNK). Of the six groups, all three FN groups (FNSO, FNNO and FN-CKD) had higher 6B 
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and 14 antibody concentrations compared to non-FN groups (NFNT, NFNK, and NFN-CKD). 
Participants were also separated based on sex, ethnicity, and health status. Healthy FN females 
had significantly higher serotype 14 antibody concentrations compared to healthy FN males. 
There were no significant differences in either 6B or 14 antibody concentrations between healthy 
males and females of non-FN, FN-CKD, or NFN-CKD groups. Regression analyses revealed a 
positive relationship between serotype 14 antibody concentrations and age for healthy FN 
females. This indicates that as age increases, serotype 14 antibody concentrations also increase. 
There are many environmental sources that can influence naturally acquired antibodies specific 
to pneumococcus or antibodies that are cross reactive for other pathogens. Based on the 
concentrations of pneumococcal 6B and 14 IgG antibodies, the data suggest that the increased 
risk of IPD in the Indigenous population is due to the increased prevalence of 
immunocompromising conditions such as CKD. The results from this study emphasize the 




 Streptococcus pneumoniae (pneumococcus) is a Gram-positive, encapsulated, 
extracellular bacterium, which asymptomatically colonizes mucosal surfaces of the upper 
respiratory tract and spreads through respiratory droplets of colonized individuals (1, 2). 
Pneumococcus is capable of causing non-invasive (otitis media, sinusitis, pneumonia) and 
invasive (meningitis, septicaemia, pericarditis) infections, which occur when it evades the host 
defences and invades sterile body sites (3, 4). Children under 5 years of age, the elderly, and 
immunocompromised adults have the highest incidence of invasive pneumococcal disease (IPD) 
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and community acquired pneumonia (CAP) (3, 5). Globally, the majority of CAP cases are 
caused by S. pneumoniae, and 30-70 % of adult CAP cases require hospitalization (6, 7).  
A total of 98 pneumococcal serotypes have been identified through antigenic differences 
in their polysaccharide capsules (8). The capsular polysaccharide is a key virulence factor in the 
pathogenesis of pneumococcal disease. The highly charged state of the capsule promotes 
colonization by allowing adherence to epithelial cells. This prevents entrapment of bacteria in 
mucus through repulsion of the sialic acid containing mucopolysaccharides. The capsule inhibits 
the classic and alternative complement pathways through prevention of complement protein 
binding. It also reduces opsonization by impeding interactions between bound complement 
proteins or antibodies with phagocyte receptors (9).   
In Canada, the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the 13-
valent pneumococcal conjugate vaccine (PCV13) are currently used. The PPV23 contains 
purified capsular polysaccharides of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 
14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. The PCV13 contains polysaccharides 1, 3, 
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F conjugated to a carrier protein (CRM197). 
PCV13 is part of the routine infant immunization schedule and is recommended for adults with 
certain immunocompromising conditions. PPV23 is recommended for adults 65 years and older 
regardless of risk factors or previous pneumococcal immunization. This includes adults with an 
increased risk for IPD, such as individuals living with chronic kidney disease (CKD), or those 
with specific lifestyle factors such as the homeless population, people with alcoholism, people 
who smoke, etc. An additional dose of PPV23 is recommended for children over 2 years of age 
with an increased risk of IPD due to underlying medical conditions (10). However, 
pneumococcal vaccine uptake (PPV23) in adults is low. Statistics Canada reported that amongst 
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the adult population with chronic conditions, only 17.3% (13.7 - 20.8, 95% confidence intervals, 
CI) of 18-64 year-olds and 36.5% (32.7 – 40.3, 95% CI) of 65 years and older, correspondingly, 
received at least 1 dose of PPV23 (11). 
The population of Thunder Bay, located in northwestern Ontario, is unique amongst other 
areas of Ontario because 25.4% of the population is of Indigenous descent. The proportion of 
Indigenous peoples is lower in other areas of Ontario such as Toronto, (located in southern 
Ontario) which has a proportion of 0.87% Indigenous peoples as well as northeastern Ontario 
where 12.7% of the population is Indigenous (12). In North America, the incidence of IPD 
remains higher in Indigenous populations compared to the general population despite the use of 
pneumococcal vaccines (13-18). Eaton et al. 2017 investigated the incidence of IPD in 
northwestern Ontario through retrospective chart review of the Sioux Lookout Meno Ya Win 
Health Center (SLMHC). The incidence of IPD over a 5.5-year period from January 2010 – July 
2015 was 23.1/ 100 000/ year, more than double the 2013 rate for all of Canada (9.0/ 100 000/ 
year). The age specific incidence of IPD was highest in the 71-75 years group (106.5/ 100 000/ 
year) (19). A recent study by our group evaluated hospitalized cases of IPD in Thunder Bay 
which occurred between 2006 and 2015. It reported that 29.1% of adult patients with IPD were 
Indigenous, and the likelihood of immunocompromising conditions was higher amongst the 
Indigenous patients than in the non-Indigenous (20). CKD is an immunocompromising condition 
that has a high prevalence in the First Nations population of northwestern Ontario. The rate of 
CKD in the First Nations population of northwestern Ontario (7%) is double the rate of the 
general Canadian population. This high rate of CKD in combination with other conditions (e.g. 
diabetes) is associated with a high rate of cardiovascular disease (21). According to the National 
Advisory Committee on Immunization’s recommendations for adult pneumococcal 
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immunization, adults with CKD are considered one of the groups at highest risk for IPD. People 
with diabetes, chronic heart disease, or lung disease are also considered at high risk for IPD (22).  
The Indigenous population of northwestern Ontario has been found to have an increased 
susceptibility to other infectious diseases, specifically invasive disease caused by Haemophilus 
influenzae type a (Hia), which co-inhabits the nasopharynx with pneumococcus (23, 24). Our 
recent study (chapter 2) compared naturally acquired immunity against Hia in Indigenous and 
non-Indigenous Canadians. Although invasive Hia disease is most predominant in the Indigenous 
population, this was not due to lack of natural immunity against this pathogen. In contrast, 
healthy First Nations adults exhibited higher levels of Hia antibodies, as well as increased serum 
bactericidal activity against Hia compared to non-First Nations individuals of the same age (23). 
However, naturally acquired immunity against S. pneumoniae has not been previously assessed 
in Canadian adults. In this study, we determined the concentrations of pneumococcal IgG 
antibodies specific for serotypes 6B and 14 in both First Nations and non-First Nations adults 
from southern Ontario and northwestern Ontario. We also included patients with severe CKD 
(glomerular filtration rate (GFR), stage 4 < 30 mL/ min/ 1.73m2, stage 5 < 15 mL/ min/ 1.73m2) 
(25) receiving dialysis at the Thunder Bay Regional Health Sciences Center (TBRHSC) due to 
their increased risk of IPD. As these serotypes have been included in all pneumococcal vaccines, 
herd immunity could have a significant impact on carriage of these serotypes, which could affect 
the antibody concentrations in unimmunized adults.  
 
Materials and methods 
Ethics Statement 
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In designing and conducting this study, we adhered to the principles of Ownership, 
Control, Access, and Possession (OCAP) as defined by the National Aboriginal Health 
Organization (26), and the guidelines of Canadian Tri-Council Policy Statement: Ethical 
Conduct for Research Involving Humans (TCPS2), specifically those outlined in Chapter 9: 
Research Involving First Nations, Inuit and Métis Peoples of Canada (27). The study was 





FN Healthy First Nations adults (FNSO + FNNO) 
Non-FN Healthy non-First Nations adults (NFNT + NFNK) 
FNSO Healthy First Nations adults from southern Ontario 
FNNO Healthy First Nations adults from northwestern Ontario 
NFNT Healthy non-First Nations adults from Thunder Bay 
NFNK Healthy non-First Nations adults from Kenora 
FN-CKD First Nations adults with severe chronic kidney disease  
NFN-CKD Non-First Nations adults with severe chronic kidney disease  
 
The study included 141 healthy adults (Table 1). First Nations (FN) participants were 
recruited from two Ojibwa First Nations communities, one in northwestern Ontario (FNNO) and 
the other in southern Ontario (FNSO). Non-First Nations participants were recruited from two 
cities in northwestern Ontario, Thunder Bay (NFNT) and Kenora (NFNK). An additional 66 
participants with CKD were recruited from the Thunder Bay Regional Health Sciences Center 
(THBRHSC), participants were separated into two groups: First Nations-CKD (FN-CKD) and 
Non-First Nations-CKD (NFN-CKD). The demographics of participants is displayed in Table 1. 
Healthy participants were considered eligible if they were over the age of 18 years, self-declared 
generally healthy, did not have a history of taking immunosuppressive medications, and declared 
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that they had not received a pneumococcal vaccine. Participants with CKD were considered 
eligible if they were over the age of 18 years, diagnosed with stage 4 or 5 CKD, had no history of 
immunocompromising conditions, had not taken immunosuppressive medications for more than 
14 days in the past 6 months, had not received a blood transfusion or blood products within the 
last 3 months, had not received any vaccines in the past month, and had not received a 
pneumococcal vaccine previously. Ethnicity was determined based on self-declaration. Serum 
samples from FNSO and FNNO communities, Kenora, and some of the Thunder Bay samples 
were collected during January - November 2015 (23). The remaining Thunder Bay samples were 
collected between November 2016 and November 2017, mainly through the Thunder Bay 55 
Plus Centre. CKD participants were recruited between May 2015 and February 2019 from Renal 
Services of the TBRHSC. Sera were collected under informed written consent and stored at         
-80°C prior to analysis. 
 
Enzyme-linked immunosorbent assay (ELISA) 
Amounts of IgG pneumococcal 6B and 14 antibodies were quantified using the ELISA 
protocol provided by the World Health Organization (28).  
 
Statistical analysis  
Statistical analyses were performed using Graph-Pad Prism 8. The lower limits of 
detection were determined by calculating the concentration of antibodies present in the standard 
serum 007sp (29) that yielded two times the assay background; the lowest serum dilution on the 
plate was used. All antibody values below the lower limit of detection were reported as half of 
the limit of detection. Data were reported as geometric means of pneumococcal antibody 
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concentrations with 95% confidence intervals (CI). Groups were compared using Mann-Whitney 
U test, Student’s t- test, or Kruskal-Wallis test with Dunn’s post-hoc test depending on the 
number of groups compared. Linear regression analysis was performed to analyze the 
relationship between age and antibody concentrations. Significance was determined at p value < 
0.05. Outliers were identified and removed (30).  
 
Results 
The age range of the 207 study participants was between 18 and 87 years old (Table 1). 
There were no significant differences between mean ages of all healthy FN and non-FN 
participants. When CKD groups were compared, NFN-CKD participants had a significantly 
higher mean age compared to FN-CKD participants. Next, CKD and healthy participant groups 
were compared. FN-CKD had a significantly higher mean age than healthy FN participants. 
NFN-CKD had a significantly higher mean age compared to healthy groups. When participants 
were separated based on community and health, there was a significant difference in the ages of 
all six groups. The highest mean age was NFN-CKD (67 years) and the lowest mean age was 
FNNO (37 years). NFN-CKD had a significantly higher mean age compared to the other five 
groups. FNNO had a significantly lower mean age compared to FN-CKD, FNSO, and FNNO. 
NFNK had the highest proportion of females (74%) while NFN-CKD had the lowest (32%).  
To determine if there were differences in pneumococcal antibody concentrations between 
healthy FN and non-FN adults, IgG specific to capsular polysaccharides of serotypes 6B and 14 
were quantified (Figures 1A and 1B). Healthy FN adults had significantly higher concentrations 
of antibodies specific for 6B and 14 compared to healthy non-FN participants. Additionally, 
when participant groups were separated based on health and community, healthy FN groups 
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(FNSO and FNNO) had significantly higher serotype 6B and 14 concentrations compared to 
non-FN groups (NFNT and NFNK) and both CKD groups. There were no significant differences 
in 6B antibody concentrations between CKD groups, but FN-CKD had significantly higher 
serotype 14 antibody concentrations compared to NFN-CKD. Healthy FN participants had the 
highest concentrations of antibodies specific to serotypes 6B and 14. Healthy non-FN and FN-
CKD participants had the lowest concentrations of serotype 6B antibodies. Healthy non-FN 
participants also had the lowest concentrations of antibodies specific for serotype 14. Serotype 
14 antibody concentrations for NFN-CKD were significantly higher compared to healthy non-FN 
participants, but significantly lower compared to healthy FN participants.  
Participants were separated based on health and community. Figure 2A displays the 
concentrations of antibodies specific for serotype 6B. Of the six groups, FNSO had the highest 
concertation of serotype 6B antibodies followed by FNNO, FN-CKD, and NFNK. NFNT and 
NFN-CKD had the same geometric mean concentrations, which were the lowest amongst the six 
groups. There were no significant differences in 6B antibody concentrations between healthy FN 
groups (FNSO vs. FNNO) or healthy non-FN participants (NFNT vs. NFNK). Serotype 6B 
antibody concentrations for FN-CKD were significantly lower compared to healthy FN groups, 
but significantly higher compared to NFNT.  
Figure 2B displays the concentrations of antibodies specific for serotype 14 based on 
health and community. FNSO had the highest concentration of serotype 14 antibodies followed 
by FNNO and FN-CKD (having the second highest concentrations), NFN-CKD, NFNK, and 
NFNT. There were no significant differences between healthy FN groups (FNSO vs. FNNO) or 
healthy non-NF groups (NFNT vs. NFNK). FN-CKD had significantly higher serotype 14 
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antibody concentrations compared to healthy non-FN groups. NFN-CKD had significantly lower 
serotype 14 antibody concentrations compared to healthy FN groups.  
To summarize, healthy FN participants had higher antibody concentrations for both 
serotypes 6B and 14 compared to healthy non-FN participants. FN-CKD had significantly higher 
serotype 14 antibody concentrations compared to NFN-CKD, but there were no significant 
differences in serotype 6B antibody concentrations. Only healthy FN participants had 
significantly higher 6B antibody concentrations compared to CKD groups. Healthy non-FN 
participants had significantly lower serotype 14 antibody concentrations compared to healthy FN 
participants and FN-CKD. When participants were separated based on health and community, all 
three FN participant groups (FNSO, FNNO, and FN-CKD) had higher serotype 6B and 14 
antibody concentrations compared to non-FN participant groups (NFNT, NFNK, and NFN-
CKD). 
Participants were also separated based on sex; results are displayed in Supplementary 
Table 1. There were no significant differences in pneumococcal antibody concentrations for 
either serotype 6B or 14 between all healthy females and all healthy males. Healthy participants 
were further separated based on ethnicity and sex. FN females had significantly higher 
concentrations of serotype 14 antibodies compared to FN males but there were no significant 
differences in concentrations of serotype 6B antibodies. There were no significant differences in 
concentrations of either serotype 6B or 14 antibody concentrations between non-FN females and 
non-FN males. When participants of the same sex but different ethnicities were compared, FN 
females had significantly higher concentrations of both pneumococcal 6B and 14 antibody 
concentrations compared to non-FN females. FN males had significantly higher serotype 6B 
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antibody concentrations compared to non-FN males, but there were no significant differences in 
serotype 14 antibody concentrations.  
CKD participant groups were also further separated based on sex. There were no 
significant differences in 6B or 14 antibody concentrations between females and males for either 
CKD group. There were no significant differences between FN-CKD and NFN-CKD females or 
males in serotype 6B or 14 antibody concentrations. Healthy participants were compared to CKD 
participant groups. Concentrations of serotype 6B antibodies were significantly higher for FN 
healthy females compared to FN-CKD females as well as FN healthy males compared to FN-
CKD males. There were no significant differences in serotype 14 antibody concentrations 
between FN healthy and FN-CKD females or males. NFN-CKD females had a significantly 
higher serotype 14 antibody concentrations compared to non-FN healthy females. There were no 
significant differences in serotype 14 antibody concentrations between non-FN healthy and 
NFN-CKD males. To summarize, the differences in antibody concentrations of participants of 
opposite sex but same ethnicity and health status, FN females had higher concentrations 
compared to FN males for serotype 14. There were no significant differences in either 6B or 14 
antibody concentrations between females and males of non-FN, FN-CKD or NFN-CKD groups. 
To determine if antibody concentrations were dependent on age, linear regression 
analysis was performed (Supplementary Table 2). When all healthy participants were combined, 
there were no significant relationships indicating dependence of antibody concentration on age 
for either 6B or 14. When participants were further separated based on ethnicity, only serotype 
14 antibody concentrations were dependent on age for non-FN participants. When the 
participants were further separated based on sex, the positive relationship between age and 
antibody concentration for serotype 14 was only found in the non-FN healthy female group. 
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There were no significant relationships indicating dependence of antibody concentration on age 
for either serotype 6B or 14 for either CKD group. To summarize, a positive relationship was 
found between serotype 14 antibody concentrations and age for healthy FN females, indicating 
that as age increases, serotype 14 antibody concentrations also increase. 
 
Discussion 
 Both pneumococcal serotypes 6B and 14 have a history of antibiotic resistance in 
children and have been documented as poorly immunogenic (31, 32). Serotypes 6B and 14 have 
also been known to cause IPD in older Alaskan adults (33). Salt et al. (2007) observed that the 
least immunogenic serotypes cause the most infections in children, and serotype 6B being poorly 
immunogenic makes it more favourable for persistent carriage (34). This indicates the 
importance of their inclusion in pneumococcal vaccines. In the most recent data obtained from 
the National Laboratory Surveillance of Invasive Streptococcal Disease in Canada annual 
summary for 2017, the prevalence of IPD was less than 1% for both serotype 6B and 14 in all 
adult age groups (15 - 49, 50 - 64, and 65 years and over). The most common serotypes that 
caused IPD in all age groups were 3, 22F, 4, 9N, and 8, all of which are serotypes included in 
PPV23, and three of these are included in PCV13 (35). The rates of IPD in Canada caused by 
PCV13 serotypes have decreased since the implementation of PCV13 (2010), with 6B 
accounting for 0.3% of cases and 14 accounting for 0.5% of cases in the 15 - 49-year group in 
2012 (36). Leblanc et al. (2019) investigated the incidence of serotypes causing pneumococcal 
CAP in Canada between 2011 and 2015 and found that serotype 14 has not caused any cases of 
CAP since 2011, and CAP cases caused by serotype 6B were last seen in 2012 and 2013, with 
both serotypes causing less than 5% of CAP cases each year. The serotypes causing the most 
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pneumococcal CAP cases from this 4-year period were 3, 7F, 19A, 6A, and 5, all of which are in 
PCV13, and four in PPV23 (37).  
Previous studies have found that since the implementation of the infant immunization 
program with PCV7, the prevalence of serotypes included in PCV7 causing IPD has decreased 
over time. This could be due to serotype replacement, which results in the increased prevalence 
of non-vaccine serotypes causing IPD. It is also possible that the reduction in vaccine serotypes 
has resulted in better detection of non-vaccine serotypes, a phenomenon also known as 
unmasking (38, 39). This suggests that the colonization rates of these serotypes have decreased 
in adults. Colonization of pneumococcus is important for adults because it is an immunizing 
event that results in the production of anti-capsular and anti-protein antibodies. The maintenance 
of pneumococcal memory B cells is reliant on repeated exposure to pneumococcus (40, 41). It 
has also been suggested that colonization with pneumococcus throughout life results in an 
increased secondary immune response to pneumococcal conjugate vaccines (41). Pneumococcal 
colonization could also be important in boosting immunity against pneumococcus in adults for 
the maintenance of pneumococcal antibody concentrations. This has been found to be important 
for maintenance of antibodies specific for other pathogens such as Haemophilus influenzae type 
b (Hib). Makela et al. (2003) found that maintenance of immunological memory post- Hib 
conjugate vaccine was dependent on repeated exposure to both Hib and cross-reactive bacteria 
(42).  
 The differences in pneumococcal antibody concentrations between FN and non-FN 
participants could be due to antibodies that are cross-reactive with other pathogens or 
environmental antigens. Lagergard et al. (1983) found that pneumococcal serotype 6B antibodies 
are cross-reactive with Hia polysaccharide (43). Disease caused by Hia is more prominent in the 
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Canadian Indigenous populations, specifically in the FN population of northwestern Ontario 
(23). It has also been reported that pneumococcal IgG antibodies cross-react with Streptococcus 
mitis, a bacterium that commensally inhabits the oral cavity and upper respiratory tract (44). 
Peoples of Indigenous descent have been found to have poor oral health due to isolation, reliance 
on processed foods, and a lack of access to dental care (45). This could cause an imbalance in the 
oral environment, making it more favorable for bacterial growth (46).  
 Pneumococcal antibodies have been found to cross-react with Klebsiella pneumoniae 
capsular polysaccharides (47). This bacterium inhabits gastrointestinal tracts of humans and 
animals and is also an opportunistic pathogen that can cause disease in humans and other 
animals. K. pneumoniae has been associated with foodborne disease outbreaks, but has also been 
known to cause extraintestinal human infections such as pneumonia (48). Heidelberger et al. 
(1986) found that pneumococcal antibodies cross-react with Pseudomonas aeruginosa 
lipopolysaccharides (49). P. aeruginosa is typically found in natural water sources such as lakes 
and rivers (50). It has been documented that Indigenous communities have a history of having 
inadequate access to safe drinking water and hence could have been exposed to P. aeruginosa 
more frequently than non-FN communities (51). Exposure to plant polysaccharides for nutrition 
or medical purposes could also result in the production of cross-reactive antibodies. Heidelberger 
et al. (1982) investigated cross-reactions of anti-pneumococcal serum and plant polysaccharides. 
Anti-pneumococcal serotype 6 serum has been found to cross-react with polysaccharides of 
Althaea officinalis (marshmallow plant) as well as Ocimum basilicum (basil), and anti-
pneumococcal serotype 14 serum has been found to cross-react with polysaccharides of linseed 
(flax) and sassafras. These are just a few examples of the plant polysaccharides tested; 
unfortunately, not many plants that typically grow in Canada were tested. Traditional Indigenous 
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medicine uses a wide variety of plants to treat ailments (52), and therefore it is possible that 
some of these plant polysaccharides induce production of natural antibodies cross-reactive with 
pneumococcal polysaccharides.   
 As mentioned previously, the FN population in northwestern Ontario not only have an 
increased incidence of IPD, they also have an increased incidence of disease caused by Hia (19, 
53, 54). In a previous study by our group, Nix et al. (2018) found that both the serum bactericidal 
activity and IgM antibody concentrations specific to Hia are higher in the FN population 
compared to non-FN individuals (23). Similarly, our FN groups (FNSO, FNNO and FN-CKD) 
had higher IgG serotype 6B and 14 antibody concentrations compared to non-FN groups (NFNT, 
NFNK, and NFN-CKD). Nix et al. (2018) reported that FNSO had the highest serum bactericidal 
activity and IgM antibody concentrations specific to Hia, and in our present study, FNSO also 
had the highest IgG antibody concentrations specific for both pneumococcal serotypes 6B and 
14. These findings suggest that there is increased carriage of Hia and pneumococcus in the FN 
population. Unfortunately, there is very limited information in the literature on risk factors for 
increased carriage in adults, and from the studies that are available, many of the factors seem to 
be dependent on the community being assessed. Some of these common risk factors that increase 
carriage include: presence of young children in the household, overcrowding in the household, 
lack of hygiene or clean water, living in a remote community, tobacco use, and lower 
socioeconomic status (55-58).   
 When comparing the CKD groups to the healthy participants of the same ethnicity, FN-
CKD participants had significantly lower serotype 6B antibody concentrations compared to 
healthy FN participants, but no significant differences in serotype 14 antibody concentrations. 
There were no significant differences in serotype 6B antibody concentrations between NFN-
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CKD and healthy non-FN participants, but NFN-CKD had significantly higher serotype 14 IgG 
concentrations compared to healthy non-FN participants. When comparing CKD groups, FN-
CKD had significantly higher concentrations of serotype 14 antibodies compared to NFN-CKD.  
It is important to consider that NFN-CKD have a significantly higher mean age compared 
to the four healthy participant groups. It is also important to note that the FN-CKD mean age is 
significantly lower compared to NFN-CKD. This is not uncommon as it has been reported 
previously that people of Indigenous descent have a tendency to develop CKD at a younger age 
(59). Five of the six groups have a mean age that is considered middle age (40 - 60 years) while 
the NFN-CKD participants’ mean age categorizes them as elderly (≥ 65 years). This is important 
to consider when comparing groups because of a phenomenon known as immunosenescence, 
which is the decline of immune system function due to aging in the elderly. In regard to humoral 
immunity, elderly people have diminished B cell responses and decreased antibody levels (60). 
However, our NFN-CKD patients have higher serotype 14 concentrations compared to healthy 
non-FN, suggesting that immunosenescence has not resulted in decreased serotype 14 
concentrations. We cannot fully explain why NFN-CKD have higher serotype 14 concentrations, 
but it is possible that the NFN-CKD patients could have increased exposure to pneumococcus or 
antigens in the hospital environment that resulted in the production of cross-reactive antibodies.  
Patients with CKD have multiple immune abnormalities due to uremia, but in terms of 
humoral immunity, these patients have reduced numbers of B cells and decreased function of 
antibody producing plasma cells (61). Watt et al. (2007) reported that IPD is 3 - 5 times more 
common amongst Indigenous Navajo adults compared to the general US population. The 
identified risk factors for IPD included CKD, congestive heart failure, alcohol use or alcoholism, 
extremely high or low body mass index (BMI), and unemployment (62). Factors that contribute 
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to the progression of carriage to IPD consist of age, cigarette smoking, alcohol consumption, and 
comorbidities (chronic obstructive pulmonary disease, heart failure, asthma, and diabetes) (63). 
Indigenous Canadians have an increased prevalence of diseases such as obesity, diabetes, 
circulatory diseases, and cancer, resulting in a decreased life expectancy (64). This suggests that 
the increased IPD rate in the FN population is due to the increased prevalence of risk factors 
such as CKD, cardiovascular comorbidities, and diabetes mellitus in the northwestern Ontario 
FN population. The immune dysfunction associated with immunocompromised individuals 
within the FN population indicates that this could also have an impact on IPD risk (21). It has 
been documented that the Canadian Indigenous population has increased rates of invasive 
bacterial diseases such as IPD, invasive Haempohilus influenzae disease, invasive Group A 
streptococcal disease, invasive meningococcal disease, and invasive Group B streptococcal 
disease (65). Reisman et al. (2014) suggested that the increased IPD rates in Indigenous Alaskan 
population was due to lack of in-home water services, and that improving sanitation services and 
decreasing overcrowding in the household could decrease the incidence of IPD (56). A major 
issue as a result of the low socioeconomic status in the FN communities is inadequate access to 
clean water, which is associated with decreased hygiene practices such as hand washing (66). 
Overcrowding in households causes increased carriage of pneumococcus, which suggests that 
there is an increased transmission of pathogens resulting in increased rates of infections such as 
IPD in FN population (56, 67).  
 A previous study by Simell et al. (2008) investigated the effects of aging and sex on 
naturally acquired pneumococcal antibodies. Participants were separated based on sex and if they 
were over the age of 65 years or under 65 years old. Concentrations of anti-capsular IgG specific 
for serotype 6B were significantly lower in the elderly, and a larger decrease in anti-
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pneumococcal capsular polysaccharide antibodies was seen in women (68). Due to a lack of 
elderly participants in this study, the effect on age could not be assessed. When participants of 
the same ethnicity but different sex were compared, the only significant difference was that 
healthy FN females had significantly higher serotype 14 IgG concentrations compared to FN 
males. Regression analyses detected only one significant relationship. A positive relationship 
between age and serotype 14 antibody concentrations indicates that as healthy non-FN female 
participants age, their serotype 14 IgG concentrations also increase. It is difficult to interpret 
these data without additional participant information, but serotype 14 IgG concentrations appear 
to have a relationship with the female sex. This could indicate that the difference between males 
and females could be due to differences in exposure to children who have a much higher rate of 
carriage of pneumococcus than adults (69). Although the previously mentioned study found that 
there is a negative relationship of antibody concentration and age specifically in women (68), 
this could be due to differences in the ages of our study participants, as well as different living 
conditions.  
 Protective antibody concentrations against pneumococcal disease have not been 
established for adults. To determine if the antibody concentrations of the adults included in this 
study were different from other adults, IgG concentrations from the literature are summarized in 
Supplementary Table 3. The range of serotype 6B IgG concentrations in healthy adults was 0.4- 
2.1 µg/ mL and for serotype 14 IgG concentrations was 0.9 - 7.4 µg/ mL. Mitra et al. (2016) 
reported a geometric mean of 0.6 µg/ mL for serotype 6B IgG antibodies and 2.1 µg/ mL for 
serotype 14 IgG antibodies in CKD patients. There is a wide range in the literature, and our 
healthy participants are within this range. The concentrations of our CKD groups are similar to 
those reported by Mitra et al. (2016) (70). The correlate of protection against IPD post-PCV 
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immunization for infants is 0.35 µg/ mL. However, it has been suggested that this may not be 
true for all serotypes, and that concentrations resulting in protection may be dependent on 
serotype (71).   
 This study has several limitations, such as not having enough elderly participants over the 
age of 65, and non-FN participants were not able to be recruited from southern Ontario.  
Carriage data was not collected, functional abilities of pneumococcal antibodies could not be 
assessed, and there was very limited information about participants available (e.g., number of 
people in household). We also did not have access to healthy participant medical records so we 
could not confirm that participants were pneumococcal vaccine naïve. The biggest limitation is 
that protective antibody titres have not been established for adults, and therefore we cannot 
determine the proportion of participants at increased risk for IPD. 
 
Conclusions 
There are many environmental factors that can influence natural antibody concentrations. 
Based on the concentrations of pneumococcal 6B and 14 IgG antibodies, the data suggest that the 
increased risk of IPD in the Indigenous population is likely due to the increased prevalence of 
immunocompromising conditions such as CKD, rather than decreased antibody concentrations. 
Determining a correlate of protection for adults would be beneficial to determine if certain adults 
need to receive pneumococcal immunizations before the age of 65 years old.  
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Tables and Figures 
 
Table 1. Participant demographics. 
* compares to First Nations Northwestern Ontario, and + compares to all other groups. Mann-
Whitney U test, **p < 0.01, *** 0.001, **** 0.0001. Kruskal-Wallis, post-hoc analysis Dunn’s 




























All healthy First Nations (FN) 77 41 (39) 18-80 49 
All healthy non-First Nations (non-
FN) 
64 45 (52) 20-72 66 
First Nations Southern Ontario 
(FNSO) 
30 46 (51) (2 
unknown) ** 
20-80 50 
First Nations Northwestern Ontario 
(FNNO) 
47 37 (34)  18-67 40 
Non-First Nations Thunder Bay 
(NFNT) 
45 46 (52) ** 22-72 62 
Non-First Nations Kenora (NFNK) 19 43 (48) 20-68 74 (1 
unknown) 
First Nations Thunder Bay- CKD 
(FN-CKD) 
41 49 (50) *** 20-73 41 
Non-First Nations Thunder Bay- CKD 
(NFN-CKD) 
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Figure  1. Concentration of pneumococcal IgG antibodies for healthy First Nations (FN) (n=77), 
healthy non-First Nations (non-FN) (n=64), First Nations with chronic kidney disease (FN-CKD) 
(n= 41) and Non-First Nations with chronic kidney disease (NFN-CKD) (n=25). Geometric 
mean antibody concentrations are displayed. Statistical significance determined by Kruskal-
Wallis test, Dunn’s post-hoc test (#), Mann-Whitney U test detected differences between groups 
except when comparing serotype 14 antibody concentrations between CKD groups, a Student’s 
t-test was performed. * indicates significance between FN and other groups, ^ indicates 
significance between NFN-CKD and other groups. *p < 0.05, *** p < 0.001, **** p < 0.0001.    
Figure 1A shows the concentration of pneumococcal 6B IgG antibodies, and 1B shows the 
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Figure 2. Concentration of pneumococcal IgG antibodies for each of the four communities; First 
Nation Southern Ontario (FNSO) (n= 30), First Nation Northwestern Ontario (FNNO) (n= 47), 
non-Indigenous Thunder Bay (NFNT) (n= 46), non-Indigenous Kenora (NFNK) (n= 19), First 
Nations with chronic kidney disease (FN-CKD) (n= 41) and Non-First Nations with chronic 
kidney disease (NFN-CKD) (n=25). Geometric mean antibody concentrations are displayed. 
Statistical significance determined by Kruskal-Wallis test, Dunn’s post-hoc test (#), Mann-
Whitney U test detected differences between groups except when comparing serotype 14 
antibody concentrations between CKD groups, a Student’s t-test was performed. * indicates 
significance between FNSO and other groups, + indicates significance between FNNO and other 
groups, $ indicates significance between NFNT and other groups, & indicates significant 
difference between NFNK and other groups and ^ indicates significance between NFN-CKD and 
other groups.  *p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Figure 2A shows the 
concentration of pneumococcal 6B IgG antibodies, and 2B shows the concentration of 


















Supplementary table 1. Sex vs. pneumococcal IgG antibody concentrations for serotypes 6B and 
14. 
Group 6B  
GM (µg/ mL), 95% CI 
14  
GM (µg/ mL), 95% CI 
All healthy females vs. all 
healthy males 
 
0.9, 0.72- 1.1 vs. 1.0, 0.76- 
1.4, p > 0.05 
2.1, 1.7-2.7 vs. 1.9, 1.4- 2.5, p 
> 0.05 
First Nations healthy 
female vs. First Nations 
healthy male 
 
1.6, 1.3- 2.0 vs. 1.4 1.0- 1.9, p 
> 0.05 
4.6, 3.7- 5.9 vs. 2.9, 2.0- 4.1, 
p < 0.05 
Non- First Nations healthy 
female vs. Non-First 
Nations healthy male 
 
0.47, 0.4- 0.6 vs. 0.62, 0.3- 
1.1, p > 0.05 
1.3, 1.0- 1.7 vs. 1.5, 0.9- 2.6, p 
> 0.05 
First Nations healthy 
female vs. Non- First 
Nations healthy female 
 
1.6, 1.3- 2.0 vs. 0.5, 0.4- 0.6, 
p < 0.0001 
4.6, 3.7- 5.9 vs. 1.3, 1.0- 1.7, 
p < 0.0001 
First Nations healthy male 
vs. Non- First Nations 
healthy male 
 
1.4, 1.0- 1.9 vs. 0.6, 0.3- 1.1, 
p < 0.05 
2.9, 2.0- 4.1 vs. 1.5, 0.9- 2.6, p 
> 0.05 
First Nations CKD female 
vs. First Nations CKD 
males 
 
0.8, 0.5-1.3 vs. 0.8, 0.5-1.3, p 
> 0.05 
3.4, 2.0-5.9 vs. 3.1, 1.9-4.9, p 
> 0.05 
Non-First Nations CKD 
female vs. Non-First 
Nations CKD male 
 
0.7, 0.1-3.4 vs. 0.6, 0.4-0.9, p 
> 0.05 
3.2, 2.7-3.8 vs. 1.9, 1.0-3.5, p 
> 0.05 
First Nations CKD female 
vs. Non-First Nations 
CKD female 
 
0.8, 0.5-1.3 vs. 0.7, 0.1-3.4, p 
> 0.05 
3.4, 2.0-5.9 vs. 3.2, 2.7-3.8, p 
> 0.05 
First Nations CKD male 
vs. Non-First Nations 
CKD male 
 
0.8, 0.5-1.3 vs. 0.6, 0.4-0.9, p 
> 0.05 
3.1, 1.9-4.9 1.9, 1.0-3.5, p > 
0.05 
First Nations healthy 
female vs. First Nations 
CKD female 
 
1.6, 1.3- 2.0 vs. 0.8, 0.5-1.3, p 
< 0.05 
4.6, 3.7- 5.9 vs. 3.4, 2.0-5.9, p 
> 0.05 
 






































First Nations healthy male 
vs. First Nations CKD 
male 
1.4 1.0- 1.9 vs. 0.8, 0.5-1.3, p 
< 0.05 
2.9, 2.0- 4.1 vs. 3.1, 1.9-4.9, p 
> 0.05 
Non- First Nations healthy 
female vs. Non-First 
Nations CKD female 
 
0.47, 0.4- 0.6 vs. 0.7, 0.1-3.4, 
p > 0.05 
1.3, 1.0- 1.7 vs. 3.2, 2.7-3.8, p 
< 0.05 
Non- First Nations healthy 
male vs. Non-First Nations 
CKD male   
0.62, 0.3- 1.1 vs. 0.6, 0.4-0.9, 
p > 0.05 
1.5, 0.9- 2.6 vs. 1.9, 1.0-3.5, p 
> 0.05 
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Supplementary table 2. Linear regression analysis of age and pneumococcal IgG antibody 
concentrations for serotypes 6B and 14. 
 
  
Group 6B (r2, p value) 14 (r2, p value) 
All healthy participants 
 
0.0070, p > 0.05 0.0001, p > 0.05 
First Nations healthy 
 
0.0051, p > 0.05 0.0010, p > 0.05 
Non-First Nations healthy 
 
1.627 x 10-7, p > 0.05 0.1181, p < 0.01 
First Nations CKD 
 
0.0151, p > 0.05 0.0085, p > 0.05 
Non-First Nations CKD 
 
0.1322, p > 0.05 0.01069, p > 0.05  
First Nations healthy female 
 
0.002427, p > 0.05 5.136 x 10-7, p > 0.05 
First Nations healthy male 
 
0.001318, p > 0.05 0.006353, p > 0.05 
Non-First Nations healthy female 
 
1.723 x 10-6, p > 0.05 0.1242, p < 0.05 
Non-First Nations healthy male 8.377 x 10-5, p > 0.05 0.1255, p > 0.05 
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Supplementary table 3. Pneumococcal 6B and 14 IgG antibody concentrations of pneumococcal 
vaccine naïve adults. 
Confidence intervals (CI) 
+ Female participants only 
# Male participants only 
*62% of participants are Indigenous 
& Indigenous Alaskan participants pre-immunization concentrations (3 groups because 3 
immunization groups) 
$ Indigenous Australian adults 








Source Study Country 6B (µg/ mL) 
(95% CI) 
14 (µg/ mL) 
(95% CI) 
All First Nations participants Canada 1.5 (1.2-1.8) 3.6 (2.9-4.5) 
All non-First Nations participants   0.5 (0.4-0.7) 1.3 (1.0-1.7) 
Southern Ontario First Nations Canada 1.6 (1.1-2.2) 4.5 (3.0-6.7) 
Northwestern Ontario First Nations  1.5 (1.2-1.9) 3.2 (2.4-4.1) 
Non-First Nations (Thunder Bay)  0.5 (0.3-0.6) 1.3 (1.0-1.9) 
Non-First Nations (Kenora)  0.6 (0.4-1.1) 1.4 (0.9-2.2) 
First Nations CKD (Thunder Bay)  0.8 (0.5-1.1) 3.2 (2.3- 4.5) 
Non-First Nations (Thunder Bay)   0.5 (0.3-0.8) 2.0 (1.3-2.9) 
21-44 years (1) USA  0.7 (0.5-1.1) 1.8 (1.0-3.3) 
20-45 years (1) USA 0.7 (0.4-1.1) 0.9 (0.5-1.7) 
22-42 years (2)  Finland 2.1 (1.5-3.1) 1.2 (0.6-2.4) 
30-64 years (3) + Finland ~ 0.6 ~ 1.2 
30-64 years (3) # Finland ~ 0.4 ~ 1.0 
55-74 years (4) * USA 1.9 (1.6-2.3) 5.5 (4.5-6.8) 
55-70 years (5) & USA 1.4 (0.7-2.7) 2.6 (1.1-6.1) 
55-70 years (5) & USA 4.0 (1.6-10.1) 3.8 (0.9-17.1) 
55-70 years (5) & USA 2.9 (1.4-6.3) 6.6 (3.2-13.4) 
15-59 years (6) $ Australia 0.9 (0.7-1.1) 2.5 (1.7-3.8) 
15-59 years (6) Australia 0.4 (0.3-0.6) 1.0 (0.5-1.9) 
20-39 years (7) Netherlands ~ 0.7 ~ 1.1 
40-59 years (7) Netherlands ~ 0.6 ~ 1.6 
60-79 years (7) Netherlands  ~ 0.5 ~ 1.3 
50-70 years (8)  UK 0.4 (0.3-0.5) 1.5 (1.2-1.9) 
50-70 years (8)  UK 0.4 (0.3-0.6) 0.9 (0.6-1.4) 
50-64 years (9) USA 1.6 (1.4-2.0) 8.2 (7.1-9.4) 
65-88 years (9) USA 1.5 (1.3-1.9) 7.4 (6.4-8.6) 
62.6 years (10) ^ USA 0.6 (0.3- 1.0) 2.1 (0.8- 5.4) 
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Abstract  
Background: While the 23-valent pneumococcal polysaccharide vaccine (PPV23) is routinely 
used in Canada and some other countries to prevent pneumococcal infection in adults with 
chronic kidney disease (CKD), patients develop a suboptimal antibody response to PPV23 due to 
their immune dysfunction. The 13-valent pneumococcal conjugate vaccine (PCV13) has superior 
immunogenicity in some categories of immunocompromised adults; however, its effect on the 
immune response in CKD patients has only been addressed by two recent studies with 
conflicting results. The effect of PPV23 or PCV13 on B cells in these patients has not been 
previously studied. We studied the absolute numbers and proportions of B cells and 
subpopulations in two groups of adult patients with severe CKD pre- and 7 days post-
immunization with PCV13: pneumococcal vaccine naïve and previously immunized with PPV23 
(over one year ago).  
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Results: PPV23 immunized patients had significantly lower proportions and absolute numbers 
of class switched memory (CD19+CD27+IgM-), as well as lower absolute numbers of IgM 
memory (CD19+CD27+IgM+) and class switched B cells (CD19+CD27-IgM-) compared to 
PPV23 naïve patients. Following PCV13 immunization, the differences in absolute numbers of 
B-cell subpopulations between groups remained significant. The PPV23 immunized group had 
higher proportions of CD5- B cells along with lower proportions and absolute numbers of CD5+ 
B cells compared to PPV23 naïve patients both pre- and post-immunization with PCV13. 
However, previous PPV23 immunization did not have a noticeable effect on the numbers of total 
IgG or serotype 6B and 14 specific antibody-secreting cells detected 7 days post-immunization 
with PCV13. Nevertheless, fold increase in anti-serotype 14 IgG concentrations 28 days post-
PCV13 was greater in PPV23 naïve than in previously immunized patients. 
 
Conclusions: The results suggest that immunization with PPV23 may result in long-term 
changes in B-cell subpopulations such as increased prevalence of CD5- B cells and decreased 
prevalence of class switched memory B cells in the peripheral blood. Because previous 
immunization with PPV23 in patients with CKD is associated with a significant decrease in the 
total class switched memory B cells in response to subsequent immunization with PCV13, this 
may reduce PCV13 immunogenicity in the setting of PPV23 followed by PCV13.  
 
Trial Registration  
Registered February 24, 2015 at ClinicalTrials.gov (NCT 02370069). 
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Key words: Chronic kidney disease (CKD), Streptococcus pneumoniae, B cells, memory B 
cells, T-cell independent response, T-cell dependent response, 23-valent pneumococcal 
polysaccharide vaccine (PPV23), 13-valent pneumococcal conjugate vaccine (PCV13), flow 
cytometry, enzyme-linked immunospot assay (ELISPOT). 
 
Background 
Chronic kidney disease (CKD) is a common condition which affects approximately 10-
15% of adults globally (1). Patients with the most advanced stages of this disease (severe CKD, 
or chronic renal failure) require life-saving renal replacement therapy, such as hemodialysis or 
kidney transplantation (2, 3). Severe CKD is characterized by high mortality rates. Adjusted for 
age, sex, and race, the total mortality rate for patients with CKD as of 2018 was 103.0 per 1000 
patient-years, more than double the total mortality rate for people without CKD (4). Acute 
infections contribute substantially to the high rates of hospitalization and mortality in CKD 
patients, following only cardiovascular disease as a major cause of death (5). High risk of 
septicaemia and other severe infections are attributed to both a compromised immune system and 
increased exposure to infectious agents in dialysis units (5-7).  
Pneumococcus (Streptococcus pneumoniae) is a Gram-positive, encapsulated 
diplococcus, which commonly colonizes the upper respiratory tract (8). Upon breaching the host 
defences, the microorganism can cause mucosal (otitis media, sinusitis, pneumonia) and invasive 
(meningitis, septicaemia, pericarditis, etc.) infections (9, 10). S. pneumoniae is the most common 
cause of community acquired pneumonia (CAP) worldwide (11). The highest incidence rates of 
CAP and invasive pneumococcal disease (IPD) are found in young children, elderly, and 
immunocompromised adults (9, 12). Patients with CKD, particularly those with nephrotic 
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syndrome and undergoing dialysis, are highly susceptible to pneumococcal infection, especially 
pneumonia (13). 
To prevent pneumococcal infection in adult patients with CKD, immunization with 
pneumococcal polysaccharide vaccine (PPV23), which contains purified capsular 
polysaccharides from 23 pneumococcal serotypes most commonly associated with IPD (1, 2, 3, 
4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F), is 
currently recommended in Canada (14).  However, the effect of PPV23 in CKD patients is 
suboptimal because of their immune dysfunction (15, 16). The second-generation 
(polysaccharide-protein conjugate) vaccines, which induce T-cell dependent antibody responses 
to polysaccharide antigens (17), have superior immunogenicity in immunocompromised adults 
and the elderly (18-20). In Canada, 13-valent pneumococcal conjugate vaccine (PCV13), which 
consists of purified capsular polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 
19A, 19F, and 23F conjugated to a carrier protein (CRM197), is recommended for several 
categories of immunocompromised adults, such as bone marrow transplantation recipients and 
HIV-infected individuals (21). Although in some countries PCV13 is now used for immunization 
of patients with CKD, PCV13 immunogenicity in adults undergoing hemodialysis was only 
recently addressed by two studies with differing results. Mitra et al. (2016) showed that the 
antibody concentrations in patients with CKD declined significantly 12 months after 
immunization with PCV13, compared to 2 months post-immunization for 11 of the 13 serotypes 
tested (22). Vandecasteele et al. (2018) demonstrated that immunization of CKD patients with 
PPV23 may have a negative effect on the immune response to PCV13 (23). It was suggested that 
immunization with PPV23 could lead to depletion of memory B cells following exposure to 
purified polysaccharide antigens potentially affecting the development of antibody responses to 
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polysaccharide antigens administered via protein-conjugate vaccines (24). However, to the best 
of our knowledge, the effect of PPV23 or PCV13 on B cells in patients with CKD has not been 
previously studied. To address this question, we studied the proportions and numbers of B cells 
(CD19+), and their subpopulations: naïve (CD27-IgM+), IgM memory (CD27+IgM+), class 
switched (CD27-IgM-), class switched memory (CD27+IgM-), CD5+ and CD5- B cells pre- and 
7 days post-immunization with PCV13. Adult patients with severe CKD were separated into two 
groups: one group was pneumococcal vaccine naïve and the other group was previously 
immunized with PPV23 (over one year ago).  
 
Results 
In patients with severe CKD, immunization with PCV13 did not result in any significant 
changes in proportions of total B cells or any B-cell subpopulation except for CD5- cells. The 
CD19+CD5- subpopulation increased on day 7 post-immunization (74.2, 68.5 - 80.4% vs. 52.0, 
39.3 - 68.7%, p < 0.05, Table 1). No significant changes in absolute numbers of total 
lymphocytes, B cells, or B-cell subpopulations assessed immediately prior to immunization and 
7 days post-immunization were noticed (Supplementary Table 1). There was a statistically 
significant positive correlation between pre- and post-immunization absolute numbers of all 
tested cells, except for class switched and total B cells, and proportions of all cells with the 
exception of class switched and CD5- B cells (Supplementary Table 2).  
To determine if PPV23 immunization had an impact on B-cell subpopulations, we tested 
the peripheral blood immediately prior to immunization with PCV13. The patients who had 
previously received PPV23 had significantly lower proportions (13.7, 9.2 - 20.3% vs. 22.9, 17.6 - 
29.8, p < 0.05, Figure 1A) and absolute numbers (1.3, 0.9-2.0 X 107 cells/L vs. 2.6, 1.8 - 3.8 X 
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107 cells/L, p < 0.05, Figure 1B) of class switched memory B cells, as well as lower absolute 
numbers of IgM memory (4.9, 3.1 - 7.5 X 106 cells/L vs. 9.6, 6.3 - 1.5 X 106 cells/ L, p < 0.05) 
and class switched B cells (1.3, 1.0 - 1.6 X 107 cells/L vs. 1.8, 1.8 - 4.1 X 107 cells/L, p < 0.05) 
compared to PPV23 naïve patients (Figure 1B). Previous immunization with PPV23 did not have 
a negative effect on total lymphocytes, as no significant difference in the absolute numbers of 
lymphocytes prior to PCV13 immunization was found between the groups (1.0, 0.8 - 1.4 X 109 
cells/ L vs. 0.9, 0.8 - 1.1 X 109 cells/ L, p > 0.05, supplementary table 3). However, PPV23 naïve 
patients had a slightly higher absolute number of B cells pre-immunization compared to PPV23 
immunized patients (9.9, 7.0 - 13.9 X 107 cells/ L vs. 8.3, 6.1 - 11.2 X 107 cells/ L, p > 0.05, 
supplementary table 3). 
Following the PCV13 immunization, the differences in absolute numbers of B-cell 
subpopulations between the groups remained significant. Those who had previously received 
PPV23 had lower numbers of IgM memory (4.6, 3.2 - 6.5 X 106 cells/ L vs. 8.9, 5.7 - 14.0 X 106 
cells/ L, p < 0.05), class switched B cells (1.2, 0.9 - 1.5 X 107 cells/ L vs. 1.6, 1.0 - 2.7 X 107 
cells/ L, p < 0.05), and class switched memory B cells (1.3, 0.9 - 2.0 X 107 cells/ L vs. 2.6, 1.8 - 
3.8 X 107 cells/ L, p < 0.05) compared to PPV23 naïve patients (Figure 2B), although no 
significant differences in proportions of B-cell subpopulations between the groups were detected 
(Figure 2A). Both groups had the same absolute numbers of lymphocytes 7 days post-
immunization (1.0, 0.7 - 1.3 X 109 cells/ L vs. 1.0, 0.8 - 1.2 X 109 cells/ L, p > 0.05, 
supplementary table 3). However, PPV23 naïve patients had slightly higher absolute numbers of 
total B cells compared to PPV23 immunized patients (9.3, 6.7 - 12.8 X 107 cells/ L vs. 7.9, 5.7 - 
10.9 X 107 cells/ L, p > 0.05, supplementary table 3). The results suggest that previous 
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immunization with PPV23 may decrease the numbers of IgM memory, class switched, and class 
switched memory B-cell subpopulations both pre- and 7 days post-immunization with PCV13.  
 As previous studies found an association between the CD5- subpopulation of B cells and 
production of IgG antibodies to pneumococcal polysaccharide antigens in response to PPV23 
(25), we attempted to determine if there were any differences in CD5-expressing B cells between 
the groups with different histories of PPV23 vaccination. Prior to immunization with PCV13, 
those patients who had previously been immunized with PPV23 had higher proportions of CD5- 
(75.5, 70.6 - 80.6% vs. 37.5, 20.6 - 68.3%, p < 0.05) and lower proportions of CD5+ cells (22.5, 
18.9 - 27.2% vs. 37.7, 24.1 - 58.86%, p < 0.05) as well as CD5+ absolute numbers (2.1, 1.6 - 2.8 
X 107 vs. 3.5, 2.0 - 6.0 X 107, p < 0.05) compared to PPV23 naïve patients (Figure 3A-B).  
Seven days post-immunization with PCV13, patients previously immunized with PPV23 
still had higher proportions of CD5- B cells (69.5, 55.7 - 86.9% vs. 37.4, 18.9 - 73.66%, p < 
0.05) and lower proportions (16.9, 13.9 - 20.6% vs. 35.2, 23.0 - 53.7%, p < 0.05) and absolute 
numbers of CD5+ cells (3.0, 1.9 - 5.1 X 107 cells/ L vs. 1.3, 0.9 - 1.9 X 107 cells/ L, p < 0.05) 
compared to PPV23 naïve patients (Figure 3A-B). Although higher absolute numbers of CD5- 
cells were present in PPV23 immunized than in PPV23 naive patients, the difference was not 
statistically significant (5.2, 3.3 - 8.1 X 107 cells/ L vs. 3.5, 1.6 - 7.7 X 107 cells/ L, p > 0.05, 
Figure 3B). These results show that immunization with PPV23 may lead to in an increased 
prevalence of the CD5- subpopulation among circulating B cells.  
To determine if the numbers of total IgG and antigen specific antibody secreting cells 
(ASC) on day 7 post-immunization with PCV13 depend on previous immunization with PPV23, 
we conducted enzyme-linked immunospot (ELISPOT) assay on peripheral blood mononuclear 
cells (PBMC) stimulated with Staphylococcus aureus Cowan strain protein A (SAC) and CpG 
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Oligonucleotide (ODN-2006). No statistically significant difference between PPV23 naïve and 
PPV23 immunized patients was found between the numbers of total IgG ASC (median ± 
standard deviation) (118.5 ± 93.8 vs. 151.0 ± 93.5, p > 0.05, Figure 4A), ASC specific for 
pneumococcal polysaccharide serotype 6B (0.5 ± 0.34 ASC vs. 0.5 ± 0.36 ASC), or serotype 14 
(1.0 ± 0.5 ASC vs. 0.8 ± 0.3 ASC, p > 0.05, Figure 4B). After outliers were removed, the number 
of patients that had antigen-specific IgG ASC below the limit of detection was calculated. There 
were 9/16 (56%) PPV23 naïve and 16/25 (64%) PPV23 immunized patients without detectable 
ASC specific for 6B; for serotype 14-specific ASC, the corresponding numbers were 7/16 (44%) 
vs.13/25 (52%), p > 0.05 (Fisher’s exact test). Hence, in this group of patients, previous PPV23 
immunization did not have a noticeable effect on the numbers of total IgG ASC or serotype 6B 
and 14 specific ASC detected at day 7 post-immunization with PCV13.  
To determine if previous immunization with PPV23 had an effect on the antibody 
response to PCV13, concentrations of pneumococcal 6B and 14 IgG antibodies were determined 
pre- and 28 days post-immunization (supplementary table 4). There were no significant 
differences between PPV23 naive and PPV23 immunized patients in the concentration of 
pneumococcal 6B antibodies pre-immunization (0.9, 0.6-1.4 µg/ mL vs. 1.1, 0.7 - 1.6 µg/ mL, p 
> 0.05) or post-immunization (2.1, 1.4 - 3.2 µg/ mL vs. 2.4, 1.4 - 3.9 µg/ mL, p > 0.05). 
Compared to PPV23 immunized patients, PPV23 naive patients had a significantly lower 
concentration of pneumococcal 14 antibodies pre-immunization (2.8, 1.9 - 4.2 μg/ mL vs. 5.0 3.0 
- 8.1, p < 0.05), but there was no significant difference in post-immunization concentrations (8.0, 
4.5 - 14.4 µg/ mL vs. 8.1, 5.0 - 14.4, p > 0.05). When pre- and day 28 post-immunization 
concentrations were compared for each patient group, both groups had a significant increase in 
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pneumococcal 6B antibody concentrations (p < 0.05), however, only PPV23 naïve patients had a 
significant increase in pneumococcal 14 antibody concentrations (p < 0.01).  
 While PPV23 immunized patients had a slightly smaller fold change in pneumococcal 6B 
antibodies compared to PPV23 naïve patients (2.3, 1.7 - 3.1 µg/ mL vs. 2.8, 1.8 - 4.3 µg/ mL, p > 
0.05), they had a significantly smaller fold change in pneumococcal 14 antibodies (1.3, 1.1 - 1.6 
µg/ mL vs. 1.9, 1.3 - 2.8 µg/ mL, p < 0.05). A strong negative correlation was found between the 
fold change of pneumococcal 14 antibodies and the pre-immunization absolute numbers of CD5- 
B cells in PPV23 immunized patients (r= -0.8576, p < 0.001, Pearson correlation). No other 
significant correlation was detected between pre-immunization or day 7 post-immunization 
proportions or absolute numbers of CD5- or class switched memory B-cell subpopulations and 
the fold change in pneumococcal 6B or 14 antibody concentrations (data not shown). These 
results suggest that previous PPV23 immunization negatively affects the pneumococcal 6B and 
14 antibody response to subsequent immunization with PCV13 in patients with CKD.  
 
Discussion  
Although both types of pneumococcal vaccines induce the production of serotype-
specific antibodies to S. pneumoniae capsular polysaccharides, PPV23 and PCV13 activate 
different immunological mechanisms. PPV23 contains purified capsular polysaccharides, which 
directly activate B cells in a T-cell independent manner. Bacterial capsular polysaccharides have 
multiple repeating epitopes which cross-link B cell receptors, causing the activation of Bruton’s 
tyrosine kinase that results in activation and proliferation of antigen-specific B cells (26). The 
memory B cells generated from T-cell independent responses are short-lived and produce a less 
robust antibody response upon re-exposure to an antigen (27). Vaccines containing capsular 
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polysaccharides alone, such as PPV23, have poor immunogenicity in immunocompromised 
individuals (28). In the case of PCV13, the conjugation of polysaccharides to CRM197, a non-
toxic mutant of diphtheria toxin, which acts as a carrier protein, results in a T-cell dependent 
response. The protein-polysaccharide conjugate binds to B cell receptors and it is then brought 
into the endosome, where the protein component is processed into peptides and binds to the 
major histocompatibility complex class II (MHC II) molecules. Antigen presentation of the 
carrier protein in the context of MHC II results in the activation of CD4+ T cells. The subsequent 
generation of signals stimulates B cell maturation, class switching, and proliferation resulting in 
the production of long-lived memory B cells and secretion of polysaccharide-specific class 
switched high affinity antibodies (29).  
 It is still uncertain whether immunization with plain pneumococcal polysaccharide 
antigens (included into PPV23) negatively impacts antibody responses to subsequent 
immunization with polysaccharide-protein conjugate vaccines, such as PCV13. A study by 
Clutterbuck et al. (2012) measured the effect of PPV23 followed by the 7-valent pneumococcal 
conjugate vaccine (PCV7) on antigen-specific B cells in older adults. It was found that while 
PCV7 immunization resulted in an increase in pneumococcal serotype-specific memory B cells, 
immunization with PPV23 depleted these cells and resulted in attenuated memory B cell 
responses (24). No studies have assessed the effect of pneumococcal immunizations on B cells in 
patients with CKD. Vandecasteele et al. (2018) found that severe CKD patients previously 
immunized with PPV23 had lower antibody response to PCV13 compared to pneumococcal 
vaccine naïve patients (23). Our results agree with this study, as PPV23 immunized patients had 
a slightly lower fold change in pneumococcal 6B IgG antibodies, and significantly lower fold 
change in pneumococcal 14 antibodies in response to PCV13 immunization. Recent studies 
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assessed the effect of previous PPV23 immunization on the response to PCV13 or PCV7 in older 
adults found that previous immunization with PPV23 decreased antibody response to subsequent 
doses of PCV13 (20, 30, 31).   
Patients with CKD are unique among other high-risk groups because they have multiple 
predisposing factors to pneumococcal infection, including uremia with its significant metabolic 
consequences, as well as the hemodialysis procedure, which causes premature aging of the 
immune system (6, 32). Patients with CKD also frequently have comorbidities, such as diabetes 
mellitus, which contribute to their immune dysfunction, and may receive immunosuppressive 
medications (33). These patients also have increased exposure to infectious agents in the hospital 
environment. Multiple immune abnormalities such as decreased bactericidal ability of 
neutrophils, granulocyte and macrophage phagocytic function, defective function of antigen 
presenting cells, reduced numbers of B cells and decreased antibody producing capacity of 
plasma cells, increased T- and B-cell apoptosis, decreased thymic T-cell output, and impaired 
activation of T-cell response have been found in CKD patients (34, 35).  
Among immune abnormalities, this group has noticeable alterations in B cells and B-cell 
function. We have recently found that patients with CKD had decreased absolute numbers of B 
cells and B-cell subpopulations compared to healthy controls (36). Pahl et al. (2010) also found 
decreased numbers of B cells in CKD patients, suggesting that B-cell lymphopenia in patients 
with CKD was due to uremia (37). It is possible that epigenetic changes caused by CKD affect 
the production of lymphoid cells at the hematopoietic stem cell level, resulting in decreased 
numbers of circulating B and T cells (38, 39).  
In this study, we found that immunization with PPV23 may have a long-term effect on B-
cell subpopulations in patients with CKD. Compared to vaccine naïve patients, PPV23 
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immunized patients of a similar age had significantly lower proportions of class switched 
memory B cells pre-immunization, and significantly lower absolute numbers of these cells both 
pre- and 7 days post-immunization with PCV13. In the literature, class switched memory B cells 
are defined as CD19+CD27+IgD- or CD19+CD27+IgM- cells (40, 41). These cells respond 
rapidly when re-exposed to the same antigen, resulting in the production of class switched, high 
affinity antibodies, and hence mediate long-lived humoral immunity (42, 43). 
Although pneumococcal-specific B cells are only a small proportion of the total B cell 
population (0.5% of the total B cell population pre-immunization and 2.0-2.75% 7 days post-
immunization with PPV23) (41), our results suggest that immunization with PPV23 results in a 
significant decrease of total class switched memory B cell population. This has not been 
previously reported as most studies focus on antigen-specific memory B cells. Chovancova et al. 
(2011) did not detect a significant change in the proportion or absolute number of class switched 
memory B cells defined as CD19+CD27+IgD-, between pre- and 7 days post-immunization with 
PPV23 in adults with common variable immunodeficiency (CVID) (44). It is possible that 
immunization with pneumococcal polysaccharides results in polyclonal stimulation of B cells, 
leading to terminal differentiation of memory B cells followed by their depletion. Polyclonal 
stimulation of memory B cells, which causes their proliferation and differentiation into plasma 
cells, helps to maintain serological memory throughout life (45). Polyclonal B cell activation by 
capsular polysaccharides of Neisseria meningitidis was previously reported by Oliveira et al. 
(1996) (46).  
The role of CD5+ and CD5- B cells in humans is not completely understood. Due to the 
lack of somatic hypermutations in CD5+ B cells, it is thought that these cells are naïve B cells 
(25, 47). The expression of CD5 decreases with age and is associated with an increase in CD27 
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expression, indicating a shift in B-cell subpopulations towards an increase in the population of 
memory B cells (48). A study by Moens et al. (2015) determined that after immunization with 
PPV23, ASC originating from CD5- B cells primarily produce pneumococcal anti-capsular 
polysaccharide IgG antibodies (25). In agreement with this study, we found significantly higher 
proportions of CD5- B cells in PPV23 immunized patients compared to PPV23 naïve ones. 
Hence immunization with PPV23 favors the generation of CD5- pneumococcal IgG memory B 
cells even in these immunocompromised adults. We found a strong negative correlation between 
the pre-immunization absolute numbers of CD5- B cells and the fold change of pneumococcal 14 
IgG antibodies in PPV23 immunized patients. Hence, although previous immunization with 
PPV23 favours the generation of CD5- B cells, it has a negative effect on the antibody response 
to subsequent immunization with PCV13 in patients with CKD.  
In an attempt to assess antigen-specific ASC, we used PBMC collected 7 days post 
immunization, given that ASC can be detected in the peripheral blood as early as 5 days after 
vaccination or infection and their numbers peak at day 7 (49). The cells were stimulated with B-
cell polyclonal activators, i.e. SAC, which induces crosslinking of surface immunoglobulins (50) 
and CpG ODN-2006, which activates TLR 9 that stimulate the differentiation of memory B cells 
(51). We measured the B-cell responses to pneumococcal capsular polysaccharides of serotypes 
6B and 14 because they have a significant impact on the global epidemiology of IPD (52). 
 As we detected only small numbers of ASC, this may reflect poor functional ability of B 
cells from CKD patients to respond to polyclonal stimulation. In addition, capsular 
polysaccharides of serotypes 6B and 14 have low immunogenicity (52). As various 
modifications of ELISPOT exist, including different methods of B cell stimulation, it is difficult 
to compare our results to other studies. One study determined that the more doses of PPV23 
 
   
137 
asplenic adults with β-thalassemia received, the lower the amount of capsular polysaccharide-
specific memory B cells in response to PCV13 was detected (53). They also found that longer 
interval between PPV23 and PCV13 vaccinations was associated with greater numbers of 
antigen-specific memory B cells (53). In that study, the range of capsular polysaccharide-specific 
IgG ASC per 1,000,000 PBMC was 0-24; in comparison, our patients had a maximum of two 
ASC specific to 6B and 14 per 200,000 PBMC. Such discrepancies could be due to differences in 
age and immune abnormalities of participants. When we attempted to measure numbers of 
plasma cells using ELISPOT, no plasma cells specific for 6B or 14 were detected (data not 
shown). Similarly, in the study by Chovancova et al. (2011), CVID patients had no detectable 
IgG ASC specific for 23 pneumococcal capsular polysaccharides due to the lack of terminal B 
cell differentiation (44). This could potentially explain the lack of B-cell response in CKD 
patients as it was demonstrated that such patients have decreased B cell activating factor receptor 
expression in transitional B cells, resulting in their decreased survival (37).  
Our study has several limitations, including small sample size that could contribute to 
lack of statistical significance in comparisons between groups. The patients received PPV23 at 
different times prior to PCV13 immunization (although always over 1 year before) that could 
contribute to the variability in results; we were unable to measure their immediate response to 
the PPV23 vaccine. Due to the large diversity among the CKD patients, we could not match our 
study participants for underlying conditions. We did not have healthy aged-matched controls that 
would have helped in the interpretation of responses by CKD patient groups. We were unable to 
calculate the fold change in antibody concentration for all participants due to sample collection 
issues such as participant withdrawal, etc.  Our ongoing study of antigen-specific antibody 
responses in these two groups will aid in the clarification of the effect of previous immunization 
 
   
138 
with PPV23 on B cells and their ability to respond to subsequent immunization with PCV13. In 
addition, our work will help determine the longevity of the antibody response to PCV13 in 
patients with CKD. 
 
Conclusions 
Immunization with PPV23 may result in long-term changes in B-cell subpopulations such 
as an increased prevalence of CD5- B cells and decreased prevalence of class switched memory 
B cells in the peripheral blood. Because previous immunization with PPV23 in patients with 
CKD is associated with a significant decrease in the total class switched memory B cell 
population as well as a decreased pneumococcal antibody response to subsequent immunization 
with PCV13, this may reduce PCV13 immunogenicity in the setting of PPV23 followed by 
PCV13. Our findings emphasize the need for further studies to optimize pneumococcal 
immunization for adults with CKD. 
 
Methods  
Patient Recruitment and Eligibility 
Sixty-one patients with stage 4 or 5 severe CKD (glomerular filtration rate (GFR), stage 4 
< 30 mL/ min/ 1.73m2, stage 5 < 15 mL/ min/ 1.73m2) (54) who were receiving hemodialysis at 
the Thunder Bay Regional Health Sciences Centre (TBRHSC) were recruited between May 2015 
and August 2018. All the patients were over 18 years old, did not have a history of 
immunocompromising conditions, were not taking any immunosuppressive medications for more 
than 14 days in the past 6 months, and had not received any vaccines in the past month or blood 
transfusions in the past 3 months. Patients were separated into two groups: 25 PPV23 naïve 
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patients (mean age 59 years, range 20 - 87 years, 32% female) and 36 previously immunized 
with PPV23 > 1 year ago (mean age 60 years, range 32 - 87 years, 47% female). This study was 
registered at ClinicalTrials.gov (NCT 02370069) and approved by the research ethics boards of 
Lakehead University and TBRHSC. 
 
Immunization protocol and sample collection 
All patients received a single dose of PCV13 (Prevnar13, Pfizer, lots: H22520, J77978, 
M573833, M73833, R56653, and T24279) administered intramuscularly in the deltoid region 
during the dialysis procedure. Ten milliliters of peripheral blood for B-cell analysis were 
collected into BD VacutainerÔ tubes with sodium heparin (BD Biosciences, Baltimore, MD, 
USA) immediately prior to immunization for flow cytometry analysis and 7 days post-
immunization for flow cytometry and ELISPOT. Blood was collected for complete blood counts 
(CBC) just before immunization and day 7 post-immunization. An additional 10 mL of 
peripheral blood for serum antibody analysis was collected into BD Vacutainer™ Venous Blood 
Collection Tubes: SST™ Serum Separation Tubes: Hemogard (BD Biosciences) pre- and 28 
days post-immunization, serum was stored at -80 °C. 
 
Analysis of B cells  
PBMC were isolated by density gradient centrifugation using Lymphoprep (Stemcell 
Technologies, Vancouver, BC, CAN). Monocytes were removed using two consecutive 
incubations in RPMI 1640 medium with L-glutamine (Thermo Fisher Scientific, Mississauga, 
ON, CAN) supplemented with 1% antibiotic-antimicotic (Life Technologies, Burlington, ON, 
CAN) and 20% fetal bovine serum (FBS, Fisher Scientific, Whitby, ON, CAN) (20% 
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supplemented medium) in a BD Falcon™ 100 X 20 mm cell culture dish (Fisher Scientific) for 1 
hr at 37°C, 5% CO2. Non-adherent cells were washed with RPMI 1640 medium with L-
glutamine supplemented with 1% antibiotic-antimicotic and 10% FBS (10% supplemented 
medium) and re-suspended at 2 X 106 cells/ mL in 10% supplemented medium. From the cell 
suspension, 200,000 cells were immunostained with PE Mouse Anti-Human CD19, APC Mouse 
Anti-Human IgM, PerCP-Cy™5.5 Mouse Anti-Human CD27, and FITC Mouse Anti-Human 
CD5 (BD Biosciences) at 4°C for 1 hr. Samples were analyzed with BD FACSCaliburä Flow 
Cytometer and CELLQUEST PRO software (BD Biosciences) to determine proportions of B 
cells (CD19+) and subpopulations: naïve (CD27-IgM+), IgM memory (CD27+IgM+), class 
switched (CD27-IgM-), class switched memory (CD27+IgM-), CD5+ and CD5- B cells as 
previously described (36). Purity of CD19+ gated B cells was verified by counterstaining cells 
with FITC Mouse Anti-Human CD3 and PerCP-Cy™5.5 Mouse Anti-Human CD14 (BD 
Biosciences).  
To determine the absolute numbers of B cells, a CBC was performed at the TBRHSC 
clinical lab. The absolute number of B cells was calculated by multiplying the percentage of 
CD19+ cells of the total gated lymphocyte population by the total lymphocyte count. The 
numbers of B cell subpopulations were determined by multiplying the percentage of each 
subpopulation by the absolute number of B cells. 
 
Enzyme-linked immunospot (ELISPOT) assay  
Preparation of ELISPOT plates 
Multi-screen IP 96-well PVDF membrane filter plates (Millipore Canada Ltd, Etobicoke, 
ON, CAN) were coated with either goat anti-human IgG (20 µg/ mL) (Cedarlane, Burlington, 
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ON, CAN), or pneumococcal capsular polysaccharides of serotypes 6B, or 14 (10 µg/ mL) 
(Cedarlane) conjugated with methylated human serum albumin (mHSA, 10 µg/ mL) (National 
Institute for Biological Standards and Control, Hertfordshire, UK). Protocol for conjugation of 
the pneumococcal polysaccharides to mHSA for coating plates was provided by the Oxford 
Vaccine Group. Wells containing solution of mHSA (10 µg/ mL) in PBS (Fisher Scientific) 
served as “no coating control”. Plates were incubated at 37°C, 5% CO2 for 5 hrs then stored at 
4°C overnight. The next day, plates were washed with PBS then blocked with 2% skim milk 
(Thermo Fisher Scientific) in PBS for 3 hrs at room temperature. The plate was washed again 
with PBS before cells were added.  
 
Detection of memory B cells 
Following removal of monocytes, 2 X 106 PBMC were plated in a 6-well plate in 10% 
supplemented medium with SAC (5 µg/ mL) (Sigma Aldrich, Oakville ON, CAN) ODN-2006 (3 
µg/ mL) (Cedarlane, Burlington, ON, CAN). After 6 days of stimulation at 37 °C, 5% CO2, the 
cells were harvested, washed with 10% supplemented medium, re-suspended in the same 
medium and counted. Cells were plated at 200,000 cells per well in the 96-well coated plate at 37 
°C, 5% CO2 for 18 hrs. After the incubation, the plate was washed using PBS with 0.01% Tween 
20 (Fisher Scientific) before the HRP conjugated mouse anti-human IgG was added (0.13 µg/ 
mL) (Hybridoma Reagent Laboratory, Baltimore, MD, USA) for 2 hrs at room temperature. To 
visualize the spots, KPL TrueBlue™ Peroxidase Substrate (Mandel Scientific, Guelph, ON, 
CAN) was added for 10 min and then washed for 5 min with distilled water. After washing, the 
plate was left to dry for a minimum of 1 day. Once dry, the spots were visualized using 2X 
magnification (Nikon Eclipse 80i).  
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ELISPOT Counting 
To determine the numbers of ASC, two lab members counted the spots per well 
individually, and a mean of the counts was calculated. Counts over 200 were considered above 
detection limits and assigned a value of 210; counts of 0 were assigned a value of 0.5 for 
statistical purposes.  
 
Enzyme-linked immunosorbent assay (ELISA) 
Amounts of IgG anti-pneumococcal 6B and 14 antibodies were quantified using the 
ELISA protocol provided by the World Health Organization (55).  
 
Statistical Analysis  
Statistical analysis was performed using Graph-Pad Prism 5 (GraphPad Prism Software 
Inc., San Diego, CA). The geometric means for the percentage of each B-cell subpopulation, 
absolute numbers of B cells, concentration, and fold change of antibody concentration with 95% 
confidence intervals (CI) and the medians of ASC with standard deviation were calculated. 
Outliers were identified and removed prior to statistical analysis (56). Groups were compared 
either using a Student’s t-test or Mann-Whitney U test, and correlation analyses performed using 
Pearson or Spearman analysis based on the distribution of the data. A p value of < 0.05 was 
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Tables and Figures 
Table 1. B-cell subpopulations in patients with severe chronic kidney disease. 





Total B cells (CD19+) 8.6 (7.0 - 10.6) 7.7 (6.9 - 8.5) > 0.05 
Naïve (CD27-IgM+) 46.3 (38.8 - 55.3) 42.5 (36.7 - 49.3) > 0.05 
IgM memory (CD27+IgM+) 7.0 (5.2 - 9.5) 7.8 (6.5 - 9.4) > 0.05 
Class Switched (CD27-IgM-) 14.3 (12.6 - 16.3) 11.6 (10.1 - 13.3) > 0.05 
Class Switched memory 
(CD27+IgM-) 
17.6 (13.5 - 23.0) 21.4 (18-0 - 25.6) > 0.05 
CD19+CD5+ 30.2 (23.9 - 38.1) 24.9 (19.7 - 31.5) > 0.05 
CD19+CD5- 52.0 (39.3 - 68.7) 74.2 (68.5 - 80.4) < 0.05 
 
Immunophenotype of peripheral blood B cells was determined by flow cytometry pre- and 7 
days post-immunization with PCV13. Geometric mean (GM) of proportions with 95% 
confidence intervals (CI) are shown. For analysis of total B cells, naïve, IgM memory, class 
switched and class switched memory B cells, 33 pre-immunization and 60 post-immunization 
samples were studied. CD5 expression analysis, 33 pre-immunization and 39 post-immunization 
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Figure 1A. B-cell subpopulations in pneumococcal vaccine naïve (n=14) and previously 
immunized with 23-valent pneumococcal polysaccharide vaccine (PPV23) (n=19) patients with 
severe chronic kidney disease prior to immunization with 13-valent pneumococcal conjugate 
vaccine. Isolated peripheral blood mononuclear cells were stained for CD19, CD27, and IgM and 
analyzed by flow cytometry. The geometric mean of each subpopulation proportion is displayed. 
Statistical significance determined by Student’s t-test (*p < 0.05). 
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Figure 1B. Absolute numbers of B-cell subpopulations in pneumococcal vaccine naïve (n=14) 
and previously immunized with 23-valent pneumococcal polysaccharide vaccine (PPV23) 
(n=19) patients with severe chronic kidney disease prior to immunization with 13-valent 
pneumococcal conjugate vaccine. Isolated peripheral blood mononuclear cells were stained for 
CD19, CD27, and IgM. Geometric means of absolute numbers of B-cell subpopulations were 
determined by multiplying the proportions of B-cell subpopulations by the absolute number of 
lymphocytes. Statistical significance *p < 0.05 (Student’s t-test for IgM memory and class 
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Figure 2A. B-cell subpopulations in pneumococcal vaccine naïve (n=25) and previously 
immunized with 23-valent pneumococcal polysaccharide vaccine (PPV23) (n=35) patients with 
severe chronic kidney disease on day 7 post-immunization with 13-valent pneumococcal 
conjugate vaccine. Isolated peripheral blood mononuclear cells were stained for CD19, CD27, 
and IgM and analyzed by flow cytometry. The geometric mean of each subpopulation proportion 
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Figure 2B. Absolute numbers of B-cell subpopulations in pneumococcal vaccine naïve (n=14) 
and previously immunized with 23-valent pneumococcal polysaccharide vaccine (PPV23) 
(n=19) patients with severe chronic kidney disease 7 days post-immunization with 13-valent 
pneumococcal conjugate vaccine. Isolated peripheral blood mononuclear cells were stained for 
CD19, CD27, and IgM. Geometric mean absolute numbers of B-cell subpopulations were 
determined by multiplying the proportions of B-cell subpopulations by the absolute number of 
lymphocytes. Statistical significance *p < 0.05 (Student’s t-test for class switched B cells, Mann-
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Figure 3A. CD5+ and CD5- B-cell subpopulations pre-immunization (day 0) and post-
immunization (day 7) with 13-valent pneumococcal conjugate vaccine in patients with severe 
chronic kidney disease. Peripheral blood mononuclear cells were stained for CD19 and CD5 and 
analyzed by flow cytometry. The geometric means are displayed. CD5+ and CD5- B-cell 
subpopulations are compared between pneumococcal vaccine naïve (day 0, n=14; day 7, n=15) 
and previously immunized with 23-valent pneumococcal polysaccharide vaccine (PPV23) (day 
0, n=19; day 7, n=24) patients. Statistical significance *p < 0.05 (Mann-Whiney U test for day 0 
CD5+, CD5- and day 7 CD5- B cells, Student’s t-test for day 7 CD5+ B cells).  
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Figure 3B. Absolute numbers of CD5+ and CD5- B-cell subpopulations pre-immunization (day 
0) and post-immunization (day 7) with 13-valent pneumococcal conjugate vaccine in patients 
with severe chronic kidney disease. Absolute numbers of B-cell subpopulations were determined 
by multiplying the proportions of B-cell subpopulations by the absolute number of lymphocytes. 
The geometric means are displayed. Comparison between pneumococcal vaccine naïve (day 0, 
n=14; day 7, n=15) and previously immunized with 23-valent pneumococcal polysaccharide 
vaccine (PPV23) (day 0, n=19; day 7, n=24) patients is displayed. Statistical significance *p < 
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Figure 4A. Numbers of total IgG antibody secreting cells (ASC) per 200,000 peripheral blood 
mononuclear cells (PBMC) pneumococcal vaccine naïve (n=18) and previously immunized with 
23-valent pneumococcal polysaccharide vaccine (PPV23) (n=29) patients with severe chronic 
kidney disease on day 7 post-immunization with PCV13. The median is displayed counts above 
the upper limit of detection (200) were assigned a value of 210 (8 pneumococcal vaccine naïve 
and 13 previously immunized with PPV23). If no spots were detected, a value of 0.5 was 
assigned for statistical purposes. PPV23 naïve and PPV23 immunized each had 4 values below 
the limit of detection. Control wells coated with methylated human serum albumin were not 
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Figure 4B. Numbers of IgG antibody secreting cells (ASC) specific for pneumococcal capsular 
polysaccharides of serotypes 6B or 14 per 200,000 peripheral blood mononuclear cell (PBMC) in 
pneumococcal vaccine naïve (n=18) and previously immunized with 23-valent pneumococcal 
polysaccharide vaccine (PPV23) (n=31) patients with severe chronic kidney disease 7 days post-
immunization with PCV13 (median is shown). If no spots were detected a value of 0.5 was 
assigned for statistical purposes. For serotype 6B, 9 pneumococcal vaccine naïve and 16 
previously immunized with PPV23 patients had ASC below the lower limit of detection. For 
serotype 14, 7 pneumococcal vaccine naïve and 13 previously immunized with PPV23 patients 
had ASC below the lower limit of detection. Control wells coated with methylated human serum 
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Supplementary Material 
Supplementary table 1. Absolute numbers of lymphocytes and B cells in patients with severe 
chronic kidney disease. 
Cells Pre-immunization  
Absolute number of cells/L 
(GM, CI) 
7 days post-immunization  
Absolute number of 
cells/L (GM, CI) 
p 
value 
Lymphocytes 1.0 (0.8-1.4 X 109) 1.0 (0.8-1.1 X 109) > 0.05 
Total B cells 9.2 (7.4-11.5 X 107) 8.4 (6.7-10.5 X 107) > 0.05 
Naïve (CD27-IgM+) 4.2 (3.0-5.9 X 107) 3.7 (2.6- 5.4 X 107) > 0.05 
IgM memory 
(CD27+IgM+) 
6.6 (4.8-9.0 X 106) 5.7 (4.3-7.5 X 106) > 0.05 
Class Switched 
(CD27-IgM-) 




1.5 (1.2-2.0 X 107) 1.6 (1.2-2.1 X 107) > 0.05 
CD19+CD5+ 2.2 (1.8-2.7 X 107) 2.2 (1.6-3.0 X 107) > 0.05 
CD19+CD5- 5.0 (3.5-7.0 X 107) 4.3 (2.9-6.3 X 107) > 0.05 
Absolute numbers of lymphocytes and B cells (geometric means, GM with 95% confidence 
intervals, CI) in 33 patients with severe chronic kidney disease pre- and 7 days post-
immunization with PCV13. Absolute numbers of B cells were determined by multiplying the 
proportion of CD19+ peripheral blood mononuclear cells by the absolute number of lymphocytes 
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Supplementary table 2. Correlation of absolute numbers and proportions of B cells and B-cell 
subpopulations pre- and 7 days post-immunization. 
Correlation between pre- and post-immunization absolute numbers or proportions of total B cells 
(CD19+), naïve (CD27-IgM+), IgM memory (CD27+IgM+), class switched (CD27-IgM-), class 













 Correlation of absolute  
numbers of cells  
Correlation of proportions of 
cells 
B cells  r p r p 
Total B cells (CD19+) 0.6275 Spearman < 0.0001 0.3414 Spearman > 0.05 
Naïve (CD27-IgM+) 0.8230 Spearman < 0.0001 0.8680 Pearson < 0.0001 
IgM memory 
(CD27+IgM+) 
0.7601 Spearman < 0.0001 0.8937 Pearson < 0.0001 
Class Switched  
(CD27-IgM-) 
0.0222 Pearson  0.9090 0.5030 Spearman 0.0064 
Class Switched memory 
(CD27+IgM-) 
0.6759 Spearman < 0.0001 0.8492 Spearman < 0.0001 
CD19+CD5+ 0.6940 Spearman < 0.0001 0.7384 Spearman < 0.0001 
CD19+CD5- 0.4501 Spearman 0.0126 0.7259 Spearman < 0.0001 
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Supplementary table 3. Absolute numbers of lymphocytes and B cells in patients with severe 
chronic kidney disease that are pneumococcal vaccine naïve or previously immunized with 
PPV23 > 1 year ago. 
Absolute numbers of lymphocytes and B cells (geometric means, GM with 95% confidence 
intervals, CI) in severe chronic kidney disease patients that are pneumococcal vaccine naïve 
(n=14) or previously immunized with PPV23 > 1 year ago (n=19) pre- and 7 days post-













Cells  PPV23 naïve 
Absolute number of 
cells/L (GM, CI) 
PPV23 > 1 year ago 





1.0 (0.8-1.4 X 109) 0.9 (0.8-1.1 X 109) > 0.05 
Total lymphocytes 7 days 
post-immunization  
1.0 (0.7-1.3 X 109) 1.0 (0.8-1.2 X 109) > 0.05 
Total B cells pre-
immunization 
9.9 (7.0-13.9 X 107) 8.3 (6.1-11.2 X 107) > 0.05 
Total B cells 7 days post-
immunization 
9.3 (6.7-12.8 X 107) 7.9 (5.7-10.9 X 107) > 0.05 
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Supplementary table 4. Concentrations and fold change of pneumococcal 6B and 14 IgG  
antibodies pre- and 28 days post-immunization.  
Geometric mean concentration (GMC) with 95% confidence intervals (CI) in severe chronic 
kidney disease patients who are pneumococcal vaccine naïve (n=22) or previously immunized 
with PPV23 > 1 year ago (n=34) pre- and 28 days post-immunization with PCV13. The fold 
change represents the response to PCV13 immunization. * compares day 0 pre-immunization 
and day 28 post-immunization antibody concentrations for each serotype and patient group, + 
compares the pre-immunization concentrations between patient groups, # compares the fold 
change for each serotype between groups. Statistical significance determined by Mann- Whitney 




















Serotype Group GMC, 95% CI (µg/ mL) 
Day 0 pre-
immunization  
GMC, 95% CI (µg/ mL) 
Day 28 post-immunization  
Fold 
change  
6B PPV23 naive 0.9 (0.6- 1.4) 2.1 (1.4- 3.1) * 2.8 
PPV23 > 1 
year ago 
1.1 (0.7- 1.6) 2.4 (1.4- 3.9) * 2.3 
14 PPV23 naive 2.8 (1.9- 4.2) + 8.0 (4.5- 14.4) ** 1.9 # 
PPV23 > 1 
year ago 
5.0 (3.0- 8.1) 8.1 (5.0- 13.3) 1.3 
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 Chapter 4B: Association of pneumococcal antibody levels with B-cell subpopulations in the 
peripheral blood of patients with CKD 
 
Abstract 
To determine the response to pneumococcal immunization, the assessment of antigen 
specific antibodies post-immunization is achieved by either quantifying the amounts or 
functional capacities of antibodies. The 23-valent pneumococcal polysaccharide vaccine 
(PPV23) is currently recommended in Canada for patients with chronic kidney disease (CKD) 
but due to their immune dysfunction, their responses are suboptimal. The 13-valent 
pneumococcal protein-polysaccharide conjugate vaccine (PCV13) has been recommended for 
other groups of immunocompromised adults due to its superior immunogenicity. However, 
antibody responses to PCV13 in CKD patients have only been assessed by two previous studies 
with conflicting results. In this study, enzyme-linked immunosorbent assay (ELISA) quantified 
IgG, IgM and IgA concentrations pre, 28- and 365- days post- PCV13 in PPV23 naïve and 
PPV23 immunized (> 1 year ago) CKD patients. Correlation analyses were preformed between 
absolute numbers and proportions of class switched memory (CD19+CD27+IgM-) or CD5- B 
cells and the fold change in IgG concentrations between day 0 – 28 and day 0 – 365. PPV23 
immunized patients had significantly higher IgG concentrations pre-immunization for serotypes 
14 and 19A, day 28 for serotype 19A, and day 365 for serotype 23F. The fold change in IgG 
concentrations for PPV23 naïve patients were significantly higher between day 0 – 28 for 
serotype 14, and day 0 – 365 for serotype 3. IgG fold changes were slightly higher for all 
serotypes except 23F for PPV23 naïve patients between both day 0 – 28 and day 0 – 365. There 
were no significant differences in IgM concentrations between groups pre- or post-immunization. 
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PPV23 naïve patients had a significantly higher IgM fold change between day 0 – 28 for 
serotype 23F as well as higher IgA concentrations pre- and day 28 for serotype 23F. PPV23 
immunized patients had a significantly higher IgA fold change day 0 – 365 for serotype 14. 
Response to immunization has been previously defined in CKD patients as a concentration of ≥ 1 
µg/ mL and a ≥ two-fold antibody concentration increase. When these criteria were applied, 
PPV23 naïve patients had a higher proportion of patients that responded to more serotypes day 
28 for IgG, IgM and IgA. Correlation results were challenging to analyze due to the small sample 
size, but general trends were similar for both CKD groups. There was a tendency towards a 
positive correlation for both proportions and absolute numbers of class switched memory B cells 
and the fold change in IgG concentrations between day 0 – 28 and day 0 – 365. For the absolute 
numbers and proportions of CD5- B cells, there was a tendency towards a negative correlation 
with the fold change in IgG concentrations between day 0 – 28 and day 0 – 365. Our previous 
study (chapter 4A) reported that PPV23 naïve patients had a higher prevalence of class switched 
memory B cells but a lower prevalence of CD5- B cells. Opposite trends were found for PPV23 
immunized patients, suggesting that previous immunization with PPV23 favored the production 
of CD5- B cells. Our findings suggest that PPV23 immunization has a negative effect on the 
humoral immune response that not only results in long-term changes in B-cell subpopulations 
but also decreases antibody responses to subsequent immunization with PCV13 in patients with 
CKD. Although a higher proportion of PPV23 naïve patients responded to PCV13 based on the 
concentrations and fold changes day 28 for IgG, IgM and IgA, our findings emphasize the need 
for further studies to optimize a pneumococcal immunization schedule for adults with CKD. 
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Introduction 
Successful long-term protection against Streptococcus pneumoniae that is formed 
through immunization, is predicted by quantifying the humoral immune response. To determine 
if immunological memory has been established, amounts of memory B cells and antigen specific 
antibodies post-immunization are measured (1). Chapter 4A focused on one aspect of the 
humoral immune response, by measuring B-cell responses to the 13-valent pneumococcal 
protein-polysaccharide conjugate vaccine (PCV13) in two groups of severe chronic kidney 
disease (CKD) patients. One group was immunized with the 23-valent pneumococcal 
polysaccharide vaccine (PPV23) more than 1 year prior to participating in the study (PPV23 
immunized), and the other was pneumococcal vaccine naïve (PPV23 naïve). This was achieved 
by collecting peripheral blood mononuclear cells (PBMC) pre and 7 days post-immunization 
with PCV13. These B cells (CD19+) were identified as: naïve (CD27-IgM+), class switched 
(CD27-IgM-), IgM memory (CD27+IgM+) or class switched memory (CD27+IgM-).  
B cell receptors (BCR) are transmembrane proteins responsible for antigen recognition. A 
single BCR consists of two immunoglobulin heavy and two light chains, which are responsible 
for ligand binding. In addition, the BCR also consists of two subunits, immunoglobulin alpha 
and beta, which are responsible for signal transduction. The constant region of the heavy chain is 
classified as either IgM, IgD, IgG, IgA and IgE isotypes. Naïve B cells express IgD and IgM, 
while the other isotypes are expressed on activated and memory B cells (2). Isotype switching 
typically occurs in response to proteins, also known as T cell-dependent antigens. In the case of 
PCV13, pneumococcal capsular polysaccharides are conjugated to a carrier protein called 
CRM197 that acts as a T cell-dependent antigen. A T cell-dependent response occurs in the 
germinal center of lymphoid follicles though interactions between CD4+ T cells and B cells. T 
 
   
173 
cell-dependent responses result in follicular B cells proliferating and differentiating into memory 
B cells and plasma cells that undergo somatic hypermutation and affinity maturation to produce 
high affinity class switched antibodies. T cell-independent (TI) antigens have the ability to 
activate B cells through crosslinking of the BCRs. Marginal zone B cells respond to TI-1 
antigens (e.g. lipopolysaccharides) and TI-2 antigens (e.g. polysaccharides), similarly to the 
capsular polysaccharides included in PPV23. These cells are important for rapid response to 
pathogens and differentiate into plasma cells that secrete IgM. The antibodies produced through 
T cell-dependent or independent pathways have the same affinity as the antigen recognition 
portion of the BCR (3).  
To fully assess the humoral immune response to PCV13 in CKD patients, concentrations 
of IgG, IgM and IgA antibodies specific to pneumococcal serotypes 3, 6B, 9V, 14, 19A, 19F and 
23F were measured pre-immunization, 28- and 365-days post immunization due to their 
inclusion in both PPV23 and PCV13. Responses to immunization are reported as the fold change 
and were calculated between day 0 - 28 as well as day 0 - 365 post-immunization. Correlation 
analyses were performed to determine if there was a relationship between B cells and the fold 
change in IgG concentrations between day 0 - 28 as well as day 0 - 365 post-immunization. This 
was performed for the absolute numbers and proportions of class switched memory and CD5- B 
cells. The correlation of these B-cell subpopulations and the fold change in IgG antibodies were 
analyzed because class switched memory B cells respond to secondary exposure to an antigen. 
When class switched memory B cells are activated, this results in the production of high affinity 
class switched antibodies, which have an important role in mediating humoral immunity (4, 5). 
The CD5- B cell population was chosen for correlation analyses because it has been found that 
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immunization with PPV23 results in the generation of CD5- B cells that differentiate into 
antibody secreting cells, which primarily produce anti-capsular IgG antibodies (6).  
This chapter has two objectives, first to determine if there are differences in antibody 
responses to PCV13 in PPV23 naïve and PPV23 immunized CKD patients, and the second is to 
determine if there is a relationship between B cells and antibody responses post PCV13 
immunization in CKD patients.  
 
Methods 
Of the 61 patients that we studied for analysis of B cells, antibody analyses were 
performed for 56 patients (22 PPV23 naïve and 34 PPV23 immunized). Amounts of 
pneumococcal antibodies were quantified using the ELISA protocol provided by the World 
Health Organization (7). Statistical analyses were performed using Graph-Pad Prism 8. The 
lower limits of detection were determined by calculating the concentration of antibodies present 
in the standard serum (007) (8) that yielded two times the assay background; the lowest serum 
dilution on the plate was used. All antibody values below the lower limit of detection were 
reported as half of the limit of detection. Data were reported as geometric means of 
pneumococcal antibody concentrations with 95% confidence intervals (CI) determined pre-, 28 
days and 365 days post-immunization with PCV13. The fold change in antibody concentrations, 
between day 0 – 28 as well as day 0 – 365 was determined by dividing the post-immunization 
concentrations by the pre-immunization concentrations for each participant. Groups were 
compared either using Mann-Whitney U test or Kruskal-Wallis test with Dunn’s post-hoc test 
depending on number of groups compared. Spearman correlation was performed between IgG 
concentration fold change between day 0 – 28 and day 0 – 365 and the proportions or absolute 
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numbers of class switched memory B cells or CD5- B cells. Significance was determined at p 
value < 0.05. Outliers were identified and removed prior to analysis (9).  
 
Results 
Due to the large amount of data and analyses performed, only significant results will be 
reported in this section. Participant demographics are the same as described in chapter 4A.  
 
IgG antibody response 
The geometric mean concentrations of IgG antibodies pre-immunization, 28- and 365-
days post- PCV13 are displayed in table 1a. Pre-immunization, serotype (ST) 14 and 19A 
concentrations were higher in PPV23 immunized compared to PPV23 naïve patients. Only ST 
19A concentrations remained higher day 28, while ST 23 concentrations were higher day 365 for 
PPV23 immunized compared to PPV23 naïve patients.  
Compared to pre-immunization, PPV23 naïve patients had higher ST 6B, 9V, 14, and 
19F concentrations day 28 as well as higher ST 19F concentrations day 365. PPV23 naïve 
patients had lower concentrations day 365 compared to day 28 for STs 3 and 9V. There were 
significant differences between day 0, 28 and 365 concentrations for ST 3, 6B, 9V, 14 and 19F 
for PPV23 naïve patients. Compared to pre-immunization concentrations PPV23 immunized 
patients had higher ST 6B, 9V, 19F and 23F concentrations day 28 as well as higher ST 3, 6B 
and 23F concentrations day 365. PPV23 immunized patients had lower antibody concentrations 
day 365 compared to day 28 for ST 3, 9V and19A. There were significant differences between 
day 0, 28 and 365 concentrations for ST 3, 6B, 9V, 19F and 23F.  
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The geometric means of the IgG concentration fold changes between day 0 – 28 as well 
as day 0 – 365  post- PCV13 are displayed in table 1b. PPV23 naïve patients had a higher fold 
change for ST 14 between day 0 – 28, as well as significantly higher fold change for ST 3 
between day 0 – 365 compared to PPV23 immunized patients. Compared to the fold change 
between day 0 – 28, PPV23 naïve patients had a lower fold change between day 0 – 365 for STs 
3, 9V, and 19A. PPV23 immunized patients had lower fold changes between day 0 – 365 for STs 
3, 6B, 9V, 19A and 23F compared to the fold change between day 0 – 28.  
 
IgM antibody response 
 The geometric mean concentrations of IgM antibodies pre-immunization, 28- and 365-
days post- PCV13 are displayed in table 2a. There were no significant differences in 
concentrations for any serotype pre- or post-immunization between PPV23 naïve and PPV23 
immunized patients. Compared to pre-immunization concentrations, PPV23 naïve patients had 
higher ST 3, 6B and 9V concentrations day 28.  PPV23 naïve patients had no significant 
differences in concentrations day 365 compared to day 28 for any ST. There were significant 
differences in concentrations for ST 6B between day 0, 28 and 365 for PPV23 naïve patients. For 
PPV23 immunized patients, there were no significant differences between: pre-immunization 
and either day 28 or 365 concentrations, day 28 and day 365 concentrations, or between day 0, 
28 and 365 when a multiple comparisons test was performed. 
 The geometric mean of the IgM antibody concentration fold change between day 0 and 
28 as well as day 0 – 365 post- PCV13 are displayed in table 2b. PPV23 naïve patients had a 
higher fold change in ST 23F between day 0 – 28 compared to PPV23 immunized patients. 
There were no significant differences in fold change specific to any ST between PPV23 naïve 
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and PPV23 immunized patients between day 0 – 365. PPV23 naïve patients had lower fold 
changes for STs 6B and 9V between day 0 – 365 compared to the fold change between day 0 – 
28. Both PPV23 naïve and immunized patients had significantly lower fold changes for ST 14 
between day 0 – 365 compared to the fold change between day 0 – 28.  
 
IgA antibody response  
 The geometric mean concentrations of IgA antibodies pre-immunization, 28- and 365-
days post- PCV13 are displayed in table 3a. Compared to PPV23 immunized patients, PPV23 
naïve patients had higher concentrations of ST 23F pre-immunization and day 28. PPV23 naïve 
patients had higher concentrations of STs 6B, 9V, 19F, and 23F day 28, but lower concentrations 
of ST 14 day 365 compared to pre-immunization concentrations. PPV23 naïve patients had lower 
concentrations day 365 compared to day 28 of STs 3, 6B, 9V, 14, 19F and 23F. When comparing 
day 0, 28 and 365 concentrations, there were significant differences in STs 6B, 9V, 14, 19F and 
23F for PPV23 naïve patients. Compared to pre-immunization concentrations, PPV23 
immunized patients had higher concentrations of ST 6B, 9V, 19A, 19F and 23F day 28. There 
were no significant differences between day 365 and pre-immunization concentrations for 
PPV23 immunized patients for any ST. PPV23 immunized patients had lower concentrations day 
365 compared to day 28 for STs 3, 6B, 9V, 14, and 19F. When comparing day 0, 28 and 365 
concentrations, there were significant differences for all STs except 14 and 19A for PPV23 
immunized patients.   
The geometric means of the IgA antibody concentration fold change between day 0 – 28 
as well as day 0 – 365 post- PCV13 are displayed in table 3b. There were no significant 
differences in fold changes between PPV23 naïve and immunized patients for any ST between 
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day 0 – 28. PPV23 immunized patients had a higher fold change between day 0 – 365 for ST 14 
compared to PPV23 naïve patients. Both PPV23 naïve and PPV23 immunized patients had a 
lower fold changes for all STs between day 0 – 365 compared to day 0 – 28.  
 
Correlation of the fold change in IgG concentrations and B-cell subpopulations 
 The comparisons used for correlation analyses are displayed in Figure 1a. Correlations 
that have been described as significant are defined as r ≥ 0.5 and p < 0.05, and a weak correlation 
as r = 0.4 - 0.5 even though p > 0.05. A meaningful correlation was used to describe correlations 
that were defined as either significant or weak, if r < 0.4, no meaningful correlation was found. 
The correlation between the proportions or absolute numbers of class switched memory (CS 
memory) B cells and CD5- B cells and the fold change in IgG concentrations between day 0 – 28 
as well as day 0 – 365 are displayed in tables 4a and b. Unfortunately, due to the small group 
sizes and large variability, significance was not reached in many cases. However, we considered 
even weak correlations (r = 0.4 - 0.5) to determine the general trends between B cells and the 
fold change in IgG concentrations. Figure 1b displays the comparisons used for each correlation 
analyses and the general relationship trend that was determined based on r values. Because weak 
and significant correlations were considered and the same trend may have not been observed for 
every serotype, correlation results were described as a tendency towards either a positive or 
negative correlation based on the majority of the trends. 
Day 0 CS memory B cell proportions had a tendency towards a positive correlation with 
the fold change between day 0 – 28 for both patient groups, but only PPV23 immunized had a 
significantly positive correlation for ST 9V. Although neither group had significant correlations 
for any ST between day 0 CS memory B cell absolute numbers and the fold change between day 
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0 – 28, PPV23 immunized patients had a tendency towards a positive correlation, while PPV23 
naïve patients had a tendency towards negative correlation. Day 0 CS memory B cell proportions 
had a tendency towards a positive correlation with the fold change between day 0 – 365 for 
PPV23 naïve patients but no significant correlation was found for any ST. PPV23 immunized 
patients had no meaningful correlations for any ST between day 0 CS memory B cell proportions 
and the fold change between day 0 – 365, indicating that there is no relationship. Day 0 CS 
memory B cell absolute numbers had a tendency towards a positive correlation with the fold 
change between day 0 – 365 for PPV23 naïve patients, but no significant correlation was found 
for any ST. When the same comparison was made for PPV23 immunized patients, there was a 
tendency towards a negative correlation, and there was a significantly negative correlation with 
the fold change between day 0 – 365 for ST 19A. To generally summarize, there appears to be a 
tendency towards a positive correlation between pre-immunization CS memory B cells and the 
antibody fold change post- PCV13 in patients with CKD.   
Day 7 CS memory B cell proportions had no meaningful correlations with the fold 
change between day 0 – 28 for any ST for either patient group. PPV23 immunized patients had 
significantly positive correlations between the CS memory B cell absolute numbers day 7 and the 
fold change between day 0 – 28 for STs 3, 6B, and 19F. PPV23 naïve patients had no meaningful 
correlations with the fold change between day 0 – 28 and the absolute numbers of CS memory B 
cells day 7. PPV23 naïve patients had a significantly positive correlation between day 7 CS 
memory B cell proportions and the fold change between day 0 – 365 for ST 9V. PPV23 
immunized patients had no meaningful correlations with the fold change between day 0 – 365 
and the proportions of CS memory B cells day 7. PPV23 naïve patients showed a tendency 
towards a positive correlation for absolute numbers of CS memory B cells day 7 and the fold 
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change between day 0 – 365, but no significant correlation was found for any ST. PPV23 
immunized patients showed a tendency towards a negative correlation for absolute numbers of 
CS memory B cells at day 7 and the fold change between day 0 – 365, but no significant 
correlation was found for any serotype. To summarize, there appears to be a slight tendency 
towards a positive correlation between day 7 post-immunization class switched memory B cells 
and the antibody fold change post- PCV13 in patients with CKD.   
Day 0 proportions of CD5- B cells for PPV23 naïve patients showed a tendency towards 
a negative correlation with the fold change between day 0 – 28, and a significantly negative 
correlation for ST 3. PPV23 immunized participants had no meaningful correlation between day 
0 proportions of CD5- B cells and the fold change between day 0 – 28 for any serotype, however 
day 0 absolute numbers and the fold change between day 0 – 28 had a significantly negative 
correlation for STs 9V and 14. In PPV23 naïve patients, there was a tendency towards a negative 
correlation between day 0 absolute numbers of CD5- B cells and the fold change between day 0 
– 28. Day 0 proportions of CD5- B cells for PPV23 naïve patients showed a tendency towards a 
negative correlation with the fold change between day 0 – 365, and a significantly negative 
correlation for ST 23F. PPV23 immunized patients showed a tendency towards a positive 
correlation with the fold change between day 0 – 365, and a significantly positive correlation for 
ST 23F. Day 0 proportions of CD5- B cells for PPV23 naïve patients showed a tendency towards 
a positive correlation with the fold change between day 0 and 365, while PPV23 immunized 
patients showed a tendency towards a negative correlation, but neither had significant 
correlations for any ST. To summarize, there appears to be a tendency towards a negative 
correlation between pre-immunization CD5- B cells and the antibody fold change post- PCV13 
in patients with CKD.   
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Day 7 proportions of CD5- B cells for both PPV23 naïve and PPV23 immunized patients 
showed a tendency towards a negative correlation with the fold change between day 0 – 28, and 
both had a significantly negative correlation for ST 3. Similarly, both PPV23 naïve and PPV23 
immunized patients showed a tendency towards a negative correlation with the fold change 
between day 0 – 28 and the absolute numbers of day 7 CD5- B cells. PPV23 naïve patients had 
significantly negative correlations for STs 3 and 23F, but PPV23 immunized patients had no 
significant correlations for any ST. Day 7 proportions of CD5- B cells for both PPV23 naïve and 
PPV23 immunized patients showed a tendency towards a negative correlation with the fold 
change between day 0 – 365. PPV23 naïve patients had a significantly negative correlation for 
ST 9V, but PPV23 immunized patients had no significant correlations for any STs. PPV23 naïve 
patients showed a tendency towards a negative correlation with the fold change between day 0 – 
365 and the absolute numbers of day 7 CD5- B cells, there was a significantly negative 
correlation for ST 19F. PPV23 immunized patients showed a tendency towards a positive 
correlation with the fold change between day 0 – 365 and the absolute numbers of day 7 CD5- B 
cells, but there was no significant correlation for any ST. To summarize, there appears to be a 
tendency towards a negative correlation between day 7 post-immunization CD5- B cells and the 
antibody fold change post- PCV13 in patients with CKD.   
 
Discussion  
 The three antibody isotypes measured in this study have different biological roles. IgM 
antibodies are produced during the primary immune response to an antigen by naïve B cells. IgM 
antibodies are polyreactive and have low affinity to an antigen because they have not undergone 
somatic hypermutation. Because of this, IgM antibodies are able to respond rapidly to multiple 
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antigens. IgA concentrations in the serum are much lower than IgG but higher than IgM. On 
mucosal surfaces, IgA is the most predominant antibody isotype and is key for neutralization of 
toxins and microorganisms as well as preventing adhesion of microorganisms attempting to bind 
to mucosal surfaces. There are two subclasses of IgA, IgA2 is the more predominant subclass on 
mucosal surfaces and is less susceptible to bacterial proteases than IgA1. IgG has the most 
predominant isotype in the body and has the longest half-life. IgG antibodies are involved in 
neutralization of toxins and viruses as well as opsonization of microorganisms for phagocytosis. 
IgG antibodies are classified into 4 subclasses. During the secondary response, IgG1 and IgG3 
antibodies are produced in response to a protein antigen while IgG2 and IgG4 antibodies are 
typically produced in response to polysaccharide antigens. IgG antibodies are important for 
classical complement pathway activation, but the affinity for complement component 1q (C1q) is 
not equal for all subclasses with IgG3 having the highest affinity followed by IgG1 and IgG2, 
while IgG4 is unable to activate the classical complement pathway (10).  
Two studies have measured the antibody response to PCV13 in CKD patients, both 
reporting the response to immunization based on IgG antibodies. Mitra et al. (2016) reported 
ELISA results as the geometric mean concentrations. Exclusion criteria included receiving a 
pneumococcal immunization ≤ 5 years, but the proportion of patients that received a 
pneumococcal immunization ≥ 5 years was not reported. The second study by Vandecasteele et 
al. (2018) measured the antibody response to PCV13 in CKD patients that were PPV23 naïve 
and patients that had received PPV23 either > 4 years ago or < 4 years ago. Antibody responses 
were reported as geometric mean titres (the mean of log transformed antibody concentrations).  
In the study by Mitra et al. (2016) response to immunization was reported as a post-
immunization IgG antibody concentration of at least 1 µg/ mL and a ≥ two-fold antibody 
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concentration increase. These criteria were applied to our study and the results are displayed in 
supplementary table 1a. Comparisons between our study and the studies by Mitra et al. (2016) 
and Vandecastele et al. (2018) are shown in supplementary tables 2a and b. The proportion of 
our patients that responded to PCV13 based on IgG concentrations and fold change between day 
0 – 28, was higher for the PPV23 naïve patients for all STs except for 23F compared to PPV23 
immunized patients. Although the proportions of our patients that responded by day 365 
decreased for both groups, a higher proportion of PPV23 naïve patients responded to all STs 
except ST 23F compared to PPV23 immunized patients.  
Mitra et al. (2016) reported that antibody concentrations decreased significantly by 12 
months compared to 2 months post-immunization for 6/ 7 STs. Significantly lower IgG 
concentrations between day 28 and day 365 were found for 2/ 7 STs in our PPV23 naïve and 3/ 7 
STs for our PPV23 immunized patients. It is difficult to determine if the decreases in antibody 
concentrations by day 365 compared to day 28 are of concern clinically because there are not any 
established protective antibody concentrations in the literature for adults. A few studies have 
used a minimum concentration of 1.3 µg/ mL of serum IgG post-PPV23 immunization as an 
indicator of protection (11, 12). The correlate of protection against IPD post-PCV immunization 
for infants is reported as 0.35 µg/ mL of serum IgG. However, it has been suggested that this 
may not be true for all serotypes and that concentrations resulting in protection may be 
dependent on serotype (13).  
Vandecasteele et al. (2018) found no significant differences in pre-immunization titres 
between PPV23 immunized and PPV23 naïve patients for any of the seven STs. However, 
PPV23 naïve patients had significantly higher day 28 titres for all seven STs, on day 365 they 
remained significantly higher for 5/7 STs compared to PPV23 immunized patients. Our PPV23 
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immunized patients had significantly higher pre-immunization concentrations for 2/ 7 serotypes 
compared to PPV23 naïve patients. On day 28, our PPV23 naïve patients had significantly lower 
concentrations for 1/7 STs, and significantly lower day 365 concentrations for 1/7 STs compared 
to PPV23 immunized patients.  
In comparison to both studies, our patients had similar responses to PCV13 as the CKD 
patients from Mitra et al. (2016). Compared to day 28, PPV23 naïve had significantly lower 
concentrations for 2/ 7 STs and PPV23 immunized patients had significantly lower 
concentrations for 3/ 7 STs day 365. Unlike the participants from Vandecasteele et al. (2018), 
our PPV23 naïve did not have significantly higher concentrations compared to PPV23 
immunized patients post-PCV13 immunization. However, it should be noted that although only 
statistically significant for serotype 19A (p < 0.05), PPV23 naïve patients had slightly higher 
fold changes in IgG concentrations between day 0 and 28 for all STs except for 23F. Similarly, 
PPV23 naïve patients had a significantly higher fold change for ST 3 IgG concentrations 
between day 0 – 365, and slightly higher fold changes for all STs except for 23F.  
There have been a limited number of studies that have evaluated the response to 
pneumococcal immunization based on serotype specific capsular polysaccharide antibody 
concentrations. The majority of studies quantify the responses to pneumococcal immunization 
using opsonophagocytic activity (OPA) titres. There is no direct relationship between antibody 
concentrations and OPA titres to make studies comparable. The studies that have reported 
antibody concentrations post-PCV13 are summarized in supplementary table 3a. There is a lot of 
heterogenicity in antibody concentrations between studies, making it difficult to compare 
concentrations between adults with different health conditions. It was clear for all studies 
displayed in supplementary table 3a that the lowest concentrations were for ST 3 (0.19 – 2.5 µg/ 
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mL) and the majority of studies had the highest concentrations for ST 19A (3.5 – 27.9 µg/ mL). 
This shows the wide range of concentrations between different participant groups, and the 
differences in immunogenicity between STs. This suggests that one concentration cannot be used 
for all STs to determine if protection has been established against IPD in adults in response to a 
pneumococcal vaccine. Because there is no accepted value or fold change to indicate response to 
PCV13, we chose to only discuss the studies that have reported the proportion of participants that 
responded to immunization based on either a minimum fold change in IgG concentrations or a 
minimum IgG concentration (supplementary table 3b).  
Studies by van Deursen and Peterson that involved healthy adults used a ≥ four-fold 
increase in IgG concentrations as a response to PCV13. Both reported that the lowest response to 
PCV13 was to serotype 3 (32.7% and 17.1%). van Deursen et al. (2017) reported their highest 
response 1 month post-PCV13 was 59.5% for ST 9V, and Peterson et al. (2019) reported their 
highest response at 2 months post-PCV13 was 46.2% for ST 6B (14, 15). There were two studies 
involving immunodeficient adults, Nived et al. (2015) assessed responses to PCV13 in adults 
with asplenia 4 – 6 weeks post-PCV13 and Belmonti et al. (2019) for HIV adults 5 years post- 
PCV13. Both studies measured responses based on IgG concentrations that were ≥ 0.35 µg/mL 
and ≥ 1.0 µg/ mL. Nearly all HIV adults had concentrations of ≥ 0.35 µg/mL, the lowest 
proportion that responded was 88% for 2/ 7 serotypes. Using IgG concentrations of  ≥ 1 µg/mL 
as a definition for response to PCV13, the range of patients that responded was between 33% - 
98%  (16). The proportion of adults with asplenia that had concentrations of ≥ 0.35 µg/mL 
ranged from ~ 55% - 100%, while the proportion of participants that had concentrations of ≥ 1 
µg/mL ranged from ~ 27% - 95%. It is difficult to compare responses to PCV13 between 
different studies due to the different response criteria used. It is also important to consider that 
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using one specific concentration or increase in fold change for all serotypes is not indicative of 
IPD prevention. The immunogenicity of capsular polysaccharides are different for each serotype 
(e.g. STs 6A and 6B are some of the least immunogenic capsular polysaccharides) therefore a 
higher concentration or larger fold change may be required for protection against certain STs 
(17). 
 No studies have measured the correlation between B cells and the antibody responses to 
pneumococcal immunizations in CKD patients. B cells from HIV-positive adults have also been 
quantified through flow cytometry and reported the correlation between antibody concentrations 
in response to PCV13 immunization. Farmaki et al. (2018) immunized HIV-positive adults with 
PCV13 and measured the correlation between polysaccharide specific CS memory B cells 
(CD19+CD10-CD27+CD21++IgM-) and IgG concentrations against pneumococcal STs 3 and 
14. Groups contained both PPV23 naïve and PPV23 immunized > 1 year ago. There was a 
positive correlation between pre-immunization absolute numbers of polysaccharide specific class 
switched memory B cells and IgG concentrations 1-month post-PCV13 immunization for both 
STs 3 and 14 (18). Similarly, both of our participant groups also showed a tendency towards a 
positive correlation between total CS memory B cells and the fold change in IgG between both 
day 0 – 28 and day 0 – 365. 
As it is described in chapter 4A, PPV23 immunized patients had significantly lower 
proportions and absolute numbers of CS memory B cells compared to PPV23 naïve patients pre-
immunization with PCV13. This suggests that immunization with PPV23 may result in long-
term changes such as a decreased prevalence of CS memory B cells in peripheral blood. 
Following PCV13 immunization, the differences in absolute numbers of class switched memory 
B cells between groups remained significant. Although statistical significance was not reached 
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for most serotypes, there was a greater increase in IgG concentration fold changes for all 
serotypes except for 23F for PPV23 naïve patients between day 0 – 28 and day 0 – 365. There 
were not many statistically significant correlations between B cell subpopulations and the fold 
change in IgG concentrations, but general trends were found. There was a tendency towards 
positive correlation between class switched memory B cells pre- and day 7, and IgG 
concentrations day 0 – 28 and day 0 – 365 for both PPV23 naïve and PPV23 immunized patients. 
This indicates that the higher pre-immunization proportion and absolute numbers, as well as the 
higher day 7 absolute numbers of CS memory B cells for PPV23 naïve patients resulted in a 
greater increase in IgG antibody concentrations between day 0 – 28 and day 0 – 365 compared to 
PPV23 immunized patients. The decreased proportions and absolute numbers of CS memory B 
cells pre- PCV13 suggests that PPV23 immunization could result in pneumococcal memory B 
cells to terminally differentiate, which caused a decreased IgG response to PCV13. Clutterbuck 
et al. (2012) demonstrated that elderly adults immunized with the 7-valent pneumococcal 
protein-polysaccharide conjugate vaccine (PCV7) had increased serotype specific memory B 
cells, but immunization with PPV23 decreased the frequency of memory B cells. In comparison 
to participants immunized with PCV7 alone, PPV23 immunized participants that received a 
subsequent dose of PCV7 had decreased memory B cell responses (19). Although Clutterbuck et 
al. (2012) did not measure the antibody responses in the setting of PPV23 followed by PCV7, 
our PPV23 immunized patients also had a decreased response to PCV13 compared to PPV23 
naïve patients based on day 0 – 28 fold changes in IgG, IgM and IgA. The decreased fold change 
in IgG antibodies (both day 0-28 and 0-365) and the decreased absolute numbers of CS memory 
B cells pre-immunization and day 7 post-PCV13 in PPV23 immunized patients suggests that 
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immunization with PPV23 reduces the immunogenicity of PCV13 when followed by PPV23 in 
CKD patients.  
The role of CD5- B cells in humans is not completely understood, but the decrease of 
CD5+ B cells and increase of CD27+ B cells with age suggests that CD5- B cells represent a 
proportion of the memory B cell population (20). A study by Moens et al. (2015) demonstrated 
that immunization with PPV23 favors the generation of CD5- B cells specific for pneumococcal 
capsular polysaccharides that primarily produce IgG (6). Similarly, our PPV23 immunized 
patients had higher proportions of CD5- B cells compared to PPV23 naïve patients both pre- and 
post-immunization with PCV13. However, there was a tendency towards a negative correlation 
between CD5- B cells pre- and day 7 and the IgG fold changes between day 0-28 and day 0-365 
for both PPV23 naïve and PPV23 immunized patients. The lower IgG fold increase in PPV23 
immunized patients compared to PPV23 naïve patients may suggest that the production of CD5- 
B cells from PPV23 results in a decreased IgG response to subsequent immunization with 
PCV13 in CKD patients.  
The IgM and IgA responses to PCV13 are difficult to interpret because responses to 
PCV13 alone or PPV23 followed by PCV13 have not been previously quantified for these 
isotypes in adults. There were no significant differences in IgM concentrations pre-
immunization, 28 or 365 days between PPV23 naïve and PPV23 immunized participants. The 
fold changes in IgM concentrations were similar for PPV23 naïve and PPV23 immunized 
patients, but ST 23F concentrations were significantly higher for PPV23 naïve patients between 
day 0 and 28. The criteria to define a response to immunization described by Mitra et al. (2016), 
were applied to IgM concentrations and fold changes (supplementary table 1b). Based on IgM 
post-immunization concentrations and fold changes, a higher proportion of PPV23 naïve patients 
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responded to all serotypes day 28 post-immunization compared to PPV23 immunized patients. 
The proportions of PPV23 naïve patients that responded was between 13.6% - 40.9% and the 
proportions of PPV23 immunized patients that responded was between 2.9% - 17.6%. 
Considering that there were no significant differences in naïve B cells between patient groups pre 
or post-immunization, the differences in the number of participants that met the response criteria 
could be due to the significantly larger absolute numbers of IgM memory B cells in PPV23 naïve 
patients pre- and 7-days post-PCV13 immunization (chapter 4A). This suggests that previous 
immunization with PPV23 could have also resulted in depletion of the total memory B cell pool 
and not just class switched memory B cells. It has been shown that stimulation with a T cell-
dependent antigen results in germinal center dependent differentiation of IgM memory B cells 
that have high affinity BCRs which have undergone somatic hypermutation similarly to IgG 
memory B cells in a murine model (21). The antibodies produced from IgM memory B cells 
could be important for early responses to a pathogen as they have higher affinity for the antigen 
compared to IgM antibodies produced by naïve B cells.   
However, IgM concentrations day 365 were higher for a larger proportion of PPV23 
immunized patients responded to 6/ 7 STs. The proportion of PPV23 immunized patients that 
responded ranged from 10.7% - 39.3% and the proportion of PPV23 naïve patients that 
responded was between 5.9% - 35.3%. The higher proportion of PPV23 immunized patients that 
responded day 365 compared to day 28 days for 6/ 7 STs suggests that some of the PPV23 
immunized patients were potentially exposed to pneumococcus shortly before the collection of 
day 365 samples. Because IgM antibodies are polyreactive, it is also possible that these 
antibodies could have been produced in response to another pathogen but are cross reactive for 
pneumococcal capsular polysaccharides (10). For example, Lagergard et al. (1983) reported that 
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pneumococcal serotype 6B antibodies are cross reactive with H. influenzae type a polysaccharide 
(22). In addition, Heidelberger et al. (1978) found that that pneumococcal capsular 
polysaccharide antibodies cross-react with Klebsiella pneumoniae capsular polysaccharides (23).  
When IgA concentrations were compared between patient groups, the only significant 
differences were found for pre- and day 28 concentrations for ST 23F, which were significantly 
higher for PPV23 naïve patients. The only significant difference between IgA fold changes 
between groups was between day 0 – 365, which was significantly higher for ST 14 for PPV23 
immunized patients. The criteria to define a response to immunization described by Mitra et al. 
(2016), were applied to IgA concentrations and fold changes (supplementary table 1c). A higher 
proportion of PPV23 naïve patients responded to 4/7 serotypes day 28, with proportions of 
patients responding ranging from 27.3% - 59.1%. The range of the proportion of PPV23 
immunized patients that responded was similar to PPV23 naïve and ranged from 20.6% - 50.0%.  
However, day 365 a higher proportion of PPV23 immunized patients responded to 4/ 7 
serotypes which had a proportion of patients that responded ranging from 3.6% - 25.0%, while 
the proportion of PPV23 naïve patients that responded ranged from 0% - 29.4%. The IgA 
response to PCV13 was quite similar between PPV23 naïve and PPV23 immunized participants. 
When taking into consideration the high amounts and importance of IgA at mucosal surfaces 
(24), differences in IgA concentrations at mucosal surfaces between CKD patient groups may be 
a better indicator of protection against IPD. Since the role of the capsule is to increase adherence 
to mucosal epithelial surfaces as well as prevent complement activation, assessing the 
differences in pneumococcal capsular polysaccharide antibodies may suggest if disease caused 
by pneumococcus would be prevented (25).   
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Our limitations are the same as those listed in chapter 4A, but the ones that seem to have 
a significant impact are mentioned. A major limitation of our study is small sample size which 
likely contributed to lack of statistical significance in some comparisons between PPV23 naïve 
and PPV23 immunized patients. The loss of participants due to study withdrawal or death also 
contributed smaller groups sizes when quantifying the antibody fold changes, particularly at day 
365. Because PPV23 is recommended for CKD patients, one of our patient groups received 
PPV23 prior to recruitment, which meant that we could not assess immediate responses to 
PPV23 in our CKD patients. Unfortunately, we do not have opsonophagocytosis assay (OPA) 
antibody titers available to determine the functionality of the antibodies produced post PCV13, 
as well as determine if there was any correlation with antibody concentrations or B-cell 
subpopulations. Another limitation is that there are no established antibody concentrations or 
titres that would indicate protection against IPD in adults making it difficult to determine the 
clinical significance of antibody data.   
 
Conclusions 
In conclusion, PPV23 naïve patients had significantly lower pre-immunization 
concentrations for STs 14 and 19, day 28 for ST 19A, and day 365 for ST 23 IgG concentrations, 
but also had slightly lower IgG concentrations pre, day 28 and day 365 for all STs (except day 28 
for ST 9V). However, PPV23 naïve patients had significantly higher IgG fold change day 28 ST 
14, and slightly higher fold changes in IgG concentrations between day 0-28 and day 0-365 for 
all STs except for ST 23F. Using the criteria to define response to immunization by Mitra et al. 
(2016) higher proportions of PPV23 naïve patients responded to 6/ 7serotypes day 28 and 365 
post- PCV13 based on IgG concentrations and fold changes. On day 28 a higher proportion of 
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PPV23 naïve patients responded to more serotypes post-PCV13 immunization based on IgM and 
IgA concentrations and fold changes, even though there were few significant differences in 
antibody concentrations between PPV23 naïve and PPV23 immunized patients. Our previous 
study also suggested that PPV23 naïve patients had a greater response to PCV13 immunization 
which was indicated by an increased prevalence of CS memory B cells pre and day 7. This was 
confirmed when correlation analyses determined that there was a tendency towards a positive 
correlation between proportions and absolute numbers of CS memory B cells and IgG fold 
changes between day 0 – 28 and day 0 – 365. It was also demonstrated in the previous chapter 
that immunization with PPV23 favors the generation of CD5- B cells, as PPV23 immunized 
patients had a higher prevalence of CD5- B cells which had a tendency towards a negative 
correlation with IgG fold changes. Our findings suggest that PPV23 immunization has a negative 
effect on the humoral immune response that not only results in long-term changes in B cell 
subpopulations but also decreases antibody responses to subsequent immunization with PCV13 
in patients with CKD. Our findings emphasize the need for further studies to optimize 
pneumococcal immunization for adults with CKD. 
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Tables and Figures  
 
 
Figure 1a. A graphic representation of the correlation analysis performed between B-cell 
subpopulations and the fold change in IgG concentrations.  
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Figure 1b. General trends in the correlation analyses between B-cell subpopulations and the fold 
change in IgG concentrations. Correlations with r ≥ 0.4 for a serotype were considered a positive 
correlation, r ≥ -0.4 for a serotype were considered a negative correlation, if no correlation was 
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Table 1a. IgG antibody concentrations in CKD patients immunized with PCV13 
 
Serotype Group  Day 0  
GM (95% CI) 
Day 28  
GM (95% CI) 
Day 365  
GM (95% CI) 
3 PPV23 
naive 
0.64 (0.40-1.03) 0.89 (0.60- 1.31) 0.37 (0.25- 0.54) // # 
 PPV23 
immunized 




0.92 (0.59- 1.44) 2.13 (1.44- 3.16) + 1.73 (0.98- 3.08) # 
 PPV23 
immunized 
1.07 (0.72- 1.61) 2.34 (1.39- 3.92) + 2.47 (1.43- 4.27) + # 
9V PPV23 
naive 




1.64 (1.20- 2.24) 2.70 (2.03- 3.59) + 1.71 (1.21- 2.42) / # 
14 PPV23 
naive 
2.81 (1.87- 4.21) 8.03 (4.49- 14.36) ++ 5.29 (3.00 -9.31) # 
 PPV23 
immunized 
5.05 (3.15- 8.12) * 8.25 (5.15- 13.22) 7.88 (5.36- 11.58) 
19A PPV23 
naive 
4.60 (2.86- 7.40) 6.77 (4.59-9.98) 5.98 (3.83- 9.33) 
 PPV23 
immunized 
8.45 (5.82- 12.27) * 12.13 (8.55- 17.20) ** 8.79 (6.45- 11.99) / 
19F PPV23 
naive 
1.37 (0.92- 2.04) 4.47 (2.62- 7.62) +++ 3.05 (1.97- 4.73) + ## 
 PPV23 
immunized 
2.44 (1.57- 3.80) 5.30 (3.43- 8.18) ++ 4.27 (2.85- 6.41) # 
23F PPV23 
naive 
0.66 (0.38- 1.15) 1.20 (0.68- 2.47) 0.93 (0.54- 1.60) 
 PPV23 
immunized 
1.05 (0.73- 1.50) 2.34 (1.34- 4.09) + 1.83 (1.17- 2.86) * + # 
Geometric mean (GM), 95% confidence intervals (CI). * compares groups for each serotype at 
each collection, + compares day 0 to day 28 and day 365 for each group and serotype, / compares 
day 28 to day 365, # compares days 0, 28, 365 for each serotype for each group. Day 0 and 28; 







   
199 
Table 1b. Fold change of IgG antibody concentrations in CKD patients immunized with PCV13 
 
Serotype Group  Fold Change 0-28 Fold Change 0-365 
3 PPV23 naive 1.31 (1.06- 1.61) 0.70 (0.41- 1.18) ^ 
 PPV23 immunized 1.03 (0.94- 1.13) 0.33 (0.27- 0.42) * ^^^^ 
6B PPV23 naive 2.77 (1.78- 4.32) 1.37 (0.86- 2.16)  
 PPV23 immunized 2.23 (1.67- 2.97) 1.20 (0.88- 1.62) ^^ 
9V PPV23 naive 1.76 (1.26- 2.46) 0.87 (0.60- 1.25) ^^ 
 PPV23 immunized 1.36 (1.20- 1.55) 0.78 (0.61- 0.99) ^^^^ 
14 PPV23 naive 1.91 (1.31- 2.77) 1.23 (0.71- 2.15)  
 PPV23 immunized 1.32 (1.10- 1.59) * 1.07 (0.78- 1.47) 
19A PPV23 naive 1.73 (1.33- 2.24) 0.97 (0.65- 1.46) ^ 
 PPV23 immunized 1.39 (1.19- 1.63) 0.89 (0.69- 1.16) ^^ 
19F PPV23 naive 2.49 (1.65- 3.74) 1.74 (0.94- 3.23)  
 PPV23 immunized 1.90 (1.30- 2.60) 1.06 (0.83- 1.34) 
23F PPV23 naive 1.57 (1.16- 2.14) 1.00 (0.65- 1.53) 
 PPV23 immunized 1.72 (1.32- 2.23) 1.09 (0.78- 1.51) ^ 
Geometric mean (GM), 95% confidence intervals (CI). * compares groups for each serotype for 
each fold change period. ^ compares day 0-28-fold change to day 0-365-fold change for each 
group. Fold change between day 0 and 28; PPV23 naïve n=22, PPV23 immunized n=34, 
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Table 2a. IgM antibody concentrations in CKD patients immunized with PCV13 
 
Serotype Group  Day 0  
GM (95% CI) 
Day 28  
GM (95% CI) 
Day 365  
GM (95% CI) 
3 PPV23 naive 0.19 (0.15- 0.25) 0.31 (0.24- 0.41) + 0.23 (0.13- 0.38) 
 PPV23 immunized 0.25 (0.18- 0.33) 0.28 (0.21- 0.37) 0.25 (0.16- 0.36) 
6B PPV23 naive 0.64 (0.45- 0.89) 1.30 (0.86- 1.97) + 0.72 (0.45- 1.15) # 
 PPV23 immunized 0.89 (0.62- 1.26) 1.06 (0.73- 1.54) 0.80 (0.57- 1.11) 
9V PPV23 naive 0.44 (0.30- 0.64) 0.66 (0.43- 1.02) + 0.39 (0.24- 0.64) 
 PPV23 immunized 0.52 (0.36- 0.75) 0.62 (0.44- 0.88) 0.61 (0.43- 0.86) 
14 PPV23 naive 0.61 (0.43- 0.89) 0.62 (0.42- 0.93) 0.46 (0.28- 0.75) 
 PPV23 immunized 0.51 (0.38- 0.70) 0.51 (0.35- 0.73) 0.55 (0.38- 0.79) 
19A PPV23 naive 0.82 (0.56-1.19) 1.26 (0.75- 2.09) 1.10 (0.67- 1.79) 
 PPV23 immunized 1.05 (0.75- 1.45) 1.25 (0.89- 1.77) 1.31 (0.93- 1.84) 
19F PPV23 naive 0.96 (0.66- 1.39) 1.72 (1.14- 2.61) 1.14 (0.72- 1.81) 
 PPV23 immunized 1.23 (0.87- 1.73) 1.42 (0.98- 2.06) 1.41 (1.04- 1.91) 
23F PPV23 naive 0.19 (0.15- 0.24) 0.24 (0.18- 0.33) 0.18 (0.10- 0.31) 
 PPV23 immunized 0.28 (0.21- 0.37) 0.24 (0.16- 0.36) 0.21 (0.15- 0.29) 
Geometric mean (GM), 95% confidence intervals (CI). * compares groups for each serotype at 
each collection, + compares day 0 to day 28 and day 365 for each group and serotype, / compares 
day 28 to day 365, # compares days 0, 28, 365 for each serotype for each group. Day 0 and 28; 
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Table 2b. Fold change of IgM antibody concentrations in CKD patients immunized with PCV13 
 
Serotype Group  Fold Change 0-28 Fold Change 0-365 
3 PPV23 naive 1.22 (1.01- 1.47) 0.94 (0.68- 1.30)  
 PPV23 immunized 1.01 (0.95- 1.08) 0.73 (0.53- 1.01) 
6B PPV23 naive 1.30 (1.05- 1.60) 0.85 (0.64- 1.13) ^ 
 PPV23 immunized 1.05 (0.98- 1.12) 0.85 (0.65- 1.12) 
9V PPV23 naive 1.60 (1.05- 2.45) 0.91 (0.60- 1.38) ^ 
 PPV23 immunized 1.04 (0.96- 1.12) 0.86 (0.64- 1.16) 
14 PPV23 naive 0.95 (0.83- 1.08) 0.59 (0.40- 0.86) ^ 
 PPV23 immunized 0.98 (0.92-1.04) 0.63 (0.46- 0.85) ^ 
19A PPV23 naive 1.21 (0.88- 1.66) 0.98 (0.75- 1.32) 
 PPV23 immunized 1.07 (1.00- 1.14) 0.97 (0.70- 1.27) 
19F PPV23 naive 1.18 (1.00- 1.39) 0.98 (073- 1.31) 
 PPV23 immunized 1.08 (0.99- 1.19) 0.97 (0.70- 1.33) 
23F PPV23 naive 1.17 (0.94- 1.45) 0.87 (0.53- 1.43) 
 PPV23 immunized 0.96 (0.89- 1.05) * 0.85 (0.60- 1.21) 
Geometric mean (GM), 95% confidence intervals (CI). * compares groups for each serotype for 
each fold change period. ^ compares day 0-28-fold change to day 0-365-fold change for each 
group. Fold change between day 0 and 28; PPV23 naïve n=22, PPV23 immunized n=34, 
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Table 3a. IgA antibody concentrations in CKD patients immunized with PCV13 
 
Serotype Group  Day 0  
GM (95% CI) 
Day 28  
GM (95% CI) 
Day 365  
GM (95% CI) 
3 PPV23 
naive 
0.32 (0.18- 0.57) 0.56 (0.33- 0.94)  0.28 (0.18- 0.45) / 
 PPV23 
immunized 
0.42 (0.30- 0.60) 0.65 (0.47- 0.89) 0.31 (0.22- 0.44) // # 
6B PPV23 
naive 
0.13 (0.07- 0.24) 0.52 (0.25- 1.08) ++ 0.16 (0.09- 0.29) / ## 
 PPV23 
immunized 
0.15 (0.10- 0.23) 0.46 (0.28- 0.75) ++ 0.20 (0.13- 0.30) / ## 
9V PPV23 
naive 
0.30 (0.20- 0.45) 0.63 (0.38- 1.06) ++ 0.27 (0.16- 0.47) // ## 
 PPV23 
immunized 
0.23 (0.18- 0.31) 0.48 (0.35- 0.66) +++ 0.32 (0.22- 0.46) ## 
14 PPV23 
naive 
0.52 (0.31- 0.86) 0.88 (0.51- 1.52) 0.29 (0.17- 0.49) + /// ## 
 PPV23 
immunized 
0.37 (0.24- 0.57) 0.62 (-.43- 0.90) 0.37 (0.25- 0.56)  
19A PPV23 
naive 
0.99 (0.52- 1.87) 1.69 (0.87- 3.27) 1.04 (0.54- 2.01)  
 PPV23 
immunized 
0.83 (0.55- 1.26) 1.48 (0.99- 2.21) + 1.08 (0.71- 1.63)  
19F PPV23 
naive 
0.20 (0.10- 0.40) 0.50 (0.25- 1.00) + 0.18 (0.09- 0.34) / # 
 PPV23 
immunized 
0.17 (0.10- 0.26) 0.52 (0.31- 0.87) +++ 0.24 (0.14- 0.41) / ## 
23F PPV23 
naive 
0.15 (0.09- 0.26) 0.32 (0.19- 0.53) + 0.13 (0.08- 0.22) // # 
 PPV23 
immunized 
0.08 (0.06- 0.12) 
* 
0.19 (0.13- 0.27) * 
+++ 
0.12 (0.08- 0.18) ## 
Geometric mean (GM), 95% confidence intervals (CI). * compares groups for each serotype at 
each collection, + compares day 0 to day 28 and day 365 for each group and serotype, / compares 
day 28 to day 365, # compares days 0, 28, 365 for each serotype for each group. Day 0 and 28; 
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Table 3b. Fold change of IgA antibody concentrations in CKD patients immunized with PCV13. 
 
Serotype Group  Fold Change 0-28 Fold Change 0-365 
3 PPV23 naive 1.45 (1.20- 1.77) 0.73 (0.45- 1.18) ^ 
 PPV23 immunized 1.44 (1.23- 1.69) 0.79 (0.56- 1.12) ^^ 
6B PPV23 naive 1.48 (0.98- 2.230 0.48 (0.23- 0.98) ^^^ 
 PPV23 immunized 1.98 (1.49- 2.64) 0.83 (0.58- 1.20) ^^^ 
9V PPV23 naive 2.09 (1.51- 2.89) 1.08 (0.72-1.62) ^ 
 PPV23 immunized 1.91 (1.48- 2.45) 1.29 (1.01- 1.64) ^ 
14 PPV23 naive 1.30 (0.86- 1.96) 0.47 (0.28- 0.78) ^^^^ 
 PPV23 immunized 1.29 (1.13- 1.47) 0.88 (0.71- 1.09) * ^^^ 
19A PPV23 naive 1.83 (1.37- 2.44) 0.83 (0.46- 1.50) ^^ 
 PPV23 immunized 1.65 (1.38- 1.98) 1.0 (0.65- 1.52) ^ 
19F PPV23 naive 2.52 (1.76- 3.60) 0.80 (0.43- 1.47) ^^^ 
 PPV23 immunized 2.56 (1.91- 3.43) 1.38 (1.01- 1.88) ^^ 
23F PPV23 naive 1.69 (1.25- 2.30) 0.59 (0.36- 0.95) ^^^ 
 PPV23 immunized 1.92 (1.49- 2.49) 0.96 (0.67- 1.39) ^^ 
Geometric mean (GM), 95% confidence intervals (CI). * compares groups for each serotype for 
each fold change period. ^ compares day 0-28-fold change to day 0-365-fold change for each 
group. Fold change between day 0 and 28; PPV23 naïve n=22, PPV23 immunized n=34, 
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Table 4a. Correlation between proportions of B cells vs. fold change in IgG antibodies. 
PPV23 naïve participants 
Fold Change Cells (day 0) (r, p value) Cells (day 7) (r, p value) 
CD27+IgM- CD5- CD27+IgM- CD5- 
  n= 13 n= 13 n= 22 n= 14 
0-28 3 -0.21, p > 0.05 -0.64, p < 0.05 -0.15, p > 0.05 -0.76, p < 0.01 
6B -0.13, p > 0.05 -0.50, p > 0.05 0.25, p > 0.05 -0.44, p > 0.05 
9V  0.055, p > 0.05 -0.43, p > 0.05 -0.14, p > 0.05 -0.49, p > 0.05 
14  0.036, p > 0.05 -0.035, p > 0.05 0.25, p > 0.05 0.14, p > 0.05 
19A 19A: 0.042, p > 0.05 -0.055, p > 0.05 0.19, p > 0.05 -0.26, p > 0.05 
19F 19F: 0.48, p > 0.05 -0.12, p > 0.05 0.28, p > 0.05 -0.33, p > 0.05 
23F 23F: -0.37, p > 0.05 -0.45, p > 0.05 0.0010, p > 0.05 -0.52, p > 0.05 
  n= 10 n= 10 n= 17 n= 11 
0-365 3 -0.017, p > 0.05 -0.43, p > 0.05 -0.24, p > 0.05 -0.41, p > 0.05 
6B -0.024, p > 0.05 -0.28, p > 0.05 -0.073, p > 0.05 -0.37, p > 0.05 
9V 0.45, p > 0.05 -0.33, p > 0.05 0.032, p > 0.05 -0.65, p < 0.05 
14 -0.15, p > 0.05 -0.47, p > 0.05 0.60, p < 0.05 0.045, p > 0.05 
19A 0.57, p > 0.05 -0.37, p > 0.05 0.15, p > 0.05 -0.44, p > 0.05 
19F 0.38, p > 0.05 -0.63, p > 0.05 0.19, p > 0.05 -0.55, p > 0.05 
23F -0.017, p > 0.05 -0.65, p < 0.05 0.16, p > 0.05 -0.45, p > 0.05 
PPV23 immunized participants 
Fold Change Cells (day 0) (r, p value) Cells (day 7) (r, p value) 
 CD27+IgM- CD5-  CD27+IgM- CD5- 
  n= 18 n= 18 n= 33 n= 22 
0-28 3 0.15, p > 0.05 -0.20, p > 0.05 -0.064, p > 0.05 -0.55, p < 0.05 
6B 0.18, p > 0.05 0.38, p > 0.05 0.15, p > 0.05 0.37, p > 0.05 
9V 0.59, p < 0.05 -0.024, p > 0.05 0.34, p > 0.05 0.26, p > 0.05 
14 0.32, p > 0.05 -0.21, p > 0.05 0.24, p > 0.05 0.29, p > 0.05 
19A 0.04, p > 0.05 0.068, p > 0.05 0.10, p > 0.05 0.36, p > 0.05 
19F 0.021, p > 0.05 0.28, p > 0.05 -0.0031, p > 
0.05 
0.15, p > 0.05 
23F 0.18, p > 0.05 -0.20, p > 0.05 0.24, p > 0.05 0.057, p > 0.05 
  n= 15 n= 15 n= 27 n= 18 
0-365 3 -0.12, p > 0.05 0.21, p > 0.05 -0.025, p > 0.05 -0.0018, p > 0.05 
6B -0.0091, p > 0.05 -0.078, p > 0.05 0.40, p > 0.05 -0.21, p > 0.05 
9V -0.029, p > 0.05 0.35, p > 0.05 0.079, p > 0.05 0.11, p > 0.05 
14 -0.25, p > 0.05 0.56, p > 0.05 0.16, p > 0.05 0.21, p > 0.05 
19A -0.015, p > 0.05 -0.31, p > 0.05 -0.17, p > 0.05 -0.21, p > 0.05 
19F 0.082, p > 0.05 0.62, p > 0.05 -0.054, p > 0.05 -0.072, p > 0.05 
23F 0.055, p > 0.05 0.68, p < 0.05 -0.085, p > 0.05 0.35, p > 0.05 
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Table 4b. Correlation between absolute numbers of B cells vs. fold change in IgG antibodies. 
 
PPV23 naïve participants 
Fold Change Cells (day 0) Cells (day 7) 
CD27+IgM- CD5- CD27+IgM- CD5- 
  n= 13 n= 13 n= 13 n= 13 
0-28 3 -0.34, p > 0.05 -0.57, p > 0.05 -0.39, p > 0.05 -0.68, p < 0.05 
6B -0.53, p > 0.05 -0.56, p > 0.05 -0.30, p > 0.05 -0.35, p > 0.05 
9V -0.24, p > 0.05 -0.61, p > 0.05 -0.045, p > 0.05 -0.0061, p > 0.05 
14 0.035, p > 0.05 0.0091, p > 0.05 -0.25, p > 0.05 -0.23, p > 0.05 
19A 0.073, p > 0.05 0.079, p > 0.05 -0.18, p > 0.05 -0.39, p > 0.05 
19F 0.18, p > 0.05 -0.28, p > 0.05 -0.079, p > 0.05 -0.26, p > 0.05 
23F -0.49, p > 0.05 -0.030, p > 0.05 -0.28, p > 0.05 -0.65, p < 0.05 
  n= 10 n= 10 n= 10 n= 10 
0-365 3 0.26, p > 0.05 0.26, p > 0.05 0.33, p > 0.05 -0.68, p > 0.05 
6B 0.23, p > 0.05 0.23, p > 0.05 0.15, p > 0.05 -0.67, p > 0.05 
9V 0.20, p > 0.05 0.20, p > 0.05 0.10, p > 0.05 -0.43, p > 0.05 
14 0.36, p > 0.05 0.36, p > 0.05 0.54, p > 0.05 -0.25, p > 0.05 
19A 0.38, p > 0.05 0.38, p > 0.05 0.27, p > 0.05 -0.69, p > 0.05 
19F 0.38, p > 0.05 0.38, p > 0.05 0.18, p > 0.05 -0.82, p < 0.05 
23F 0.30, p > 0.05 0.30, p > 0.05 0.53, p > 0.05 -0.47, p > 0.05 
PPV23 immunized participants 
Fold Change Cells (day 0) Cells (day 7) 
 CD27+IgM- CD5- CD27+IgM- CD5- 
  n= 18 n= 18 n= 18 n= 18 
0-28 3 0.37, p > 0.05 -0.97, p > 0.05 0.62, p < 0.01 -0.0049, p > 0.05 
6B 0.49, p > 0.05 0.82, p > 0.05 0.62, p < 0.05 0.34, p > 0.05 
9V 0.088, p > 0.05 -0.56, p < 0.05 0.22, p > 0.05 -0.29, p > 0.05 
14 -0.039, p > 0.05 -0.84, p < 0.0001 -0.018, p > 0.05 -0.47, p > 0.05 
19A -0.16, p > 0.05 -0.46, p > 0.05 0.12, p > 0.05 0.12, p > 0.05 
19F 0.29, p > 0.05 -0.094, p > 0.05 0.58, p < 0.05 0.30, p > 0.05 
23F 0.23, p > 0.05 -0.32, p > 0.05 0.46, p > 0.05 0.093, p > 0.05 
  n= 15 n= 15 n= 15 n= 15 
0-365 3 0.34, p > 0.05 0.16, p > 0.05 -0.0022, p > 0.05 -0.14, p > 0.05 
6B 0.045, p > 0.05 -0.40, p > 0.05 0.084, p > 0.05 0.13, p > 0.05 
9V -0.033, p > 0.05 0.23, p > 0.05 -0.0071, p > 0.05 -0.018, p > 0.05 
14 -0.31, p > 0.05 -0.15, p > 0.05 -0.049, p > 0.05 0.011, p > 0.05 
19A -0.56, p < 0.05 -0.27, p > 0.05 -0.37, p > 0.05 -0.018, p > 0.05 
19F -0.30, p > 0.05 -0.13, p > 0.05 0.049, p > 0.05 0.52, p > 0.05 
23F 0.099, p > 0.05 0.20, p > 0.05 -0.061, p > 0.05 0.29, p > 0.05 
 




Supplementary table 1a. Number and proportion of participants that had a post-immunization 
IgG concentration of ≥ 1 µg/ mL and antibody fold change increase of ≥ two-fold. 
 
Serotype Group Day 28 Day 365 
3 Naïve  5/ 22 (22.7%) 2/17 (11.8%) 
 PPV23 5/34 (14.7%) 2/28 (7.1%) 
6B Naïve  14/ 22 (63.6%) 10/17 (58.8%) 
 PPV23 19/34 (55.9%) 10/28 (35.7%) 
9V Naïve  15/ 22 (68.2%) 4/17 (23.5%) 
 PPV23 16/34 (47.1%) 5/28 (17.9%) 
14 Naïve  14/ 22 (63.6%) 8/17 (47.1%) 
 PPV23 12/34 (35.3%) 9/28 (32.1%) 
19A Naïve  14/ 22 (63.6%) 6/17 (35.3%) 
 PPV23 14/34 (41.2%) 7/28 (25.0%) 
19F Naïve  16/ 22 (72.7) 9/17 (52.9%) 
 PPV23 18/34 (52.9%) 10/28 (35.7%) 
23F Naïve  11/ 22 (50.0%) 3/17 (17.6%) 
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Supplementary table 1b. Number and proportion of participants that had a post-immunization 
IgM concentration of ≥ 1 µg/ mL and antibody fold change increase of ≥ two-fold. 
 
Serotype Group Day 28 Day 365 
3 Naïve  3/22 (13.6%) 1/17 (5.9%) 
 PPV23 3/34 (8.8%) 3/28 (10.7%) 
6B Naïve  8/22 (36.4%) 2/17 (11.8%) 
 PPV23 3/34 (8.8%) 5/28 (17.9%) 
9V Naïve  9/22 (40.9%) 6/17 (35.3%) 
 PPV23 2/34 (5.9%) 5/28 (17.9%) 
14 Naïve  3/22 (13.6%) 2/17 (11.8%) 
 PPV23 1/34 (2.9%) 4/28 (14.3%) 
19A Naïve  6/22 (27.3%) 4/17 (23.5%) 
 PPV23 4/34 (11.8%) 11/28 (39.3%) 
19F Naïve  8/22 (36.4%) 3/17 (17.6%) 
 PPV23 6/34 (17.6%) 8/28 (28.6%) 
23F Naïve  3/22 (13.6%) 1/17 (5.9%) 
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Supplementary table 1c. Number and proportion of participants that had a post-immunization 
IgA concentration of ≥ 1 µg/ mL and antibody fold change increase of ≥ two-fold. 
 
Serotype Group Day 28 Day 365 
3 Naïve  6/22 (27.3%) 1/17 (5.9%) 
 PPV23 12/34 (35.3%) 5/28 (17.9%) 
6B Naïve  7/22 (31.8%) 3/17 (17.6%) 
 PPV23 15/34 (38.2%) 4/28 (14.3%) 
9V Naïve  13/22 (59.1%) 4/17 (23.5%) 
 PPV23 13/34 (38.2%) 4/28 (14.3%) 
14 Naïve  13/22 (59.1%) 2/17 (11.8%) 
 PPV23 8/34 (23.5%) 4/28 (14.3%) 
19A Naïve  13/22 (59.1%) 5/17 (29.4%) 
 PPV23 14/34 (41.2%) 7/28 (25.0%) 
19F Naïve  9/22 (40.9%) 2/17 (11.8%) 
 PPV23 17/34 (50.0%) 7/28 (25.0%) 
23F Naïve  7/22 (31.8%) 0/17 (0%) 
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Supplementary table 2a. Comparison of Mitra et al. (2016) results to our study 
Comparison Our PPV23 naïve 
CKD patients 
Our PPV23 immunized 
CKD patients 
Mitra et al. (2016) CKD 
patients 
The lowest response day 28,  
2 months Mitra et al. (2016) 
ST 3 (22.7%) ST 3 (14.7%) ST 3 (47%) 
Highest response day 28,  
2 months Mitra et al. (2016) 
ST 19F (72.7%) ST 23F (58.8%) ST 6B (~ 94%) 
A minimum of 50% of that responded to a ST STs 6B, 9V, 14, 19A, 
19F, and 23F 
STs 6B,19F, and 23F STs 6B,14,19A,19F, and 
23F 
Concentrations day 365 that were significantly 
lower than day 28, 2 months Mitra et al. (2016) 
STs 3 and 19A STs 3, 9V and 19A STs 3, 6B, 9V, 19A, 19F 
and 23F 
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Supplementary table 2b. Comparison of Vandecasteele et al. (2018) results to our study. 
 Our Study Vandecasteele et al. (2018) 







CKD patients < 4 
years 
PPV23 immunized 
CKD patients > 4 
years 
Day 28 that were 
significantly higher 
than pre-immunization 
STs 6B, 9V, 14, 
and 19F 
STs 6B, 9V, 19F and 
23F 
STs 3, 6B, 9V, 
14, 19A, 19F, 23F 
STs 6B, 9V, 14, 
19A, 19F, and 23F 
STs 6B, 9V, 14, 
19A, 19F, and 23F 
Day 365 that were 
significantly higher 
than pre-immunization 
ST 19F STs 6B and 23F 
(ST 3 was 
significantly lower) 
STs 6B, 9V, 14, 
19A, 19F, 23F 
STs 6B, 9V, 14, 
19A, 19F, and 23F 
STs 6B, 9V, 14, 19A 
and 19F 
PPV23 naïve vs. 
PPV23 immunized 
pre-immunization  
PPV23 immunized patients had 
significantly higher pre-immunization 
concentrations for STs 14 and 19A 
compared to PPV23 naïve patients. 
No significant differences  
PPV23 naïve vs. 
PPV23 day 28 
PPV23 naïve had significantly lower ST 
19A concentrations 
PPV23 naïve patients had significantly higher titres for STs 3, 
6B, 9V, 14, 19A, 19F, and 23F 
PPV23 naïve vs. 
PPV23 day 365 
PPV23 naïve had significantly lower ST 
23F concentrations 
PPV23 naïve patients had significantly higher titres for STs 6B, 
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Supplementary table 3a. Antibody concentrations of adults in response to PCV13 
Study Location  Time post-PCV13 
immunization 
IgG concentrations (µg/ mL) 
3 6B 9V 14 19A 19F 23F 
Severe CKD pneumococcal 
vaccine naïve adults  
mean age = 59 years (this 
study) 
Canada Pre- immunization 0.64 0.92 1.50 2.81 4.60 1.37 0.66 
28 days post-
immunization  
0.89 2.13 3.43 8.03 6.77 4.47 1.20 
365 days post-
immunization  
0.37 1.73 1.55 5.29 5.98 3.05 0.93 
Severe CKD adults immunized 
with PPV23 ≥ 1-year pre-
PCV13  
mean age = 60 years (this 
study) 
Canada Pre- immunization 0.97 1.07 1.64 5.05 8.45 2.44 1.05 
28 days post-
immunization  
1.04 2.34 2.70 8.25 12.13 5.30 2.34 
365 days post-
immunization  
0.52 2.47 1.71 7.88 8.79 4.27 1.83 
Severe CKD adults received a 
pneumococcal vaccine > 5 
years ago mean age = 63 years 
(1) 
USA Pre- immunization 0.47 0.57 1.11 2.09 2.18 1.36 0.62 
2-months post-
immunization 
1.88 8.35 3.47 13.84 9.86 9.99 6.12 
12-months post-
immunization 
0.79 3.08 1.36 5.95 3.11 4.56 2.24 
Healthy pneumococcal vaccine 
naïve adults 
mean age = 30 (2) 
USA 1-month post-
immunization 
2.21 24.47 5.13 12.89 17.25 14.43 17.45 
Healthy pneumococcal vaccine 
naïve adults 
mean age = 71 years (3) 
South Africa 1-month post-
immunization  
 
2.5 14.6 11.9 18.7 27.9 12.0 10.8 
Healthy pneumococcal vaccine 
naïve adults (group 1a) 
mean age = 55 years (4) * 
USA 1-month post-
immunization  
1.15 7.58 4.96 20.77 26.80 6.13 7.17 
Healthy pneumococcal vaccine 
naïve adults (group 2a) 
mean age = 55 years (4) * 
USA 1-month post-
immunization  
1.46 10.09 6.97 14.05 18.84 7.13 8.54 
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Healthy pneumococcal vaccine 
naïve adults (group 1b) 







1.08 6.24 4.97 8.95 11.93 4.78 5.82 
Healthy pneumococcal vaccine 
naïve adults (group 2b) 







1.15 6.43 6.21 12.44 17.10 7.39 6.11 
Pneumococcal vaccine naïve 
adults  
mean age = 73 years (6) ^ 
Netherlands Pre- immunization 0.44 2.18 1.21 1.97 3.45 1.32 1.43 
1-month post-
immunization  
1.35 9.30 7.57 11.99 18.07 7.23 7.36 
12-months post-
immunization  
0.7 5.35 3.91 7.66 8.62 3.67 3.97 
Adults received PPV23 ≥ 1-
year pre-PCV13  
mean age = 73 years (7) / 
USA Pre- immunization 0.19 0.67 1.04 4.1 3.29 1.45 0.68 
1-month post-
immunization  
0.46 3.7 2.72 6.45 9.41 4.35 0.6 
Pneumococcal vaccine naïve 
adults 18- 49 years group (8) + 
USA 1-month post-
immunization 
1.77 16.78 6.36 20.05 18.93 10.92 14.10 
Pneumococcal vaccine naïve 
adults 60- 64 years (8) + 
USA 1-month post-
immunization 
1.65 7.87 6.32 7.09 12.30 4.57 6.98 
Adults with asplenia received 
PPV23 ≥ 0.5 years pre-PCV13 
median age= 61years (9) & 
Sweden Pre- immunization 0.24 1.85 2.06 3.44 4.45 2.99 2.07 
4- 6 weeks post-
immunization 
0.47 1.33 2.11 3.99 7.02 3.79 6.06 
HIV-positive adults received 2 
doses of PCV13  
mean age = 50 (10)  
Italy  Pre- immunization 0.74 1.38 0.56 5.75 3.8 4.57 1.78 
1-year post-
immunization 
0.79 3.09 1.35 12.3 6.03 6.76 3.24 
HIV positive pneumococcal 
vaccine naïve adults  
mean age= 41 years (11) 
 
South Africa + 
Romania 
Pre- immunization 0.48 3.13 1.56 2.45 4.78 1.33 1.61 
1-month post-
immunization 
0.77 7.29 5.16 16.54 13.03 4.88 5.30 
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* group 1a- PCV13 administered with trivalent inactivated influenza vaccine (TIV) followed by placebo, group 2a- placebo with TIV 
followed by PCV13, group 1b- PCV13 with TIV followed by placebo, group 2b- placebo with TIV followed by PCV13 
^ includes healthy adults, adults with heart disease, diabetes mellitus, lung disease and asthma 
/ pre-existing conditions were not listed 
+ adults that are stable but have chronic conditions e.g., cardiovascular, pulmonary, renal, or liver diseases including alcoholic liver 
disease and alcoholism, and diabetes mellitus 


















HIV positive adults received at 
least 1 dose of PPV23 ≥ 6 
months prior to PCV13 
Mean age = 47 years (12) 
USA Pre- immunization 0.2 1.17 0.92 2.40 2.69 0.72 0.81 
1-month post-
immunization 
0.49 3.06 2.63 6.29 6.53 2.71 2.70 
Chronic lymphocytic leukemia 
adults, received a 
pneumococcal vaccine > 5 
years ago, median age = 70 
years (13) 
Sweden Pre- immunization 0.2 0.7 0.5 0.9 2.0 0.7 0.7 
1-month post-
immunization 
0.3 1.3 1.4 1.8 3.5 1.5 1.4 
6-months post-
immunization 
0.2 1.2 1.1 1.9 3.3 1.3 1.5 
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Supplementary table 3b. Studies that have reported responses to PCV13  
 
Study  Definition of response Response post-
immunization 
Proportion of participants that responded (%) 
3 6B 9V 14 19A 19F 23F 
Severe CKD pneumococcal 
vaccine naïve adults  
mean age = 59 years   
(this study) 
post-immunization IgG 
concentration of at least 
1 µg/ mL and a ≥ two-
fold antibody 
concentration increase 
Day 28 22.7 63.6 68.2 63.6 63.6 72.7 50.0 
Day 365 11.8 58.8 23.5 47.1 35.3 52.9 17.6 
Severe CKD adults 
immunized with PPV23 ≥ 1-
year pre-PCV13  
mean age = 60 years  
(this study) 
post-immunization IgG 
concentration of at least 
1 µg/ mL and a ≥ two-
fold antibody 
concentration increase 
Day 28 14.7 55.9 47.1 35.3 41.2 52.9 17.6 
Day 365 7.1 35.7 17.9 32.1 25.0 35.7 39.3 
Severe CKD adults (could 
have received a 
pneumococcal vaccine > 5 
years ago) 
 mean age = 63 years (1) 
post-immunization IgG 
concentration of at least 
1 µg/ mL and a ≥ two-
fold antibody 
concentration increase 
2 months ~ 47 94.1 ~ 47 ~ 82 58.8 ~76 ~71 
1 year ~ 23 ~ 65 ~ 29 ~ 53 47 ~59 ~59 
Pneumococcal vaccine 
naïve adults 
mean age = 73 years (6) ^ 
4-fold increase in IgG 
concentrations post-
immunizations  
1 month 32.7 43.1 59.5 55.2 50.9 53.4 51.9 
Adults received PPV23 ≥ 1-
year pre-PCV13  
mean age = 73 years (7) / 
4-fold increase in IgG 
concentrations post-
immunizations 
1 month 17.1 46.2 23.9 9.4 35.0 33.3 45.3 
Adults with asplenia 
received PPV23 ≥ 0.5 years 
pre-PCV13 
median age= 61years (9) & 
IgG level ≥ 0.35 µg/ml 4- 6 weeks post-
immunization 
~ 55 ~ 77 ~ 90  ~ 83  100 ~ 91 ~ 95 
IgG level ≥ 1 µg/ml ~ 27 ~ 75 ~ 85 ~ 77 ~ 95 ~ 90 ~ 90 
IgG level ≥ 5 µg/ml ~ 5 ~ 23 ~ 23 ~ 55 ~ 65 ~ 50 ~ 70 
HIV-positive adults 
received 2 doses of PCV13  
mean age = 50 (10) 
IgG level ≥ 0.35 µg/ml 5 years post-
immunization 
88 100 88 98 100 100 100 
IgG level ≥ 1 µg/ml 44 88 33 98 95 98 90 
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* group 1a- PCV13 administered with trivalent inactivated influenza vaccine (TIV) followed by placebo, group 2a- placebo with TIV 
followed by PCV13, group 1b- PCV13 with TIV followed by placebo, group 2b- placebo with TIV followed by PCV13 
^ includes healthy adults, adults with heart disease, diabetes mellitus, lung disease and asthma 
/ pre-existing conditions were not listed 
+ adults that are stable but have chronic conditions e.g., cardiovascular, pulmonary, renal, or liver diseases including alcoholic liver 
disease and alcoholism, and diabetes mellitus 
& received between 1-3 doses of PPV23 prior to PCV13 immunization, mean number of years before PCV13 immunization was 4.6 
years
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 Chapter 5: Conclusions  
The goal of this dissertation was to address two questions, the first was: are there 
differences in naturally acquired humoral immunity against Hia and pneumococcus in healthy 
adults and adults with CKD, or First Nations (FN) and non-First Nations (non-FN) adults of the 
same health status? Due to the immune dysfunction in adults with CKD, it is hypothesized that 
humoral immunity against Hia and pneumococcus could be decreased in CKD patients compared 
to healthy adults. The increased incidence of invasive disease in the FN population of 
northwestern Ontario, also suggests that humoral immunity in FN adults could be decreased 
compared to non-FN adults. It was found that patients with CKD had a significantly higher 
proportion of B cells compared to healthy adults (this group consists of primarily non-FN with a 
couple FN adults) which is thought to be due to the chronic inflammation caused by uremia as 
well as comorbidities such as diabetes mellitus. Non-FN CKD had an increased proportion of 
IgM memory and double negative B cells. This was thought to be due to the higher mean age of 
the non-FN CKD patients because it has been previously found that amounts of these B cells 
increase with age. When Hia specific capsular polysaccharide IgG and IgM concentrations were 
compared between CKD groups, the FN patients had significantly higher concentrations of Hia 
capsular polysaccharide IgM which could be an indication of recent exposure to Hia, or part of 
the natural IgM antibody repertoire. Both healthy and CKD FN groups had higher naturally 
acquired pneumococcal 6B and 14 IgG concentrations compared to healthy and CKD non-FN 
groups. The higher concentrations in the FN groups is thought to be due to antibodies that are 
cross-reactive with other pathogens or environmental antigens (i.e. Pseudomonas aeruginosa and 
Klebsiella pneumoniae). It is also important to consider that issues associated with low 
socioeconomic status within the FN communities such as inadequate accesses to clean water 
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(decreased hand washing) and overcrowding in households increases carriage of pneumococcus 
and Hia. This contributes to the increased rates of invasive disease caused by pneumococcus and 
Hia in the FN population. The collective data suggest that the increased prevalence of invasive 
disease caused by pneumococcus and Hia within the FN population is not due to decreased 
numbers of B cells or concentrations of naturally acquired antibodies. The increased prevalence 
of diseases such as CKD causing immune dysfunction in a higher proportion of the FN 
population increases their risk for invasive disease.  
The second question was: are adults with CKD able to respond to PCV13 immunization 
and does previous immunization with PPV23 affect their ability to respond to subsequent 
immunization with PCV13? It was hypothesized that although patients with CKD are 
immunocompromised, they have shown the ability to respond to the conjugate Hib vaccine, 
therefore it is expected that they will also be able to respond to PCV13. Other studies have 
shown that previous immunization with PPV23 has a negative effect on pneumococcal specific 
humoral immune response to subsequent immunization with PCV13. It is hypothesized that 
patients with CKD that have previously been immunized with PPV23 will also have decreased 
humoral immune responses to immunization with PCV13. Humoral immune responses to 
immunization with one dose of PCV13 was evaluated in two groups of adults with CKD, one 
group was pneumococcal vaccine naïve and the other received PPV23 ≥ 1 year ago. The results 
demonstrated that patients with CKD were able to respond to PCV13, however, a higher 
proportion of PPV23 naïve patients were able to meet the response criteria (a postimmunization 
IgG antibody concentration of at least 1 μg/ mL and a ≥ two-fold antibody concentration 
increase). The data suggest that immunization with PPV23 may result in long-term changes in B-
cell subpopulations such as increased prevalence of CD5- B cells and decreased prevalence of 
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class switched memory B cells in the peripheral blood. The significant decrease in the total class 
switched memory B cells in PPV23 immunized CKD patients in response to subsequent 
immunization with PCV13, suggests that previous PPV23 immunization may reduce PCV13 
immunogenicity. Previous studies have found an association between the CD5- B cells and 
production of IgG antibodies in response to PPV23. Therefore, we attempted to determine if 
there were any differences in CD5-expressing B cells between CKD groups. There was an 
increased prevalence of CD5- B cells and decreased prevalence of class switched memory B 
cells in PPV23 immunized patients. When correlation analyses were performed, there was a 
negative correlation of CD5- B cells and the fold change in IgG concentrations. A positive 
correlation of class switched memory B cells and the fold change in IgG concentrations was 
found. This suggests that previous immunization with PPV23 favored the production of CD5- B 
cells and is associated with decreased antibody responses to subsequent immunization with 
PCV13 in patients with CKD.  
These findings emphasize the need for further studies to optimize a pneumococcal 
immunization schedule for adults with CKD. Taking into consideration that immunization with 
PPV23 is recommended for adults with CKD, immunization with additional doses of PCV13 
when following PPV23 to elicit a stronger humoral immune response should also be 
investigated. Currently the National Advisory Committee on Immunization recommends for 
adults ≥ 65 years old receive PCV13 followed by PPV23, perhaps this schedule could also be 
assessed for adults with CKD. Analysis of antibody secreting cells for serotypes other than 6B or 
14 should also be quantified since these serotypes have been found to be less immunogenic than 
other serotypes. Quantification of pneumococcal specific peripheral blood memory B cells using 
flow cytometry rather than enzyme-linked immunospot assay (ELISPOT) may also provide more 
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information on the effects of previous PPV23 immunization in response to PCV13. All of the 
studies emphasize the need for establishment of protective antibody titres for adults. This 
information could determine adults that need to receive penumococcal immunization before the 
age of 65 years old and provide a better means of interpretation of clinical data since many 
studies use different definitions of a response to immunization. Determination of protective 
antibody concentrations should also be determined for adults with CKD specifically as they may 
need higher concentrations to protect them from invasive disease caused by pneumococcus and 
Hia. Additional studies on carriage as well as risk factors that contribute to invasive diseases 
caused by pneumococcus and Hia may also provide valuable insight to better understand the 
increased burden of invasive disease in the FN population.  
 
 
 
 
